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Summary of the main findings of my PhD research 
The overall objectives of my PhD were to investigate the expression pattern of 
various TAM receptors and ligand Gas6 in different brain regions throughout 
development, effect of Gas6 on glial cell development, in particular 
oligodendrocytes, demyelination and remyelination, as well as revealing the 
signalling mechanisms through which Gas6 exerts it effects, by looking at alterations 
of genes involved in MS with Gas6 stimulation. And the last but not the least, to 
reveal Gas6 as a potential new therapeutic target for treatment of multiple sclerosis 
(MS). My main findings are as follow: 
1. By analysing mRNA and protein extracts in qPCR and western blotting, we 
observed that the peaks of Tyro3 expression during postnatal development, 
overlaps with peaks of myelination periods in mice (Chapter 3). 
2. Using qPCR analysis, we observed that Tyro3 mRNA was uniquely 
expressed in oligodendrocytes, but not in astrocytes. In contrast, the 
expression of Axl mRNA was higher in astrocytes compared to 
oligodendrocytes. Gas6 was highly expressed in astrocytes and was absent in 
oligodendrocytes (Chapter 3). 
3. Using in vitro culture models, we obtained the functional effect of Gas6 on 
oligodendrogenesis and demyelination. We showed that treatment of optic 
nerves in culture with Gas6 for 72 hours, resulted in a significant increase in 
the number of oligodendrocyte precursor cells (OPCs). This suggests the 
involvement of Gas6 in glial cell development. We also showed that addition 
of Gas6 to organotypic cerebellar slice culture treated with lysolecithin, 
significantly attenuated the extent of demyelination in the brain sections. 
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Although we did not observe a positive effect for Gas6 on remyelination, but 
this observation indicate the inhibitory role of Gas6 in a demyelination model 
(Chapter 4). 
4. By using a mouse multiple sclerosis micro array kit, we analysed the effect of 
Gas6 on 84 different genes, all of which are involved in MS. We showed that 
Gas6 resulted in downregulation of Mmp9, Epha1 and Gfap, which suggest a 
positive regulatory role for Gas6 in cell development and differentiation as 
well as maintenance of blood brain barrier (BBB). Our analysis also showed 
the upregulation of Il10 gene with the effect of Gas6, which indicate Gas6 to 
have anti-inflammatory and immune regulatory properties (Chapter 5). 
5. By using in vivo animal models, we tested the effect of acute and chronic 
vitamin K administration on Gas6 and protein S gene expression. We showed 
that treatment of mice with various concentrations of vitamin K and at 
different time points resulted in alteration of Gas6 and protein S gene level in 
brain and liver. This suggest that vitamin K can be used to induce the 
production endogenous Gas6 in the brain for therapeutic purposes (Chapter 
6). 
Taken together, these observations indicate the positive role for Gas6 in a number of 
cellular processes, including cell proliferation, differentiation and survival, all of 
which are central in the progression of MS. In addition provide evidence that shows 
Gas6 to be a potential immune suppressive or an immune modulator that has the 
ability to control the immune response in MS patients. Therefore it can be used as a 
therapy that can be both regenerative and immune suppressive at the same time, 
something that can be effective in the progressive form of MS. 
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1.1 Anatomy of the CNS 
The nervous system is a unique organ system with enormous complex processes. It 
receives millions of bits of information per minute from sensory nerves and organs 
and integrates all of these inputs to tell the body what responses to make (1). There 
exist more than 100 billion neurons, each of which transfers the signals through a 
few hundred or as many as 200,000 synaptic connections, based on the types of 
neurons (1). 
The central nervous system (CNS) consists of the brain and the spinal cord, both of 
which are encased in bone. The brain is composed of three main parts: the cerebrum, 
the cerebellum, and the brain stem (Figure 1). The cerebrum is the largest part of the 
brain, which is divided into right and left cerebral hemispheres, separated by the deep 
sagittal fissure. Each hemisphere, receives signals and controls movements of the 
opposite side of the body. The cerebellum is the part lying behind the cerebrum and, 
despite its smaller size, it contains as many neurons as both cerebral hemispheres 
together. The cerebellum has extensive connections with the rest of the CNS and is 
the central controller of the body’s movements. In contrast to the cerebral 
hemispheres, the right side of the cerebellum is responsible for controlling the 
movements of the right side of the body, and the left side controls the movement of 
the left side of the body. The brainstem forms the stalk and is a complex nexus of 
fibres and cells and is responsible for transmitting signals from the cerebrum to the 
spinal cord and cerebellum and vice versa, as well as regulating some important 
functions of the body including breathing, consciousness and body temperature. The 
brainstem is considered to be the most vital part of the CNS for life, since one can 
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survive from damage to the cerebrum and the cerebellum, but damage to the 
brainstem is followed by rapid death (2). 
 
Figure 1. Diagram of the human brain, indicating the main parts: the cerebrum, the cerebellum, and 
the brain stem (2). 
 
1.1.1 Brainstem 
The brainstem is the part of the brain that transfers the messages between the spinal 
cord and the brain. All the nerves that transfer signal between the spinal cord and all 
parts of the brain including the cerebellum and forebrain cross the brainstem (3). 
Reticular formation is a special structure deep within the brainstem, which is 
composed of neurons and fibres and passes all the way through the brainstem and its 
axons extend to the spinal cord from below and to the diencephalon from above. 
Within the reticular formation, neurons form different groups or centres that are each 
involved in controlling various functions including breathing, heart rate and 
controlling the diameter of blood vessels for regulation of blood pressure (4). The 
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brainstem is located in the most inferior part of the brain and is composed of three 
parts: medulla oblongata, which is the lowermost portion, the pons, which is the 
middle part, and the midbrain, which is the superior portion of the brainstem (5).  
Medulla oblongata is mainly composed of white matter and has three different types 
of nerve bundles: ascending which are sensory input, descending or motor output, 
and transverse which form the interconnection between the medulla and cerebellum. 
The largest motor tracts are coming from the cerebral cortex and are located in 
special triangular structures called pyramids, which are located on the ventral sides 
of the medulla. The dorsal side of the medulla contains the sensory tract (5). Three 
vital reflex centres exist in the medulla, the cardiac centre that is responsible for 
regulating heart rate, the respiratory centres that is involved in regulating the rhythm 
of breathing, and the vasomotor centre which is responsible for controlling the blood 
flow by regulating the diameter of the vessels, thereby controlling blood pressure (5).  
The pons is connected to the anterior part of the medulla. There are two respiratory 
centres in the pons which, together with those centres in the medulla, control the 
rhythm of breathing (6). The midbrain is involved in controlling various functions. It 
has two main parts, a dorsal or top half known as tectum, and a ventral or bottom half 
known as tegmentum. There is a channel at the midline that separates the tectum 
from tegmentum and is named the cerebral aqueduct, which contains cerebrospinal 
fluid (CSF). Around the cerebral aqueduct are special types of cell bodies known as 
periaqueductal gray, which are involved in perception of pain. A number of nuclei 
related to the cranial nerves can also be found in the midbrain. The Red nucleus is 
responsible for transferring motor information between the cerebellum and the spinal 
cord. The other group of nuclei is substantia nigra that is connected to the basal 
ganglia of the forebrain. There are two pairs of bumps on the dorsal surface of the 
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midbrain, superior colliculi or the upper pair and inferior colliculi or the lower pair. 
Superior colliculi are part of the visual system and receive signal from the eyes 
through the optic nerves. Inferior colliculi are part of the auditory system and are 
involved with hearing. The signal travelling from the ears to the auditory cortex 
passes through this centre in the midbrain (7). 
 
Figure 2. Structure of the brainstem, indicating medulla, pons and midbrain (8). 
 
1.1.2 Cerebellum 
After the cerebrum, the second largest part of the human brain is the cerebellum. The 
cerebellum is composed of both white and grey matter, with most of the interior part 
being white matter, and the folded outer surface grey matter, which provides a large 
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area for nervous connections in order to process a large amount of information. The 
white matter tracts in the inner part form a treelike pattern known as arbor vitae. The 
main function of the cerebellum is to control the movement of the body in order to 
produce smooth, coordinated movements (9). The cerebellum is made up of two right 
and left cerebellar hemispheres and a median vermis. The flocculus is formed from a 
small part of each cerebellar hemisphere that lies on the middle cerebellar peduncle 
of the same side and is completely separated from the cerebellum. The outer layer of 
the cerebellum is composed of a number of narrow folia and lobules, which are 
formed by a few deep fissures. These fissures form the arbor vitae on the inner part 
(10) (Figure 3). 
 
Figure 3. Structure of the cerebellum, indicating the vermis, lobes, folia and arbor vitae (8). 
Figure 3.  
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The inner part of the cerebellum is made of both short and long tracts, in which the 
short ones transfer impulses within the cerebellum, between neurons in the cerebellar 
cortex and neurons in the interior part of the cerebellum, and the longer tracts are 
responsible for transferring signals to and from cerebellum. The long tracts transfer 
the impulses through three pairs of peduncles. Inferior cerebellar peduncles are 
made of tracts from the medualla and cord to the cerebellum; middle cerebellar 
peduncles are composed of tracts from the pons into the cerebellum; and superior 
cerebellar peduncles that is made of tracts into the cerebellum from dentate nuclei 
(11). 
The cerebellar cortex is formed of a large number of transversely oriented folia. 
Inside the cerebellar cortex lie the dendrites, synapses and cell bodies of cerebellar 
neurons. It is divided into three distinct layers: the outermost layer, known as the 
molecular layer, whilst the middle one is called the Purkinje cell layer, and the 
innermost layer is called the granular layer, which is dominated by the granule cells 
(Figure 4) (12). 
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Figure 4. Cerebellar cortex at three different magnifications, showing the three different layers, outer 
molecular layer, middle Purkinje cell layer and inner granular layer, as well as the white matter (12). 
 
1.1.3 Cerebrum 
In humans, the cerebrum is the largest portion of the brain, although it is far smaller 
in most other animals. The outer surface of the cerebrum, which is grey matter is 
called cerebral cortex and has a folded morphology in order to provide a larger 
surface area to have more neuronal cell bodies for processing information. These 
folds are called gyri and between them can be found shallow grooves called sulci. 
The very deep grooves are called fissures, like the longitudinal fissure that separates 
the right and left hemispheres of the cerebrum (5). The axons in the white matter 
transfer signals in two directions. One group sends axons from the cortex to other 
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cortical areas in both hemispheres, thalamus, basal ganglia, the brainstem or the 
spinal cord. The second group send axons from the thalamus to the cortex. Therefore, 
three types of neuronal fibres can be found in the white matter: the first one is known 
as association fibres that connect two different areas in the cortex within the same 
hemisphere. The second one is called commissural fibres, which are connecting a 
cortical area of one hemisphere to the same cortical area in the opposite hemisphere. 
The two main commissural fibres are anterior commissure and corpus callosum, 
both of which are the link between the two cerebral hemispheres. The third one is 
known as projection fibres, and they are the link between the cerebral cortex and 
other parts of the brain including the basal ganglia, thalamus, brainstem and spinal 
cord (4). 
The right and left cerebral hemispheres have the same appearance, although each is 
responsible for different functions. The left hemisphere usually is involved in speech, 
writing, analytic though processes, language comprehension and calculation. 
Whereas, the right hemisphere is more active in other functions including simple 
language comprehensive, appreciation of spatial relationships, general thought 
processes and conceptual nonverbal ideas (4). 
The cerebrum is composed of different lobes, which their names matches the bones 
overlying them, frontal and parietal, temporal and occipital lobes. The cerebral 
white matter is located below the grey matter and is composed of nerve fibres 
transferring signals between neuronal cell bodies and other parts of the CNS (5). The 
frontal lobe is responsible for two functions: one is to regulate voluntary movements 
and the second is to control emotional expressions as well as moral and ethical 
behaviours. The motor output is usually expressed through different areas of the 
frontal lobe including frontal eye field, Broca’s speech area and prefrontal cortex. 
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The frontal eye field is the area that controls the eye scanning movements such as 
looking for objects. Broca’s speech area is responsible for speech. The prefrontal 
cortex is the part in front of the motor area and is involved in various emotional 
expressions (4). The parietal lobe is involved in integration of general information to 
make awareness, and is mainly responsible with the evaluation of general senses. It 
has three main parts; postcentral gyrus, the superior and inferior parietal lobules as 
well as the supramarginal gyrus. The temporal lobe is the part of the cerebrum, 
which is near the ears, and is responsible for functional activities including hearing, 
equilibrium and partly emotion and memory. The auditory cortex that its stimulation 
generates some basic sounds like clicks is situated in the transverse temporal gyrus. 
Stimulation of the vestibular or equilibrium area may result in dizziness (4). The 
occipital lobe is relatively small compared to other lobes of the cerebrum and 
contains the visual cortex (Figure 5). The insula or central lobe is situated below the 
parietal, frontal and temporal lobes, deep in the lateral cerebral fissure. Very little is 
known about the function of insula, but it seems to be related with gastrointestinal 
properties. The medial surface of each hemisphere that surround the central core of 
the cerebrum is called limbic lobe or ring of cortex, which is composed of cingulate 
gyrus, isthmus and parahippocampal gyrus. The limbic system is composed of a 
number of structures around the brainstem that are actively involved in memory and 
emotions. It includes structures such as amygdala, limbic lobe, the hippocampus and 
parts of midbrain and thalamus. Among those, hippocampus and amygdala are 
closely related with the limbic lobe. The hippocampus is mainly responsible for 
memory traces of recent events (4). 
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Figure 5. Structure of the cerebrum, indicating different lobes (13). 
 
1.1.4 Diencephalon 
Deep within the brain, the region that is the link between midbrain and cerebral 
hemispheres is called diencephalon. It contains the thalamus, hypothalamus, 
epithalamus and ventral thalamus (4). The diencephalon is the part of the brain that 
is adjacent to the midbrain and surrounds the third ventricle (14). It consists of the 
third ventricle as well as the structures that make up its boundaries. Posteriorly, the 
diencephalon extends to the region where the third ventricle becomes continuous 
with the cerebral aqueduct and from the other side it extends as far as the 
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interventricular foramina, which makes diencephalon a midline structure that 
contains right and left symmetrical halves (15) (Figure 6). 
 
Figure 6. Cronal section of the brain, showing the position of diencephalon containing thalamus and 
hypothalamus (16). 
 
1.1.4.1 Thalamus 
The thalamus consists of a symmetrical pair of ovoid structures that is located above 
the hypothalamus, in the heart of cranial cavity directly below the cerebrum, and is 
composed of two egg-shaped forms of grey matter that is covered by white matter 
(Figure 7). The right and left thalamus are medially being separated by the third 
ventricle, and laterally are bounded by the posterior limb of the internal capsule. The 
thalamus is the processing centre for all the sensory inputs travelling from spinal 
cord, cerebellum, brainstem, basal ganglia and other parts to the cerebral cortex. The 
thalamus is involved in four major activities: 
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1) Sensory systems, neurons in the thalamus project their axons in the sensory 
parts of the cortex, therefore, the sensory signals are transferred to those areas 
to be analysed. 
2) Motor systems, some neurons in the thalamus transfer the input received from 
cerebellum and basal nuclei, to the motor cortex. 
3) General neural background activity, some of the background 
neurophysiological activities of the brain including sleep-wake cycle and the 
electrical brain waves are produced and monitored in the thalamus but are 
expressed in the cortex. 
4) Expression of the cerebral cortex, since the thalamus is linked with limbic 
system, it can help to control human emotions and behaviour (4). 
 
1.1.4.2 Hypothalamus 
The hypothalamus is a small region situated at the bottom of the diencephalon, 
directly below the thalamus (Figure 7). Even though the hypothalamus is a very tiny 
structure, comprising only less than 1% of total brain weight, it is composed of 
various different cell types that make up a master command centre that is coordinated 
by both the nervous and endocrine systems. The hypothalamus is a crucial control 
centre that regulates the homeostasis of the internal environment including control of 
water balance and regulating body temperature. It also regulates the anterior pituitary 
gland, which is part of the endocrine system, as well as regulating eating and 
drinking behaviours and the reproductive system (16). A number of functions that the 
hypothalamus is involved in, are listed in detail below: 
1) Integration within the autonomic nervous system (ANS). The hypothalamus is 
one of the most important brain regions related to the ANS. The 
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hypothalamus regulates autonomic functions including blood pressure, 
glandular secretions in the digestive system, sweat glands and salivary glands 
secretions, heart rate as well as controlling the bladder (4). 
2) Temporal regulation. The hypothalamus has a vital role in controlling body 
temperature. 
3) Water and electrolyte balance. There are some neuronal centres in the 
hypothalamus that maintain the balance of fluids and electrolytes in the body. 
4) Sleep-wake patterns. The hypothalamus is also involved in controlling the 
level of awareness and regulating the sleep-wake patterns. 
5) Food intake. There are neuronal centres in the hypothalamus that are 
sensitive to the levels of glucose, fatty acids and amino acids in the blood. 
Once the level of these factors is reduced in the blood, those centres become 
activated and the person experience hunger. 
6) Endocrine control. The hypothalamus is capable of provoking production of 
hormones including antidiuretic and oxytocin. 
7) Sexual responses. In the dorsal region of the hypothalamus, there is a 
neuronal centre that is linked with genital organs and that responds to 
stimulations of those organs (4). 
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Figure 7. Structure of the diencephalon, showing the position of the thalamus and hypothalamus (13).  
 
 
1.2 Glial cells 
In the mid nineteenth century the German anatomist Rudolf Virchow showed that 
there are two main types of cells in the CNS, neurons and a group of cells far larger 
in number, which surround the neurons and fill the gap between them. He named the 
second group neuroglia, or nerve glue, since one of their main functions is to hold 
the neurons in their place (17). There are some fundamental differences between 
these two cell types, neurons are electrically excitable cells whereas glial cells are 
considered to be non-excitable neural cells. This means that by an external 
stimulation, only neurons are capable of generating an action potential, which can 
spread through the neuronal network. This is the functional characteristic that 
distinguishes the neurons from glial cells, since the latter cannot produce an action 
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potential (although not all neurons can generate action potentials). However, the glial 
cells comprise nearly 90% of all cells in the human brain. In the CNS, there are three 
types of glial cell type originating from neural cell precursors; these are the 
astrocytes, the oligodendrocytes and the ependymal cells. These three cell types are 
often referred to as ‘macroglial cells’. In addition to these, there are glial cells of 
non-neuronal origin known as microglia; these are derived from macrophages that 
invade the brain during early development and settle through the CNS. In the 
peripheral nervous system (PNS), the main type of glial cells are the Schwann cells, 
which are responsible for myelinating the axons in the PNS. Other types of glia 
residing in the PNS are satellite cells (18). 
 
1.2.1 Oligodendrocytes 
Oligodendroglia or oligodendrocytes are a type of glial cell with a small number of 
processes, whose main function is to generate a myelin sheath around the neuronal 
axons of the CNS, enabling fast transfer of action potential through the axons (Figure 
8). Oligodendrocytes were described for the first time by Del Rio Hortega in 1928. 
He introduced four main subtypes of oligodendrocytes (I-IV) based on their 
morphological features including the number of their processes. Type I and II 
oligodendrocytes are cells with a small cell body, each one capable of myelinating 10 
to 30 small diameter axons. Type II can only be found in the white matter, whereas 
type I can be observed in the forebrain, cerebellum and spinal cord. Type III are the 
cells, which has the capacity to myelinate up to 5 thick axons, and have a bigger cell 
body compared to type I and II, and can be observed in the spinal cord, medulla 
oblongata as well as cerebral and cerebellar peduncles. Type IV oligodendrocytes are 
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present only around the entrance of the nerve roots to the CNS. They express no 
processes and make a single long myelin sheath around the thickest axons (18). 
 
 
Figure 8. Schematic diagram of OPCs and myelinating oligodendrocytes (19). 
 
Oligodendrocytes are the cells in the CNS responsible for producing a myelin sheath 
around axons (described in Section 1.4), and they do this by extending their cell 
membrane via processes. Between the myelinated areas are unmyelinated regions on 
the axons called nodes of Ranvier, which are required for the fast conduction of 
action potentials (20). In addition to speeding up the conduction of action potentials, 
oligodendrocytes also provide support for long term maintenance of myelinated 
axons as well as providing further metabolic support for neurons (20, 21). In case of 
demyelinating injury, due to rich sources of oligodendrocyte precursor cells (OPCs) 
within the CNS, the nervous system has the ability to regenerate oligodendrocytes 
and replace damaged myelin (described in Section 1.5.2) (20). 
During development, different stages of OPC maturation can be distinguished by 
specific antigenic phenotypes. During early stages of development, OPCs are A2B5+ 
cells, which when they differentiate into preoligodendrocytes can be recognised by 
 35 
O4 antibody. Expression of galactocerebroside (GalC) is the result of emergence of 
premyelinating oligodendrocytes, which start to express myelin proteins, including 
myelin basic protein (MBP), once they differentiate into mature myelinating 
oligodendrocytes (22). 
 
1.2.2 Astrocytes 
Astrocytes are the largest group of glial cells in the CNS. They are known as the cells 
with a star-like shape (18). In 1858, the German neurologist Rudolf Virchow referred 
to these cells as “nerve glue”. They play key roles in a number of brain functions, 
including maintenance of the blood-brain barrier (BBB), feeding neurons, regulating 
extracellular ions, participating in neurotransmitters metabolism as well as 
contributing to repair and regeneration mechanisms (23). During the late nineteenth 
and early twentieth century, Santiago Ramon y Cajal revealed the polarised three-
dimensional structure of astrocytes, by using the silver and gold impregnation 
technique that was developed by Camillo Golgi. In astrocytes, major processes 
extend from a small soma, which is as little as only 10 µm in diameter. From those 
processes, various membranes emerge which enwrap the synaptic terminals as well 
as contacting blood vessels (23). 
In addition to contributing the blood brain barrier (BBB) maintenance (24). 
Astrocytes are involved in homeostasis of neurons; in response to neuronal activity 
they provide neurons with important metabolite components including lactate (Figure 
9). They also contribute to tissue regeneration after insult or injury as well as 
performing other metabolic functions including ion, water and glutamate buffering 
(25). Astrocytes release a wide range of substances all of which are required for 
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maintenance and support of the CNS. It was not very long after their discovery that 
astrocytes were identified to also be secretory cells. Indeed, during the past couple of 
years astrocytes have been shown as capable of releasing a wide array of substances 
including classical neurotransmitters, neurotransmitter precursors, neuromodulators, 
hormones and peptides, eicosanoids, metabolic substrates, growth factors and 
inflammatory factors; all of these are involved in a number of important functions 
within the CNS, including homeostasis, cognitive function and development of the 
CNS as well as synaptogenesis. These substances can be secreted through different 
mechanisms including vesicle-based exocytosis, diffusion through plasmalemmal 
pores or channels and extrusion through plasmalemmal transporters (26). 
 
Figure 9. The well established functions of astrocytes. Astrocytes have several homeostatic functions 
that help to maintain a viable environment for neurons. These functions include: 1) providing 
metabolic support for neurons, 2) uptake of neurotransmitters, 3) synaptogenesis, and 4) BBB 
maintenance (24). 
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Astrocytes are characterised by special types of intermediate filaments, which can 
only be found in the astrocyte cytoskeleton: Glial Fibrillary Acidic Protein (GFAP) 
and vimentin (18). GFAP is a 50 kDa protein that was identified to be the main 
component of the intracellular astroglial fibres and its high immunogenic properties 
made it possible to raise a range of mono- and polyclonal antibodies against GFAP. 
Nowadays, anti-GFAP is the most common antibody used for labelling astrocytes 
and due to the reliability of these antibodies, it is very easy to distinguish astrocytes 
from other cells in the healthy and pathologic brain (23). Another marker that is 
widely used to label astrocytes is S100β, which is a small 11 kDa protein that 
belongs to the S100 family of proteins, which can form calcium-binding and homo- 
and heterodimer complexes. S100β is a soluble protein that is present in the astrocyte 
cytoplasm, and it can act as a neurotrophic factor once secreted into the extracellular 
environment. Since GFAP only labels the main processes of astrocytes, the 
advantage of S100β over GFAP as a marker is that S100β can reveal the complete 
three-dimensional structure of the astroglial cells due to cytoplasmic staining (23). 
 
1.2.3 Microglia 
For the first time Pio del Rio-Hortega introduced the concept of microglia as a 
defined cellular element of the CNS (Figure 10) (27, 28). Microglia are the immune 
cells of the brain, which in pathologic conditions or brain injuries, are activated to 
defend the CNS. They comprise about 10% of the total number of glial cells of the 
brain. In the adult brain, they can present three different forms: resting microglia, 
activated microglia and phagocytic microglia (18). Under normal conditions in the 
brain, microglia are in the resting state, and express a small soma and a large number 
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of highly branched processes of very small diameter. This form of microglia can be 
found everywhere in the brain, although they appear to be more in the hippocampus, 
basal ganglia, olfactory telencephalon and substantia nigra. Microglia contains a 
large number of receptors, which help them to monitor and control the state of the 
brain. In case of brain injury, the insult is immediately sensed by the receptors, which 
then converts resting microglia into activated microglia or reactive microglia to deal 
with the injury. Some of these reactive cells even proceed further and turn into the 
next state that is phagocytic microglia, in order to remove tissue and cell debris from 
the site of injury (18). 
Under normal conditions, microglia have distinct characteristics in comparison with 
macrophages in the rest of the body. They appear in a special form known as 
ramified, which reflects the resting state. In this form they appear as a cell with a 
large number of short processes that gives them a larger surface area so that they 
constantly monitor the condition of the CNS, looking for threats and, if they find an 
injury or infection, they quickly change their phenotype and become activated 
microglia. This was confirmed by showing the movement of microglia processes as 
if they are constantly sampling the CNS by time-lapse video microscopy in vivo in 
the mouse (29, 30). They use a range of receptors to regulate and control their 
activation and innate immunity, including scavenger receptors and toll-like receptors. 
Under pathologic conditions, activated microglia have many similar characteristics to 
macrophages that cross the BBB and infiltrate into the brain (although the latter have 
different origins since macrophages are originated from the bone marrow). Because 
it is usually not easy to distinguish activated microglia from macrophages, in injured 
CNS they are usually referred to as microglia/macrophages (30). Microglia cells with 
macrophage morphology start to increase in the CNS in response to acute destruction 
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of the CNS tissue, which show different morphological features compared to resting 
microglia, and are recognised by their spherical shape and amoeboid appearance 
while lacking processes, and with a high phagocytic capacity (29, 31). Once 
activated, microglia start to secrete different cytokines and chemokines, all of which 
play a role in regulating the immune response, for example by promoting 
inflammation and recruiting T-cells and macrophages from the blood circulation 
(30). 
 
 
Figure 10. Microglial cells discovered by A) Pio del Rio-Hortega (1882-1945). B) Ramified 
microglial cells drawn by del Rio-Hortega. C) Development of microglia through its phagocytic 
activity: A) the cell contain rough prolongation, B) it contains short prolongation, C) Hypertophic cell 
with pseudopodia, D) & E) amoeboid and pseudopodic forms, F) cells with phagocytic leukocyte, G) 
contains a number of phagocytosed erythrocytes, H) fat-granule cell, I) cell in mitotic division (27). 
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One of the difficulties in identifying microglia is that most of the available markers 
cannot distinguish different levels of activation. CD45 has been suggested to mark 
out all microglia despite their activation state, but in addition to microglia, it is also 
present on other immune cells that are located in the CNS, including lymphocytes. 
However, in 1996 a specific marker for microglia was discovered known as ionised 
calcium-binding adaptor molecule 1 (Iba1). Iba1 is a 17 kDa protein whose 
expression appears specific to microglia. Although it cannot distinguish microglia in 
between activation states, the expression of Iba1 has been shown to be up-regulated 
in the CNS during inflammatory conditions (29). 
 
1.3 Oligodendrogenesis 
During CNS development, the three main types of neuronal cells including neurons, 
oligodendrocytes and astrocytes, are all derived from neuroepithelial cells of the 
neural tube during development. Neurons which are the cells in the CNS, responsible 
for conduction of action potentials are highly related and dependent on the glial cells 
around them (32). During development, neurons, astrocytes and oligodendrocytes are 
all derived from the same tissue, whereas microglia are derived from macrophages, 
known as foetal macrophages, which migrate into the neural tube at early stages of 
development and later transform into microglia (18, 32).  
Cells in the neuroepithelium have the capacity to differentiate into all neural cells 
with equal probability, therefore they can be designated neural progenitors, which 
can differentiate into neuronal (also known as neuroblasts) or glial precursor cells 
(also known as glioblasts). For many years scientists thought that neuroblasts and 
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glioblasts derive from neural progenitors at early stages of development, which form 
non-interchangeable pools of progenitor cells that then differentiate into neurons or 
glial cells. However, this theory has been challenged during the past couple of years 
and it seems that these two types of progenitor cells are more closely related to each 
other than was thought before (18). The new theory of neural cell development 
proposes that at the beginning, the neural progenitors, which morphologically appear 
as elongated cells, differentiate into radial glial cells. The radial glial cells are in fact 
the main type of cells involved in neurogenesis as they can transform into neurons, 
astrocytes and to some extent oligodendrocytes. Astrocytes can also be derived from 
glial precursors, which can give rise to oligodendrocytes as well as astrocytes. 
Moreover, during brain maturation and adulthood, both radial glial cells and 
astrocytes that are derived from them can still function as stem cells and transform 
into oligodendrocytes or neurons (Figure 8) (18). 
 
Figure 11 Schematic diagram comparing the modern and classic theories on neural cell development 
(18). 
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During development and also afterwards through to adulthood, oligodendrocytes are 
produced from oligodendrocyte precursor cells (OPCs), which are classified as a 
subtype of glial cell. Oligodendrocytes are derived from two main sources of OPCs, 
either from early postnatal-derived OPCs or from OPCs that are continuously 
generated from progenitor cells in the subventricular zone (SVZ) (33). During 
development in vertebrate embryos, OPCs are raised in multiple distinct foci that are 
located in several parts of the CNS, which then migrate out of the foci to reside in 
various parts of the CNS (22). 
During development, the oligodendrocytes are produced through three different 
waves of OPC proliferation and migration. The first one takes place at embryonic 
day 12.5 (E12.5) and contains the production of OPCs from ventral ganglionic 
eminence. The second wave occurs at E15.5 and OPCs are derived from lateral and 
caudal ganglionic eminence and the last wave takes place after birth with OPCs 
originating from the cortex (33, 34). 
During development, OPCs maturation can be divided into different stages based on 
differences in migratory capacity and morphological features as well as expression of 
various markers that can be observed in different steps of differentiation. 
Oligodendrocytes maturation can be divided into four different levels, the first step 
being when the cells are at OPC level; during the second stage OPCs convert into 
preoligodendrocytes or late OPCs which is followed by the third level when the late 
OPCs transform into immature or pre-myelinating oligodendrocytes that finally 
differentiate into mature or myelinating oligodendrocytes, which is the fourth stage. 
During the first stage, OPCs are considered as proliferative cells with abundant 
migratory capacity that specifically express platelet-derived growth factor receptor α 
(PDGF-Rα), ganglioside A2B5, proteoglycan NG2, polysialic acid-neural cell 
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adhesion molecule as well as fatty acid binding protein 7 (FABP7) (35). When OPCs 
differentiate into preoligodendrocyte, in addition to OPC markers they start to 
express GPR17 protein as well as sulfatide that is recognised by O4 antibody. These 
markers are expressed until the cells transform into immature oligodendrocytes. By 
the third stage (immature oligodendrocytes), the cells lose the expression of NG2 and 
A2B5 and start to express galactocerebroside C, as well as continuing to express the 
O4. Once the cells differentiate into mature myelinating oligodendrocytes, they 
extend membrane and start ensheathing the axons. In the final stage they specifically 
express myelin proteins including MBP, proteolipid protein, myelin associated 
protein (MAG) as well as myelin oligodendrocyte glycoprotein (MOG) (Figure 9) 
(35). 
 
 
Figure 12. Different stages of oligodendrocytes maturation (OPCs, preoligodendrocytes, immature 
oligodendrocytes, mature myelinating oligodendrocytes), showing specific markers expressed in each 
stage. These stages are identified based on differences in proliferation activity and migration capacity 
as well as changes in morphological features of the cells (35). APC expression begins in the immature 
stage and carries on until the mature stage. 
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1.3.1 Oligodendrogenesis during adulthood 
In adult CNS, a special type of stem cells known as neural stem progenitor cells 
(NSPCs) are retained in the SVZ and subgranular zone (SGZ), which make these 
areas the biggest areas within the CNS for generating new neurons and glial cells. 
NSPCs are a special type of multipotent cells, which has the ability to differentiate 
into all types of neural cells, including neurons as well as oligodendrocytes and 
astrocytes. Newly formed oligodendrocytes from NSPCs, migrate towards the corpus 
callosum and white matter tracts of striatum and fimbria fornix (36, 37). However, 
after early postnatal days the ratio of NSPCs converting into oligodendroglial lineage 
will decrease. In the adult brain, under pathologic conditions, the fate of the NSPCs 
can change according to the type of the disease, for example their fate can be 
switched to produce more OPCs in case of demyelinating disorders, in which the 
newly formed OPCs proliferate in order to increase in number and migrate to sites of 
injury (36, 37). 
SVZ contains slowly dividing subpopulation of progenitor cells that have the 
characteristic of astrocytes, they are called type-B cells and function as NSPCs. 
Type-B cells give rise to actively proliferating intermediate progenitor cells (IPCs) or 
type-C cells, which divide further and give rise to type-A cells that are immature 
neuroblasts, and later, they migrate to the olfactory bulb where they differentiate into 
interneurons. In addition to the olfactory interneurons, a smaller portion of type-B 
cells can also differentiate into mature myelinating oligodendrocytes, which migrate 
into the corpus callosum, fimbria fornix as well as striatum (36, 37). 
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1.3.2 Generation of oligodendrocytes in the spinal cord 
The process of oligodendrogenesis in the spinal cord has widely been studied using 
in vivo models, mostly focusing on sites of origin as well as mechanisms that 
regulate the process during development (38). The ventricular zone (VZ) of the 
spinal cord is elongated during early stages of embryonic development, and the radial 
glial cells from dorsal and ventral spinal cord appear to be the same. Therefore, 
neural stem cells were believed to have equal ability to differentiate into different 
cells regardless of their position in the spinal cord. However, this was compromised 
when embryonic rat spinal cord was split into dorsal and ventral fragment, and it was 
observed that only cells from ventral spinal cord could generate OPCs in dissociated 
cells and explant culture (38, 39). Once the PDGFRα was introduced as lineage 
marker for OPC, it was also shown that generation of oligodendrocytes was restricted 
in the ventral VZ (38, 40). Later on O4
+
 OPCs in the spinal cord of chik embryo 
showed similar appearance in the ventral spinal cord (38, 41). These data strongly 
suggested a focal restricted origin of OPCs within the spinal cord (38), and later, this 
was also observed by using a number of various markers including Sox10, Plp1, 
Olig1, Olig2 as well as Nkx2.2 (38). 
Sonic hedgehog (Shh), which is released from the notochord, has been shown to 
induce ventral OPCs (38, 42). However, it was shown that, during later embryonic 
stages of the spinal cord development, OPCs are also originated from the dorsal VZ 
in a shh-independent manner (38, 43-45). Although the OPCs originated from the 
dorsal VZ prefer to settle and myelinate axons in the dorsal funiculus, but OPCs 
generated within the ventral VZ migrate to both dorsal and ventral portions of the 
spinal cord (38).  
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1.4 Myelination 
In the vertebrate nervous system, myelin is responsible for fast conduction of action 
potentials. Myelin is produced by oligodendrocytes and is extended to form 
membranes around neuronal axons. Oligodendrocytes are very numerous within the 
CNS, particularly in the white matter, and their role in myelination has been 
established for nearly a century, and the important role of myelin for normal 
functioning of the CNS has been appreciated through the study of some human 
diseases including multiple sclerosis (MS). Indeed, during the past few years the 
research on myelin and oligodendrocytes has mainly been focussed on signalling 
mechanisms that regulate myelination in order to develop therapies to promote 
regeneration in demyelinating disorders (46). 
The term “myelination” is used to describe the ensheathment of nerve fibres by 
extending membrane from oligodendrocytes with compaction into segments of 
compacted myelin, which forms internodes. Intermodal segments are being separated 
by nodes of Ranvier, which are naked axonal membranes without a myelin sheath. 
Nodes of Ranvier are the parts with a concentration of voltage-gated sodium 
channels that allow the propagation of action potentials (Figure 13) (47).  
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Figure 13. Myelin sheath and formation of nodes of Ranvier in CNS and PNS (18). 
 
During development, myelination occurs in four different stages that require complex 
interaction between the oligodendrocyte and neuronal axon. These interactions 
within the CNS and PNS are similar, although the specific mechanisms involved in 
myelination might be different. One of the main differences is that in the CNS, the 
oligodendrocyte has the ability to identify a number of axons that need to be 
myelinated, whereas in the PNS, each Schwann cell can only identify one axon. The 
number of axons that oligodendrocytes can myelinate depends highly on the type of 
myelinating oligodendrocyte as well as the axon diameter (discussed in Section 
1.2.1).  
The first phase of myelination is axon contact, in which axon diameter plays a 
critical role. Premyelinating Schwann cells and oligodendrocytes make connections 
with a large number of axons, but only those that have reached a certain diameter are 
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myelinated. Through the second phase, the ensheathment of the neuronal axons by 
Schwann cells or oligodendrocytes starts. In phases three and four, which are called 
remodelling and maturation, myelin and axons undergo interdependent maturation. 
As the axons grow and enlarge in diameter, myelin becomes compacted and 
increases the number of lamellae. Also, nodes of Ranvier are established in this 
phase (18). Another important difference between myelination in CNS and PNS is 
the formation of nodes of Ranvier. In the PNS, Schwann cells extend special 
processes called microvilli in order to fill in the nodal gaps, which then is completely 
covered by basal lamina of Schwann cells, and as a result a tube along the axon is 
formed. In the CNS, oligodendrocytes do not possess microvilli; therefore, perinodal 
processes of astrocytes and NG2 glia cells perform this function. Oligodendrocytes 
also do not form a basal lamina around the axons (Figure 10) (18). 
As well as insulating properties, myelin sheaths are also very important in separating 
sodium and potassium channels at nodes of Ranvier. The sodium channels that are 
responsible for generation of action potentials by depolarisation of the axonal 
membrane are situated at the nodes of Ranvier, whereas potassium channels that are 
responsible for repolarisation of the action potential are located at the juxtaparanodal 
regain under the myelin sheath (18). 
 
1.4.1 Role of neuronal activity in myelination 
During myelination, the threshold axonal diameter to be myelinated by 
oligodendrocytes is more variable compared to Schwann cells, it can be as low as 0.2 
μm (48, 49). Therefore, in addition to the axonal diameter and factors, within the 
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CNS the process of myelination is also influenced by other factors including 
electrical activity (50), the spatial density of OPCs (51), cues from astrocytes (52, 
53), as well as microglia and machrophages (48, 54-56).  
The idea of the involvement of neuronal activity in myelination and also in 
oligodendrocyte development is supported by a number of evidences. For 
example, inhibiting the neuronal activity by tetrodotoxin (a potent neurotoxin) or 
by axotomy (cutting of an axon) in developing optic nerve, resulted in reduced 
proliferation of OPCs (50, 57). In addition, optogenetic stimulation of CNS 
neurons has been shown to increase cell proliferation (particularly OPCs) in the 
premotor cortex by approximately fourfold (50). In the same study, the fate of 
these proliferating OPCs was also investigated and was shown that after 
stimulating the neuronal activity, these proliferating OPCs finally differentiate 
into mature oligodendrocytes (50). In addition, it was shown that stimulating 
neuronal activity also increase the thickness of the myelin sheath around axon, as 
well as increasing the expression of myelin related proteins, such as MBP (50). 
Taken together, these finding indicate the unique role of neurons in performing 
successful myelination throughout development by regulating oligodendrocytes 
development and myelin formation. 
 
1.5 Multiple sclerosis 
Multiple sclerosis (MS, also known as disseminated sclerosis or encephalomyelitis 
disseminate) is an inflammatory condition in which the myelin sheath around nerve 
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fibres in the CNS and oligodendrocytes are damaged through a process called 
demyelination, which results in a wide range of signs and symptoms (58, 59). MS is 
considered to be the most chronic demyelinating condition of the CNS (60). The 
aetiology of MS is still unknown, although present data indicate that a combination 
of genetic and environmental factors, such as some virus infections and dietary 
conditions, result in the initiation of an inflammatory response that targets the myelin 
and oligodendrocytes (61). Demyelination in the CNS is followed by a wide range of 
signs and symptoms (58), which were first described by Charcot and Vulpian in 1866 
(62). In fact, the French neurologist Jean-Martin Charcot (1825-1893) was the first 
scientist who recognised MS as a distinct disorder. Charcot collated previous 
knowledge and reports with his own observations, which helped him to describe the 
disease and called it “sclerose en plaques” in French. Three signs of MS (although 
these are not unique to MS) described by Charcot are as follows: 
1) Nystagmus (involuntary movement of eye) 
2) Intention tremour (problem of movement as a result of cerebellum 
dysfunction) 
3) Telegraphic speech (deficient communication) (58). 
The usual symptoms that occur in MS are sensory and visual disturbances, bladder 
and bowel incontinence, loss of balance, pain, fatigue and weakness. In 45-65% of 
patients, MS can also result in cognitive impairment. At onset of the disease, 
although 85% of cases happen between the ages of 14-55, primary symptoms usually 
present in early adulthood between the ages of 20-40 (58). MS is more frequent in 
women than men with a ratio of 2:1, and the prevalence varies between 2 to 150 per 
100,000 (58, 62). 
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Demyelination in MS include two critical steps: (i) invasion of activated immune 
cells from the vascular system into the CNS, (ii) CNS tissue damage, including 
destruction of the myelin sheath resulting in formation of demyelinating lesions, also 
known as plaques (61). However, recovery of damaged tissue usually happens 
through a process known as remyelination, which involves generation of new myelin 
around damaged axons in MS lesions, thus enabling the axons to regain their ability 
to conduct action potentials (63). However, remyelination always fails or is 
incomplete, due mainly to inability of OPCs to differentiate into mature myelinating 
oligodendrocytes (64). Also, astrocytes and microglia are usually present in 
demyelinating lesions, with both cell types playing both beneficial and detrimental 
roles. The glial scar, which is a physical barrier around the lesion during chronic 
stages of the disease, is the result of astrogliosis. The glial scar prevents the entry of 
both OPCs and axons into the lesion, thereby preventing remyelination. In addition, 
astrocytes express tumour necrosis factor-α (TNF-α), whose expression shows a 
positive correlation with demyelinating activity. As for the beneficial role of 
astrocytes, these are linked to production and secretion of a number of neurotrophic 
factors, including insulin-like growth factor-1 (IGF-1), fibroblast growth factor 2 
(FGF2), brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor 
(CNTF), which regulate OPCs differentiation (65). In the case of microglia, recent 
studies have shown that microglia/macrophages can polarise into M1 and M2. M1 
and M2 microglia/macrophages have different properties. The former is involved in 
secretion of pro-inflammatory mediators that result in destruction of normal tissue, 
whereas the M2 phenotype shows protective characteristics and increases 
remodelling and repair of the tissue. The potentially harmful properties of microglia 
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could include secretion of TNF-α while, in contrast, their beneficial effect is the 
efficient removal of myelin debris in MS lesions (65). 
 
1.5.1 Different types of MS 
In majority of MS cases, the disease starts with a relapsing-remitting clinical course, 
which is characterised by periods of neurological dysfunction known as relapses that 
is related to the formation of lesions within the CNS. The relapse period is usually 
followed by a remission episode, which is the recovery period. This form of MS is 
known as relapsing-remitting MS (RRMS) (66, 67). The complete remission of the 
symptoms normally happens within the early stages of disease development. Most of 
the RRMS patients usually enter a new phase of the disease, which is gradual 
progression of the disability, this type is known as secondary progressive MS 
(SPMS) (66, 68). In about 10-15% of the MS patients, at the onset of the disease, it is 
characterised by gradual progression of neurological disability. These patients are 
diagnosed with primary progressive MS (PPMS) (66, 69, 70).  
 
1.5.2 Progression of the disease in MS 
In order to identify an effective therapeutic target, it is essential to understand the 
mechanisms through which MS progression occurs and causes demyelination. One 
possible mechanism is the “outside in” hypothesis that suggest the activation of T 
cells in the vascular system, which alongside other immune cells cross the BBB and 
invade the CNS, which ultimately results in demyelination. Some of the cells that 
contribute to acute inflammation are activated T cells, macrophages, microglia and 
astrocytes (59). In the adaptive immune system, CD8 T cells are one of the important 
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cell types contributing to the defence mechanism. They have the ability to kill target 
cells by perceiving peptide-MHC (major histocompatibility) class I complexes. Since 
most CNS cells including neurons, oligodendrocytes and astrocytes express MHC 
class I molecules on their surface, they are all potential targets for CD8 T cells. In 
MS patients, the expression of MHC class I molecule is already upregulated before 
demyelination starts to develop (71). 
A number of environmental and genetic factors are involved in initiating the immune 
response, which involves dendritic cells (DCs) actively presenting self-antigens to 
autoreactive T cells, which themeselves differentiate into various subsets. These 
regulatory and effector subsets (including cytotoxic T cells known as CTLs) are 
capable of migrating to the CNS by crossing the blood brain barrier (BBB). 
Furthermore, macrophages as well as resident microglia in the CNS can present self-
peptide via the MHC class I complex, and thereby also induce clonal expansion of 
autoreactive CTLs. These active CTLs can then directly attack those 
oligodendrocytes and axons/neurons that express the MHC class I peptide, resulting 
in tissue injury that includes demyelination. Furthermore, cytokines and chemokines 
which are generated by effector CD8 T cells play a key role in maintaining the 
inflammatory reaction (Figure 14) (71, 72). 
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Figure 14. Hypothetical scheme of the involvement of CD8 T cells in modulation of the immune 
response in MS. CTLs differentiated from CD8 T cells can cross the BBB and enter the CNS, where 
they become activated by MHC class I complexes generated by microglia and macrophages, and 
directly target the oligodendrocytes and myelinated axons (71). 
 
However, during the past few years, scientists have come up with observations that 
have challenged the widely held concept of MS as an “autoimmune disorder”. For 
instance, it has been shown that during early stages of the disease, the damage to 
oligodendrocytes and myelin can occur in the absence of T cells and B cells in the 
CNS; this therefore suggests involvement of process other than cell-mediated 
immunity. Also, some large demyelinated lesions in the cerebral cortex and grey 
matter have shown a paucity of infiltrated immune cells from the blood. 
Furthermore, in MS patients who have received autologous bone marrow 
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transplantation, expansion of the demyelinating lesion was observed to feature little 
or no T cells, which suggests that the progression of the MS lesion is regulated by 
pathological processes inside the CNS. These observations, coupled with the fact that 
in nearly all MS lesions active microglia/macrophages are present, suggest that an 
innate response by microglia/macrophages resident in the CNS might be responsible 
and therefore the term “autoimmune” needs to be reconsidered (73). 
In the innate immune response one of the very first cell types that become activated 
are microglia/macrophages. These cells monitor the condition of the CNS and look 
for threats and play an active role in fighting against microorganisms, with the ability 
to recognise common structures expressed on the membrane of bacteria and viruses. 
In detection of mircoorganisms, the first line of defence in the immune system is the 
recognition of pathogens associated molecular patterns (PAMPs) through specific 
host recognition receptors. PAMP receptors are expressed on a large number of cells 
with ectodermal and mesodermal origins. Members of the Toll like receptor (TLR) 
family are considered to be some of the main PAMP receptors, which are involved in 
regulating a proper immune response against foreign antigens. Many of the PAMP 
receptors, including the TLR family, are present on microglia. Although it is still not 
clear what factors contribute to microglia activation in demyelinating lesions, there 
are some hypotheses put forward. First of all, microglia may be activated by the 
effect of pro-inflammatory cytokines that are initially released by T and B cells. 
Second, the activation of microglia could be the result of phagocytosis of myelin and 
myelin debris from MS lesions. Lastly, activation of TLR receptors on microglia 
cells could occur via an unknown pathogen. Moreover, TLR receptors are not only 
susceptible to activation by various pathogens, but also by cellular proteins that are 
normally present in the CNS, some of which can be produced as a result of damage 
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or tissue injury. These CNS microglia can remain active even after the injury or 
damage which initiated their activation is eliminated (73). 
 
1.5.3 Remyelination 
Following demyelination, remyelination usually occurs, which is the process of 
recovery that generates a new myelin sheath around nerve fibres, thus enabling them 
to regain their lost function, e.g the conduction of action potentials. The regenerative 
process of remyelination is very important particularly for the CNS, which is 
believed to have a limited ability to regenerate. The process of remyelination can be 
classified in four stages. First of all, following demyelination, OPCs start to 
proliferate and increase in number, following which they migrate and move towards 
demyelinated areas. Once there, they start to differentiate and form mature 
myelinating oligodendrocytes. The final stage is their interaction with demyelinated 
axons in order to start the remyelination process (65).  
In animal models of demyelination, remyelination is usually complete, whereas in 
MS patients it is always incomplete or fails (63). The reason for this is still unclear. 
Limited OPC differentiation could be one reason, since about 70% of MS lesions that 
remain demyelinated contain a large number of undifferentiated OPCs (65). 
Understandably, the failure of remyelination is one aspect of MS that many 
researchers are attempting to resolve by finding new therapeutic targets that can 
reactivate or enhance this regenerative process (63). Several strategies have been 
used in animal models of MS that resulted in increased remyelination, however none 
of these were successful as a clinical therapy for MS patient. Therefore, there is a 
need for developing new strategies, which in particular would be much easier if it 
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was clear why remyelination fails, and thus which aspects of the process need to be 
corrected. Since the lesions in each MS patient can fall into any of the many different 
pathologic classifications, the reason for failure of remyelination can therefore differ 
from patient to patient, with the failure moreover being likely being due to many 
reasons (63). 
As remyelination involves recruitment and differentiation of OPCs, it is therefore 
possible that failure of recruitment or differentiation could be reasons for incomplete 
remyelination in MS. Failure in recruitment of OPCs might happen if the number of 
OPCs are reduced and therefore not enough OPCs are available for recruitment, and 
recent studies have provided data that show this may be the case in some patients 
(63, 74, 75). One possible reason for OPC depletion is the repeated cycle of 
demyelination followed by remyelination that may lead to OPCs exhaustion and 
therefore becoming limited in their availability. Indeed, some animal models of MS 
have shown repeated episodes of demyelination and remyelination to result in less 
efficient remyelination; this appears to be the same in MS. Although this is one 
explanation for a lack of OPCs for recruitment, recent findings have shown that 
OPCs nevertheless have a very strong desire to migrate towards the areas where they 
are needed and, moreover, that no reduction in OPCs are apparent in and around 
remyelinating areas. Therefore, it is possible that in the case of high demand for 
OPCs, a reduction in OPCs number may result in inefficient remyelination. 
However, in the case where OPCs availability is not limited due to OPCs depletion 
or repeated episodes of demyelination and remyelination, then the recruitment failure 
may be as a result of insufficient factors that induce recruitment (63). 
A further distinct observation in recent years has been that in some MS lesions, 
failure of remyelination is due to OPCs failure to differentiate into mature 
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myelinating oligodendrocytes. Use of an O4 antibody for labelling oligodendrocyte 
lineages identified a large number of immature oligodendrocytes in MS lesions. 
Furthermore, other researchers reported similar data using different antibodies 
against immature oligodendrocytes including NG2 and PDGF-Rα. In conclusion, it 
has been shown that in some MS lesions, incomplete remyelination occurs due to a 
recruitment failure of OPCs, whereas in others, as a result of failure in OPCs 
differentiation (63). 
 
1.5.4 Current MS therapy 
There is still no therapy that can cure MS, and most of the treatments available on the 
market are mainly focussed on management of the progression of the disease, 
including suppressing the immune response in order to prevent the immune cells 
from invading the CNS. The aims of the treatments are to reduce the symptoms, 
prevent progression and decreasing the number of relapses as well as reducing long 
term disabilities (60). There are three strategies that can be followed in treating MS, 
and a good treatment ideally should possess the characteristic of all three. The first 
strategy is to target the immune response by looking for something with an 
immunomodulatory effect that can reduce the activation of microglia and decrease 
the level of immune cells and their products in the CNS. The second is to enable the 
neuroprotection, which can reduce the damage of nerve fibres. The final strategy is to 
promote regeneration by inducing endogenous remyelination and maturation of 
oligodendrocytes (59). 
Currently most of the available therapies target the immune response in MS patients. 
The main treatments that are widely been used are β interferons (available as β1a and 
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β1b) and glatiramer acetate (60). The actual mechanism of β interferons that 
dampens the immune dysfunction is still not clear, however, it is believed that they 
might be related to suppression of T-helper cell response. Although they help to 
manage the progression of the disease, they come with some side effects such as 
worsening depression, possible liver toxicity as well as flu-like symptoms following 
injections; however these can be treated by acetaminophen and might disappear over 
a period of time (60). 
The other treatment, glatiramer acetate, is administered through a subcutaneous daily 
injection. Its mechanism of action is still not fully understood. Its efficacy is the 
same as that of β interferons, and it also has some side effects that include acute 
reactions on sites of injection such as inflammation and pain and systemic immediate 
post-injection reactions (60). The latter includes a number of symptoms such as 
facial flushing, chest tightness, dyspnoea and palpitations usually happens during the 
first couple of seconds or sometimes minutes following injection and can continue 
for 30 minutes (60). 
 
1.6 TAM receptors 
Growth factors are important modulators of differentiation, migration and growth, 
and act through activation of cell surface receptors known as receptor tyrosine 
kinases (RTKs). RTKs are a large family of homologous transmembrane proteins 
that share a conserved intracellular tyrosine kinase domain, whilst their extracellular 
domain differ between various subfamilies. In humans, the RTKs are classified into 
20 different sub-families based on their amino acid sequence identities and the 
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structure of their extracellular regions; therefore, members of a subfamily often share 
the same ligand (76, 77).  
The focus of this study is on the RTK subfamily comprising Tyro3, Axl and Mer 
(TAM). The extracellular region (N-terminal) of the TAM RTK sub-family is 
composed of two immunoglobulin (Ig)-like domains and two fibronectin type III 
(FNIII) domains. The intracellular region (C-terminal) is similar in all RTKs, 
containing a domain with interinsic tyrosine kinase enzymatic activity. Although the 
extracellular domains of RTK subfamilies are different, there are nevertheless some 
similarities shared amongst different sub-families. For example, the Ig-like domain is 
also found in platelet-derived growth factor receptors (PDGFR), whereas the FNIII 
domain is also present in the Eph RTK sub-family  (Figure 15) (77). Upon activation 
by the ligands, TAM receptors participate in a number of cellular processes including 
cell survival, proliferation, migration and phagocytosis (76, 77). 
 
Figure 15. The domain organisations of four RTK subfamilies including the TAM receptors (77). 
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The ligands for the TAM subfamily of RTKs are two vitamin K-dependent proteins, 
known as Gas6 (product of growth arrest-specific gene 6) and protein S, which is a 
negative regulator of blood coagulation. Both Gas6 and protein S share the same 
structural domains, containing an N-terminal that is composed of γ-carboxylglutamic 
acid residues (Gla domain), followed by four epidermal growth factor (EGF)-like 
repeats. In protein S, there is a loop region that contains thrombin-sensitive cleavage 
sites, between the Gla domain and EGF repeats, which is key to its role in blood 
coagulation, whereas this loop region is missing in Gas6, and hence Gas6 plays no 
role in regulation of blood coagulation. The C-terminal in both ligands comprises a 
globular sex hormone binding globulin (SHBG)-like region, composed of a pair of 
laminin G-like (LG) domains (Figure 16) (76, 77). The Gla region has the ability to 
form complexes with 7 to 8 calcium ions, which together allow the Gla region to 
interact with membrane phospholipids that have negative charges. In this manner, the 
Gla acts as the interface between Gas6 and protein S and apoptotic cells, which 
display negatively charged phospholipids on their outer membrane surfaces. The 
other special feature about the Gla region in Gas6 and protein S is that it is the part of 
these molecules which confers dependence on vitamin K. In the endoplasmic 
reticulum, glutamate residues in the Gla domain are post-translationally modified by 
an enzyme known as γ-glutamyl carboxylase, which requires vitamin K as its 
cofactor. This as γ-carboxylation in the N-terminal allows both Gas6 and protein S to 
bind to calcium ions and to form a certain 3D fold, which is also required in order for 
both proteins to activate TAM receptors. Thus in the presence of vitamin K blockers 
such as warfarin, the produced Gas6 or protein S are functionally ineffective (76-78). 
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Figure 16. Structural domains of Gas6 and Protein S and their binding to the TAM receptors. Gas6 
has been shown to bind to all three receptors of the family, whereas protein S is known to bind to 
Tyro3 (Sky) as well as Mer, but not to Axl (76). 
 
Interaction of TAM receptors and their ligands has widely been investigated and it is 
generally accepted that Gas6 phosphorylates all three receptors, whereas, protein S 
activates only Tyro3 and Mer (79-81). However, they do not have similar affinities 
towards different receptors, since Gas6 affinity for Axl is significantly higher than its 
affinity for Tyro3 and Mer (79, 82). Gas6 has lower affinity to Tyro3 compared to 
Axl, but Tyro3 might be the main receptor in the brain due to its high level of 
expression. Mer has the highest dissociation rate and lowest affinity for Gas6, 
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however, it may be the main receptor in some tissues and certain conditions (79, 82, 
83). 
 
1.6.1 Tyro, Axl and Mer 
Axl is a protein with 140 kDa molecular weight while is fully glycosylated, and 120 
kDa while partially glycosylated. It was first observed as an unknown gene in 1988 
when Liu et al. were trying to identify transformants in chronic myelogenous 
leukemia, and after a few years, the gene was characterised and called Axl (78). A 
few years later following Axl characterisation, the full human sequence for Tyro3 as 
a homologous gene for Axl was discovered after which a range of various names has 
been used to term the gene, including Brt, Rse, DTK, Tif, Sky and Tyro3. Axl and 
Tyro3 share the same genomic structure in human, which suggest very close 
conservation within the TAM receptors. Axl has a ubiquitous expression pattern and 
is observed in a wide range of organs and cell types, including epithelial and 
mesenchymal cells, cells with haematopoietic origins and non-transformed cells, but 
it is not expressed in lymphocytes and granulocytes. Both Axl and Tyro3 are 
expressed in many cell types during embryonic development, and Axl expression 
starts from day 12.5 followed by Tyro3 expression beginning on day 14 up until 
birth. Notably, expression of Tyro3 is highest within the brain, which suggests the 
involvement of Tyro3 in CNS development. During adulthood, Tyro3 expression is 
also high in the kidneys, ovary and testis (77). The third member of the family, Mer, 
was identified through its proto-oncogenic chicken orthologue, c-eyk. After cloning 
of the human proto-oncogene, based on its mRNA expression pattern it was named 
c-mer (monocytes, epithelial, reproductive tissues). At mRNA level, Mer is 
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expressed in peripheral blood monocytes as well as bone marrow. It is not present in 
normal B and T lymphocytes, but its gene is then switched on in neoplastic B and T 
cell types (77). Mer expression is predominantly in ovaries, testis, prostate, lungs and 
kidneys, with lower expression in the thymus, spleen, liver, small intestine as well as 
placenta (84). 
In many cell lines, once TAM receptors are activated by the ligand, this initiates a 
signalling pathway that involves amongst others activation of Akt kinase, which is 
part of the phosphoinositide 3 kinase (PI3K) pathway. In this signalling pathway, 
phosphorylation of the intracellular tyrosine kinase domain of the TAM receptor 
recruits and results in activation of PI3K, which in turn causes phosphorylation of 
Akt. In addition, TAM receptors are also capable of activating other kinases 
including phospholipase C, Ras and ERK1 and 2 MAP kinases. These signalling 
mechanisms that are regulated by TAM receptors can become activated in all TAM-
expressing cells. However, in macrophages, dendritic cells and other immune cells in 
particular, activation of the JAK/STAT signalling pathway can also be a main feature 
downstream of TAM receptors (85). 
 
1.6.2 Gas6 and protein S 
In humans and mice, protein S is encoded by the PROS1 and Pros1 genes 
respectively. Protein S is an anti-coagulant that is involved in breakdown of 
coagulation factors (F) Va and FVIIIa and also can inhibit coagulation by binding to 
FXa and FVa. It circulates in the plasma at a concentration of 346 nmol/L. In 
humans, 30% to 40% of protein S is in active form and the rest is in an inactive form 
that is bound to C4b-binding protein (C4BP). However, an interesting difference is 
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that in mice, C4BP lacks a β-chain, which is the region responsible for binding to 
protein S, and therefore in mice protein S is only found in free form in the plasma 
(84). 
In addition to its well-established anti-coagulation properties, a new function for 
protein S has recently been revealed, which shows protein S to contribute to anti-
inflammatory activities via initiating a negative feedback response on dendritic cells 
(DC). In response to pathogens, DCs, which are professional antigen presenting cells, 
become activated, a process followed by activation of T cells. However, 
overactivation of DCs must be controlled, since it can result in conditions such as 
allergy that is characterised by an over-reactive immune response. Protein S has the 
ability to regulate the activation of DCs through being secreted by T cells that are 
activated in response to DC activation. The released protein S binds to TAM 
receptors on the surface of DCs and inhibits their further activation in a negative 
feedback manner, ultimately resulting in reduced inflammation (86). 
Gas6 is a 75 kDa protein, which shares 42% amino acid sequence identity with 
protein S. Its concentration in the plasma is about 20-50 ng/ml (around 0.25 nmol/L), 
which is much lower than other vitamin K-dependent proteins, although in severe 
sepsis patients it can be upregulated up to 110 ng/ml. In contrast to other vitamin K-
dependent proteins (i.e. most blood coagulation regulators, including protein S), 
Gas6 production in liver is very low, but it is instead expressed at high levels in the 
heart, kidneys and lungs. At the tissue level, Gas6 is expressed in endothelial cells, 
vascular smooth muscle cells as well as bone marrow (84). 
In 1988, the gas6 gene was first identified as one of several genes that were 
upregulated in growth arrested embryonic fibroblasts (87). A few years later in 1993, 
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the gas6 gene was sequenced and found to share 44% homology with protein S. 
Although the two proteins have similar structures, their tissue expressions differ, 
with Gas6 expression being very low in liver and more abundant in the heart, lungs, 
kidneys and intestine, whereas protein S is mainly expressed in the liver. Also, unlike 
protein S, no role in thrombin generation has been found for Gas6. Instead, the fact 
that Gas6 was found with its expression increased in growth-arrested cells suggests 
an involvement of Gas6 in cellular homeostasis. Other identified roles for Gas6 
include its involvement in sequestration and migration of leukocytes, platelet 
aggregation and haematopoiesis, proliferation and phagocytosis; and an overall 
association with conditions of injury, inflammation and repair (88).  
In the nervous system, Gas6 has been shown to induce a number of cellular processes 
such as chemotaxis, mitogenesis, cell growth and myelination, each occurring as a 
result of Gas6 binding to a specific TAM receptor. For instance, Gas6 protects 
gonadotropin-releasing hormone (GnRH) neurons from undergoing apoptosis, a 
function achieved through ERK and PI3K/Akt pathway signalling. In addition, 
activation of ERK via Gas6 leads to migration of GnRH neurons from the olfactory 
bulb to the hypothalamus. Gas6 has also been shown to protect cortical neurons from 
undergoing amyloid β protein-induced apoptosis by inhibiting Ca2+ invasion into the 
cell. In addition, Gas6/TAM signalling can have a pro-survival effect via MAPK and 
PI3K/Akt pathways (89). Significantly, as well as neurons, Gas6 can also regulate 
glial cell function, including oligodendrocytes, Schwann cells and microglia. It has 
been shown to protect oligodendrocytes from TNF-α toxicity as well as enhancing 
their survival from apoptosis via the PI3K/Akt pathway (89). 
Nowadays, there are knockout animals available for each of the TAM receptors, 
Gas6, as well as triple knockout of all three receptors and double knockout (e.g 
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Tyro3 and Axl) that can be purchased and used in research. They are summarised in 
Table 1 below. 
 
Table 1. A summary of knockout animals for TAM receptors and Gas6. 
Type of knockout 
mice 
Phenotype 
Tyro3 -/- Enhanced type 2 immunity (90). Impaired formation of 
myelin segments in Schwann cells (91). Inhibition of 
synovial hyperplasia and bone damage in arthritis (92). 
Axl -/- Leads to exaggerated lung inflammatory disease upon 
influenza infection (93). Enhanced inflammation in the CNS 
and delayed removal of myelin debris during EAE (94). 
Mer -/- Enhanced local and systemic inflammatory responses (95). 
Inefficiency in clearing the dead cells (96). Impaired 
phagocytosis (97). 
TAM triple -/- Developing a severe lymphoproliferative disorder 
accompanied by broad-spectrum autoimmunity (98), they 
exhibit systemic autoimmune diseases, with characteristics 
of increased proinflammatory cytokine production, 
autoantibody deposition and autoreactive lymphocyte 
infiltration into a variety of tissues (99). Depletion of 
spermatogonia, spermatocytes, spermatids and mature 
sperms from seminiferous tubules, as well as loosing 
photoreceptors in retinae, by three month after birth (96, 
100, 101). Development of a spontaneous liver disease 
(102). 
Axl/Tyro3 double -/- Exhibit a selective loss of GnRH neurons, delayed sexual 
maturation and irregular estrous cycles (103). 
Gas6 -/- Altered GnRH neuron migration, delayed vaginal opening 
and sexual maturation in mice (104). Also, EAE mice 
exhibit higher clinical scores, with significantly increased 
axonal swellings and microglia/macrophages, enhanced 
expression of several proinflammatory mRNA molecules, 
and decreased expression of early oligodendrocyte 
maturation markers, as well as increased macrophage 
infiltration in the spinal cord (105). Also, greater 
demyelination in cuprizone model, as well as increased loss 
of oligodendrocytes and microglial activation (72). 
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1.6.3 Role of Gas6/TAM signalling in de/remyelination 
In the past few years, scientists have started to work on the effect of Gas6 on 
protecting oligodendrocytes during demyelination and its stimulatory effect on 
remyelination, and the effect of Gas6 on myelin production in demyelination models 
has become a focus of interest. The absence of Gas6 (Gas6 knockout mice) in a 
cuprizone-induced demyelination model has been shown to reduce oligodendrocyte 
survival, greater cell loss, less myelinated axons as well as a decrease in overall 
myelination (106, 107). The first clue about the role of Gas6 on oligodendrocyte 
survival was reported in 2003 by Shankar et al. (108). In an attempt to identify 
growth factors involved in oligodendrocytes development, they used microarray 
analysis to study RNA samples isolated from O4
+
 oligodendrocytes at week 18 and 
22 of gestation, and as a result nine kinases were revealed including Axl and Mer, all 
of which were significantly upregulated during the peak of myelination in spinal 
cord. Therefore, they analysed the possible effect of Gas6 on oligodendrocyte growth 
and survival, and they observed that Gas6 supported the viability of human foetal 
oligodendrocytes through activation of the PI3K/Akt pathway. However, they did not 
identify the actual TAM receptor that was involved in this novel function of Gas6 
(108). Later, the action of Gas6 on oligodendrocytes was investigated in a cuprizone 
demyelination model, in which demyelination occurs in the absence of infiltration of 
the adaptive immune system and therefore is also T cell independent (109). When 
Gas6 knockout mice were treated with cuprizone for 3 weeks to induce 
demyelination, both myelination and activation of microglia were altered, and 
compared to wild-type animals fewer numbers of oligodendrocytes were observed in 
the corpus callosum that was in parallel with decreased myelination and less 
myelinated axons, as well as increased activation of microglia (72). Axl knockout 
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mice were also subjected to cuprizone, but no significant loss of oligodendrocytes 
were observed compared to wild-type animals; however, a reduction in myelination 
was observed after six weeks of cuprizone challenge (110). These different results in 
the rate of oligodendrocyte survival in the absence of Gas6 compared to the absence 
of Axl, suggest that either Axl is not the main receptor involved in oligodendrocyte 
survival (and therefore Tyro3/Mer is), or the loss of signalling through one receptor 
(Axl) is less effective than the loss of signalling through all three TAM receptors, 
such as with the absence of Gas6 (111). 
The next step was to investigate the effect of Gas6 on remyelination. It has been 
shown that in Gas6 knockout mice, remyelination was delayed after cuprizone-
induced demyelination, which featured a reduction in the number of 
oligodendrocytes. Gas6 has also been shown to induce myelination in vitro (112). 
Gas6 was also tested in experimental autoimmune encephalomyelitis (EAE), which 
is a model of autoimmunity with pathologic features that are very close to MS. 
During EAE, the BBB is disrupted and as a result immune cells, including T cells 
and monocytes, infiltrate the CNS and increase inflammation, ultimately leading to 
demyelination and axonal damage. During the course of EAE, direct 
intracerebroventricular administration of Gas6 protein did not delay the onset of the 
disease but resulted in a significant reduction in the clinical scores and was protective 
during peak and chronic EAE. Also, mice receiving Gas6 during the course of EAE, 
showed significantly fewer axonal swelling and less demyelinated areas compared to 
control. In addition, in the absence of Gas6 more immune cells infiltrated the CNS 
(105). In addition to the MS animal models, Gas6 concentration was also measured 
in cerebrospinal fluid (CSF) of MS patients, and was found to be slightly higher in 
patients that were suffering a first relapse of the disease than in control. However in 
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patients with more severe relapse, no increase in Gas6 concentration in the CSF was 
observed (113). 
Currently all the available treatments for MS are mainly focused on blocking the 
immune component of the disease (105). However, Gas6 is not only capable of 
reducing inflammation, but also has the ability to affect the other aspect of the 
disease, such as regeneration of the damaged areas. Thus, it is hypothesised that 
Gas6 can dampen inflammation as well as concomitantly increase oligodendrocyte 
survival, reduce axonal swelling and boost myelination in vitro as well as increasing 
remyelination in animal models of MS, all of which makes it an attractive 
consideration for novel therapeutic approaches for MS. 
In conclusion, studies on Gas6 during the past 15 years have pointed out the crucial 
role of Gas6 in cell survival, growth and process of myelination in the nervous 
system (89). 
 
1.7 Other RTK families involved in oligodendrocytes 
development and myelination 
The role of other RTK families in oligodendrocytes maturation and differentiation as 
well as myelination has also been studied. One of these families that recently has 
come into interest as potential regulator of myelination is the family of Eph receptors 
(114). The Eph family of proteins are one of the largest families of RTKs and are 
playing important roles in the formation of neural circuitry. This sub-family of RTKs 
is composed of Eph receptors and their ephrin binding partners (ligand), both of 
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which are membrane associated proteins (115). Therefoer, since ephrins are also 
attached to the cell membrane, the Eph receptors are considered as bidirectional 
signalling receptors, which has the ability to activate both forward and reverse 
signalling pathways. Forward signalling is occurring in cells containing the Eph 
receptor, via binding of the ligand to the receptor and consequently phosphorylation 
of the tyrosine residue, and reverse signalling is referred to signal transduction events 
that occur in cells containing ephrin upon binding of an Eph receptor (115-118).  
In a recent study, the effect of Eph-ephrin interaction on CNS myelination was 
evaluated, and was shown that Eph-ephrin forward and reverse signalling has distinct 
and opposite effects on the process of myelin sheet formation and extension (114). It 
was shown the forward signalling had no effect on oligodendrocytes differentiation, 
but activation of EphA forward signalling resulted in a reduction in the ability of 
oligodendrocytes to form complex branching networks and myelin sheets. On the 
other hand, reverse signalling via ephrin B was observed to be a positive regulator of 
myelination (114). 
Another family of RTKs, known as PDGF receptors (PDGF-R), has been shown to 
be effective in OPCs maturation and migration as well as myelination (119, 120). 
PDGF-AA, which is the ligand for PDGF-R, has been shown to a positive regulator 
of myelination (120). It also has been shown that Schwann cells can enhance OPCs 
proliferation and migration, which is induced via secretion of PDGF-AA by 
Schwann cells that subsequently binds to PDGF-R on OPCs membrane (119). 
 
  
 72 
1.8 Aims 
The overall aims of my PhD are to investigate: 1) the expression pattern of TAM 
receptors and Gas6 within the mouse CNS and throughout post-natal development; 
2) to determine the functional effect of Gas6 on OPCs/oligodendrocytes development 
and also on toxin-induced demyelination model; 3) to investigate the signalling 
mechanisms through which Gas6 induce its effects; and 4) to investigate whether 
vitamin K can be considered as a potential therapeutic agent for MS treatment by 
inducing the production of endogenous Gas6. These aims will be achieved by 
pursuing the following objectives: 
 
1.9 Objectives 
1. Expression: to determine the changes in the expression pattern of TAM 
receptors and Gas6 in the mouse CNS during development to find out if there 
is any overlap in the peak of TAM expression and peak of myelination at 
both mRNA and protein levels by using qPCR and western blotting. Also to 
characterise the specific TAM receptors in different types of glial cells using 
qPCR analysis. 
2. Oligodendrogenesis: to determine the functional effect of Gas6 on glial cell 
development particularly OPCs, in order to find out if addition of Gas6 to 
optic nerves will result in increasing the number of OPCs. Also using 
cerebellar slice culture to investigate whether Gas6 can block demyelination 
in an in vitro lysolecithin-induced demyelination model. 
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3. Signalling: to determine if STAT3 is a downstream intracellular target of 
TAM receptors activation by using optic nerve culture and western blotting. 
Also to analyse changes in genes involved in different aspect of MS 
progression with the effect of Gas6 in a microarray PCR analysis. 
4. Therapy: to determine whether intra-peritoneal injection of vitamin K will 
stimulate endogenous production of Gas6 and protein S, in order to find out if 
Gas6 function on OPCs development and de/remyelination can be induced in 
the CNS by treatment with vitamin K. 
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2.1 Animals 
C57/BL6 mice aged postnatal day 7 (P7), P14 and adults were used for 
developmental studies and 2-month old adults were used for ex vivo experiments 
using optic nerves and organotypic cerebellar slices cultures. Also, a transgenic 
mouse line was used in which green fluorescent protein (GFP) was expressed under 
control of the SOX10 gene promoter (121, 122). All experiments involving animals 
were approved by University of Portsmouth Ethics Committee and also by the Home 
Office Animals Scientific Procedures Act (1986). Animals were killed humanely by 
cervical dislocation, and brains were removed rapidly and placed in ice-cold saline or 
fixative prior to experiments. 
 
2.2 Cell culture 
2.2.1 Cultured human astrocytes 
Human astrocyte cerebellar (HA-c) were purchased from ScienCell Laboratories 
(1810; ScienCell; CA). Cells were cultured in astrocyte medium (AM; 1801; 
ScienCell) supplemented with 1% astrocyte growth supplement (AGS; 1852; 
ScienCell), 2% foetal bovine serum (FBS; 0010; ScienCell) and 1% 
penicillin/streptomycin (0503; ScienCell), Cells were kept at 37°C in an incubator 
with a humidified atmosphere of 5 % CO2 in air. Cells were plated on a 75cm
2
 (T75) 
flask, which were previously coated with poly-L-lysine (10 mg/ml; P9155; Sigma-
Aldrich; Poole). The next day after establishing the culture from cryopreserved cells, 
the medium was replaced to remove residual DMSO and unattached cells, the 
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medium was replaced every 3 days thereafter. Once the cells were about 70% 
confluent the medium was replaced every day until the cells reached 90% 
confluency. Then they were washed in PBS and were trypsinised using trypsin 
EDTA, and about 10% of cells were subcultured in poly-L-lysine coated T75 flasks. 
After re-plating, cells were grown and used once they were 80% confluent. The 
human astrocyte cerebellar could be subcultured for about 8 passages. 
 
2.2.2 Cultured human oligodendrocyte precursor cells 
(OPCs) 
Human oligodendrocyte precursor cells (HOPCs) were purchased from ScienCell 
Laboratories (1600; ScienCell). Cells were cultured in OPC Medium (OPCM; 1601; 
ScienCell) supplemented with 1% OPC growth supplement (OPCGS; 1652; 
ScienCell) and 1% penicillin/streptomycin solution (0503; ScienCell). Cells were 
kept at 37°C in an incubator with a humidified atmosphere of 5 % CO2 in air. Cells 
were plated on a T75 flask previously coated with poly-L-lysine (10 mg/ml). Cells 
were recovered after thawing as described above for HA-c, and the medium was 
replaced every 3 days thereafter. Once the cells were about 90% confluent, they were 
plated on 8-well chamber slides (154534; Thermo Fisher Scientific; Loughborough) 
coated with poly-L-lysine, cultured in OPC differentiation medium (OPCDM; 1631; 
ScienCell), supplemented with 1% FBS, 1% OPC differentiation supplement 
(OPCDS; 1672; ScienCell) and 1% penicillin/streptomycin solution. These cells 
could not be subcultured, therefore, could be used for only one single experiment. 
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2.2.3 Cell culture 
Human embryonic kidney 293 (HEK 293) and SNB-19 human glioma cells were 
cultured as previously described by us (123). Briefly, cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10 % foetal calf 
serum (FCS), 100 U/ml penicillin, 100 g/ml streptomycin and 2 mM L-glutamine 
(Lonza, Slough). Cells were kept at 37
o
C in an incubator with a humidified 
atmosphere of 5 % CO2 in air, and passaged once a week. Once cells were about 
90% confluent, they were washed in PBS 3 times, then were trypsinised using 
Trypsin EDTA. Then, a few drops of the cells were added to the new T75 flask or 
culture plate containing fresh culture media. 
 
2.2.4 Assessing antibody specificity 
The specificities of one Tyro3 antibody (1:200; PAS-22999; Thermo Fisher 
Scientific) and one Axl antibody (1:50; AF154; R&D Systems; Abingdon) were 
tested using human cell lines. HEK293 cells, SNB-19 and human cerebellar 
astrocytes were plated on eight well chamber slides (154534; Thermo Fisher 
Scientific). Once the cells were roughly 90 % confluent, they were fixed and used in 
immunohistochemistry following standard protocol. HEK293 cells were used as 
negative control as they do not express Axl and Tyro3 (personal communication with 
Dr S.Hafizi), while SNB-19 cells were used as positive control as they express both 
Axl and Tyro3 (124). 
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2.3 mRNA preparations 
For gene expression analysis in pure human glial cell cultures, HA-c and HOPCs 
were plated in six well plates pre-coated with poly-L-lysine. Once they reached about 
90% confluence, total RNA was extracted using GeneJET RNA purification kit 
(Thermo Fisher Scientific). For gene expression analysis in mouse brain, total RNA 
was extracted from mouse tissues (cortex and cerebellum of different ages (P7, P14 
and adult) and adult optic nerve). All the extracted total RNA samples were reverse 
transcribed using a first-strand cDNA synthesis kit (NanoScript RT; Primerdesign, 
Southampton) prior to use in real-time quantitative PCR (qRT-PCR) analysis. 
 
2.4 Real-time quantitative PCR 
All cDNA samples for gene expression analysis were included into a sample mix 
containing specific primers and probes (Integrated DNA Technologies; 
Interleuvenlaan, Belgium), and a qPCR master mix (FastStart Essential DNA Probes 
Master; Roche; Burgess Hill). Also, cDNA from cultured optic nerves was analysed 
for expression of 84 MS-related genes in a qPCR mini-array format (RT² Profiler™ 
PCR Array Mouse Multiple Sclerosis; PAMM-125Z; Qiagen, Hilden, Germany). 
The human samples were normalised to expression of GAPDH as housekeeping 
gene, whilst mouse samples were normalised to Cdc40. The data from mouse tissues 
at different ages were analysed using the relative standard curve method, and the data 
from human cell cultures and from optic nerves in qPCR mini array were analysed 
based on the 2
-ΔΔCt
 method, where ΔCt is CtTarget gene – Cthousekeeping gene and ΔΔCt is 
ΔCtGas6 – ΔCtMock and 2
-ΔΔCt
 shows the fold up/downregulation, where values >1 are 
 79 
upregulated and <1 are downregulated (125). The PCR mini-array contains 84 
different genes involved in different aspects of the disease including myelination, T-
cell activation and signalling, adaptive immunity, inflammation, apoptosis. 
 
2.5 Assessment of reference gene stability 
In order to choose an appropriate internal control gene for gene expression analysis, 
the expression of 12 commonly used housekeeping genes was examined using RNA 
extracts from various mouse brain regions including cortex and cerebellum at 
different ages, P7, P14 and adult. A commercial kit containing all 12 housekeeping 
genes was purchased (geNorm 12 gene kit for mouse; ge-DD-12; PrimerDesign). All 
the samples were tested in qPCR using all the 12 housekeeping genes. The data from 
the qPCR experiment were analysed using the qbase
PLUS
 software and the stability of 
the genes were compared between different brain regions and between various ages, 
and based on the data acquired from the software, the most stable housekeeping 
genes were identified. 
 
2.6 Western blotting 
Total protein extracts were obtained from fresh brain regions from mice at P7, P14 
and adult ages, as well as from cultured optic nerves, using lysis buffer composed of 
50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% NP-40, 1 mM EDTA, 10 
mM Na4P2O7, pH 8.0. The extracts were loaded in equal total protein amounts on a 
10% SDS-polyacrylamide gel and proteins were separated by electrophoresis as 
previously described (SDS-PAGE) (126). Separated proteins were then were 
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transferred to a polyvinylidene fluoride membrane (PVDF; Immobilon-P; Millipore; 
Watford). Membranes were first blocked in 3% non-fat dry milk (for normal 
antibodies) or 3% bovine serum albumin (for phospho-specific antibodies) in 25mM 
Tris, 150mM NaCl, 0.05% Tween-20, pH 8.0, for 1h at room temperature (RT), after 
which they were incubated at 4°C overnight with primary antibodies. The primary 
antibodies and their dilutions were: anti-Tyro3 (1:500; C-20), anti-Axl (1:500; C-20), 
anti-GAPDH (1:500; V-18) (Santa Cruz Biotechnology; Heidelberg; Germany), anti-
actin (1:10000, A2066; Sigma-Aldrich) anti-phospho-STAT3 (1:500; Cell Signalling 
Technology; Leiden; Netherlands), anti-phospho-Tyro3 (anti-phospho-MER/SKY; 
1:1000; Phospho-Tyr749/681 Abbexa; Cambridge), and anti-myelin basic protein 
(MBP; 1:500, MAB386; Millipore; Darmstadt; Germany). All antibodies are 
summarised in table 2 below. Post-incubation washing of the membrane (25 mM 
Tris-HCl, 150 mM NaCl, 0.05% Tween-20, pH 8.0) was followed by 1h incubation 
with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000; 
Promega; Southampton; Dako; Denmark) at RT. Chemiluminescence detection 
reagent (Luminata Forte Western HRP Substrate; Millipore; Watford) was used to 
generate the signal and bands were visualised using a CCD-based digital gel imaging 
system (ChemiDocTM MP Imaging System; Bio-Rad; Hemel Hempstead). The 
intensity of each band was quantified by densitometry using ImageJ software (127), 
and query protein band intensities were normalised against those of GAPDH or actin 
protein in each sample. 
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Table 2. List of antibodies used in western blotting. 
 
2.7 Optic nerve culture 
Mouse optic nerves were isolated and established in culture for several days as 
previously described (128). Briefly, two month old transgenic Sox10-GFP or 
wildtype mice were killed by cervical dislocation, and optic nerves were removed 
while still attached to the eyeball and immediately placed in ice-cold artificial 
cerebrospinal fluid (aCSF). The tissue was placed onto semiporous membrane inserts 
(0.4 µm; Millipore) and covered with 2ml culture medium containing 50% Opti-
MEM
TM
, 25% horse serum, 25% Hanks Balanced Salt Solution (HBSS) (Gibco 
Invitrogen; Paisley), supplemented with 25 mM D-glucose (Sigma), and antibiotics 
(Penicillin G sodium 10,000 U/mL, streptomycin sulfate 1,000 µg/mL; Gibco 
Invitrogen) diluted to 1:500, in a six-well culture plate. For experiments, 
recombinant Gas6 protein (diluted in cell culture medium containing Dulbecco’s 
Antibody 
 
Company Source Dilution 
anti-Tyro3 Santa Cruz Biotechnology 
 
Goat 1:500 
anti-Axl Santa Cruz Biotechnology 
 
Goat 1:500 
anti-GAPDH Santa Cruz Biotechnology 
 
Goat 1:500 
anti-actin Sigma-Aldrich 
 
Rabbit 1:10000 
anti-phospho-STAT3 Cell Signalling Technology 
 
Rabbit 1:500 
anti-phospho-Tyro3 Abbexa 
 
Rabbit 1:1000 
anti-MBP Millipore 
 
Rat 1:500 
anti-Rabbit HRP Dako 
 
Swine 1:5000 
anti-Goat HRP Dako 
 
Rabbit 1:5000 
anti-Rat HRP Dako 
 
Rabbit 1:5000 
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Modified Eagle Medium, supplemented with 10% FCS, 100 U/ml penicillin, 100 
μg/ml streptomycin and 2 mM L-glutamine; Lonza, Slough) in the presence or 
absence of specified Gas6 antagonists (Axl/Fc; R&D Systems; and warfarin Gas6 
(produced in-house)) was added directly to the culture medium at 400 ng/ml final 
concentration, and Axl antagonist BGB324 (gift of BergenBio; Bergen, Norway) was 
used at a concentration of 1 µM as reported by our group (Vouri et al, 2015). The 
cultures were incubated for 3 days, or for 3 h in signalling activation experiments. 
Cell culture medium alone was used as mock treatment and this medium was exactly 
the same as medium in which Gas6 was present (Vouri et al. 2015). The culture 
medium and treatments were replenished on the second day of incubation. After 3 
days, optic nerves were detached from the eyeball and the tissue processed for either 
western blotting or qPCR, and samples from Sox10-GFP mice were fixed (4% 
paraformaldehyde (PFA), 15% picric acid) for 1 h at RT, prior to whole mounting on 
slides in mounting medium (Vectashield; Vector Labs; Peterborough), followed by 
confocal microscopic examination of Sox10+ cells. A control for toxicity was not 
included in the experiment where two different typs of Gas6 antagonists were tested, 
since each of them were controls for each other and neither caused toxicity when 
Sox10+ cells were observed. 
 
2.8 Organotypic brain slice culture 
Sagittal sections of 300 μm thickness were made from cerebellum of C56/BL6 mice 
at ages P8-12, using a tissue chopper (Campden Instruments, Loughborough). The 
sections were placed onto semiporous membrane inserts (0.4 µm; Millipore) and 
covered with 1ml culture medium composed of 50% Minimum Essential Medium 
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with Glutamax-1, 18% Earle’s Balanced Salt Solution (EBSS), 5% EBSS + D-
glucose, 1% penicillin-streptomycin and 10% horse serum (Gibco Invitrogen) (129). 
The slices on the membrane inserts were placed in a six-well plate and maintained at 
37
o 
C in a humidified atmosphere with 5% CO2, for a total of 7 days. After 3 days in 
culture, the slices were either treated with Gas6 for 3 h to investigate signalling 
mechanisms, or in separate experiments to induce demyelination, on day 3 of 
incubation, the medium was replaced with fresh media containing 1mg/ml 
lysophosphatidylcholine (LPC; lysolecithin; Sigma) or methanol as vehicle. In order 
to investigate the effect of Gas6 on demyelination, 400ng/ml of recombinant Gas6 in 
conditioned culture medium, and mock medium as control, were added to the same 
wells as the LPC treatments. All treatments with LPC were incubated further for 24 
h, following which the medium was removed and the slices were incubated for 
another 3 days in fresh medium in the presence of freshly added Gas6 or mock 
treatments. Symmetrical cerebellar sections were used for direct comparisons 
between mock and Gas6 treatments. MBP immunofluorescent staining was then 
performed on the sections and analysed by confocal microscopy. For quantification 
of myelination, the numbers of complete myelinated axons of length greater than 50 
µm were counted for each treatment using ImageJ software. The values were 
converted to percentages and normalised against the values for vehicle-treated 
sections. 
 
2.9 Immunofluorescence confocal microscopy 
Cell counts of Sox10-GFP-positive oligodendrocytes/OPCs in optic nerves were 
performed on images taken with a laser scanning confocal microscope (Zeiss LSM 
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710; Cambridge). z-stack images were taken from each optic nerve with dimensions 
of 212.34 μm × 212.34 μm in the x- and y-plane and 70 μm in the z-plane at 10 μm 
intervals. The values of cell counts represent the mean (±SEM) % cells per field of 
view (FOV). 
Cerebellar sections were fixed in 4% PFA overnight, then blocked for 1 h in 20% 
normal horse serum diluted in TBS-TX (41.9 mM, Tris HCl, 8 mM Tris base, 154 
mM NaCl, 4.6 mM Triton-X). The sections were then incubated overnight with 
primary antibodies diluted in TBS-TX at the following dilutions: anti-MBP (1:300; 
MAB386; Millipore), anti-APC (5ug/ml; Ab-7; Millipore), anti-NeuN (1:250; 
MAB377; Millipore), anti-GFAP (1:400; AB5541; Millipore). The next day, after 
washing with TBS-TX, the slices were incubated with the secondary antibodies 
(1:1000; Thermo Fisher Scientific) diluted in TBS-TX buffer for 2 h at RT. All the 
primary and secondary antibodies used in immunostaining are summarised in table 3 
below. 
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Table 3. List of antibodies used in immunostaining. 
 
 
2.10 Statistical analyses 
Animals were randomly assigned to treatment groups. All results are expressed as 
mean ± SEM, with each experiment performed a minimum three times, using 
multiple replicates per treatments. Differences between multiple treatments in optic 
nerve cultures and organotypic cerebellar slice culture were compared using one-way 
Antibody 
 
Company Source Dilution 
anti-Tyro3 Santa Cruz Biotechnology 
 
Goat 1:50 
anti-Tyro3 Thermo Fisher Scientific 
 
Rabbit 1:200 
anti-Axl Santa Cruz Biotechnology 
 
Goat 1:50 
anti-Axl R&D Systems 
 
Goat 1:50 
anti-phospho-STAT3 Cell Signalling Technology 
 
Rabbit 1:50 
anti-MBP Millipore 
 
Rat 1:300 
anti-APC Millipore 
 
Mouse 5ug/ml 
anti-NeuN Millipore 
 
Mouse 1:250 
anti-GFAP Chemicon International 
 
Chicken 1:400 
Kv2.1 NeuroMab 
 
Mouse 1:1000 
Tuj1 Millipore 
 
Mouse 1:300 
anti-Goat 488 Santa Cruze Biotechnology Donkey 
 
1:1000 
anti-Rat Cy3 Jackson Immunoresearch Donkey 1:1000 
anti-Chicken 488 Jackson Immunoresearch Donkey 1:1000 
anti-Mouse 488 Invitrogen Donkey 1:1000 
anti-Mouse Cy3 Jackson Immunoresearch Donkey 1:1000 
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ANOVA followed by Bonferroni post-hoc test and comparison between two groups 
was carried out using un-paired Student t-test. A P-value of less than 0.05 was 
considered to be statistically significant. All statistical analyses were performed 
using the software SPSS Statistics 20 (IBM) or Prism 6 (GraphPad Inc; La Jolla; 
CA). 
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3.1 Introduction 
3.1.1 Expression of Gas6 and TAMs throughout the body 
The expression of TAM receptors at mRNA level has widely been investigated at 
embryonic stages. It has been shown that during embryonic development, the 
absence of all three receptors does not affect the process of development, and the 
animal is born without developmental defects (100, 130-132). However, in adult 
mice the absence of TAM receptors results in the development of a range of various 
phenotypes in many organs and tissues, which indicate some of their significant 
cellular functions (130). 
During adulthood, all three receptors of the TAM family are widespread throughout 
the body, each of them showing unique expression patterns, however with some 
overlap in these patterns. The nervous system is the tissue in which Tyro3 is most 
abundantly expressed, whilst it is also expressed in other organs including ovaries, 
testis, breast, lung, kidneys, osteoclasts and retina, as well as a number of 
hematopoietic cell lines such as monocytes/macrophages and platelets (81, 130, 132-
136). Axl has a ubiquitous expression pattern, which within the nervous system is 
notably apparent in the hippocampus and cerebellum (130, 137). It is also expressed 
in monocytes/macrophages, platelets, endothelial cells, heart, skeletal muscle, liver, 
kidney and testis (130, 133, 138, 139). Mer is mostly expressed in haematopoietic 
cells, including monocytes/macrophages, dendritic cells, natural killer (NK) cells, 
megakaryocytes and platelets (130, 133, 140, 141). In addition, Mer is also expressed 
in ovaries, prostate, testis, lung, retina and kidneys at high levels, and in heart, brain 
and skeletal muscle at lower levels (81, 130, 141). 
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In addition to their natural expression in the body, all 3 TAM receptors have been 
found to be overexpressed in various cancers, including breast, lung, colon, liver, 
gastric, kidney, ovarian, uterine and different types of brain cancers. However, there 
may be some distinction in their overexpression patterns depending on the specific 
disorder; for example, Mer is present whereas Axl is not in lymphoid leukaemia 
(130, 139, 141). 
 
3.1.2 Expression of TAMs and Gas6 in the CNS 
Among the many functions of RTKs, one of these is in the development of the 
nervous system. For instance, one of the RTK sub-families that has been well 
characterised the best in the nervous system is the family of trks and their ligands, 
which are involved in the regulation of neuronal number by enhancing survival of 
these cells (142). Another notable group is the Eph RTK subfamily for which ephrins 
are the ligands, and which have been shown to play crucial roles in CNS during 
injury and disease. Signalling through Eph receptors can inhibit regeneration of 
axons and also is an important regulator of astrocyte reactivity and glial scar 
formation (143). 
The main focus of this chapter is to investigate the expression patterns of TAM 
receptors and their common ligand Gas6 in the CNS and throughout development, 
and to identify the specific glial cells that express each receptor. Identifying the 
expression pattern on specific cell lines can help us to reveal the potential signalling 
inter-relationships that can take place utilising the Gas6-TAM pathway amongst 
different cell types in the CNS. 
Each member of the TAM family of receptors has been designated various names 
due to its first or concurrent identification by different research groups. For example, 
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UFO, Tyro7 and Ark are other known names for Axl; Mer is also known as Tyro12, 
eyk and Nyk; Tyro3 has also been called etk2, Dtk, brt, Rse, sky and tif (142). In this 
thesis, we refer to each TAM member by its most commonly used name today. 
In situ hybridisation and northern blot analysis using adult rodent brain have revealed 
a high level of Tyro3 mRNA expression, with the highest expression observed in the 
olfactory bulb, the piriform cortex, tenia tecta, the subiculum and the granule neurons 
of the cerebellum. Tyro3 mRNA was also detected in the cortex, mostly in layers II-
VI, and in the hippocampus, primarily in CA1 and to lesser extent in CA3 region. 
When it comes to Axl and Mer, their expression was found to be present at low 
levels in the CNS (144). 
Northern blot analysis of Gas6 has also revealed its expression pattern during 
development. Within the CNS, Gas6 mRNA is first expressed in the spinal cord in 
the first born motor neurons at E14; at this stage it was also expressed in dorsal root 
ganglia, although to a lesser extent compared to spinal cord. At E14, in situ 
hybridisation in the brain has shown that Gas6 was mainly expressed in the blood 
vessels. In adult rat, Gas6 mRNA was expressed in different cellular layers of the 
olfactory bulb (144). In the cerebellum at P3 when granule neurons are undergoing 
active proliferation, Gas6 was not observed in the external granule cell layer at both 
mRNA and protein levels, but was observed in Purkinje neurons and in deep 
cerebellar nuclei. At later stages of development during P8, Gas6 was still high in 
Purkinje neurons and very low or near background expression level in the granule 
neurons. During adulthood, Gas6 expression in Purkinje neurons remains high, 
whereas in the granule cell layer it is low but detectable (144). In the hippocampus, 
at P3 the expression of Gas6 was mostly observed in pyramidal neurons within the 
CA3 region at mRNA level, whereas in dentate gyrus, very little or no expression 
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was observed. In the adult hippocampus, Gas6 was highly expressed in the pyramidal 
neurons of CA1 and CA3 regions as well as dentate gyrus. In the adult rodent CNS, 
as well as cortex, cerebellum and hippocampus, Gas6 is also expressed in various 
brain regions, including the third ventricle, choroid plexus, optic tract and so on 
(144). 
With the receptors, during embryonic development at E14, Tyro3 expression was 
generally low in the brain overall although high in certain regions, with the highest 
signal detected in the olfactory neuroepithelia of the nasal cavity. In contrast, at E14, 
Axl and Mer were not observed within the neural tissues themselves but they were 
highly present in the mesenchyme that surrounded neural structures undergoing 
development (142). In the adult brain, Tyro3 mRNA is highly expressed in the 
olfactory bulb, piriform cortex, in which Gas6 is also expressed at high levels, as 
well as all cortical layers (142, 144). 
During development, the expression of Tyro3 is very low at early stages of postnatal 
development, and between P3 and P15 its level increases significantly, which reaches 
the maximum at P24 in the fourth week of postnatal development and remains at that 
level during adulthood. In contrast to Tyro3, Axl remains low at all stages (142). In 
the cerebellum, at P3, all the TAM receptors are expressed in the deep cerebellar 
nuclei, but in the internal granule cell layer, only Tyro3 is expressed. At P14, 
expression of all three receptors is detected in the presumptive white matter, and at 
this stage Axl and Mer are highly expressed in Purkinje neurons. During adulthood, 
expression of Tyro3 is high in the granule neurons and expression of Axl and Mer 
remain at high level in the Purkinje cell layer (142). 
In general, Tyro3 is more abundantly expressed in the CNS when compared to Axl 
and Mer, which suggest that Tyro3 could be the main receptor involved in Gas6 
 92 
signalling within the CNS. Prior to this study, in the brain, Tyro3 has been shown to 
be very high in the cerebellum, cerebral cortex and hippocampus. The other members 
of the TAM family, Axl and Mer, were mostly observed in Purkinje neurons of the 
cerebellum and in presumptive white matter oligodendroglia. Although a previous 
study indicated that Gas6 is most likely expressed in neurons (144), the TAM 
receptors appear to be present in both neurons and glial cells; in the rat CNS white 
matter, the expression of Tyro3 has clearly been shown in oligodendrocytes at 
protein level (142). Therefore, as Tyro3 is also expressed in these cells, the glial cells 
could be the most prominent sites in which all the TAM receptors are functional 
(142). 
Expression of Gas6 in adult was also explored as a matter of ageing. Synaptosomes 
from the striatum, hippocampus and frontal cortex were used to study the expression 
pattern of Gas6 in rat at three different ages, 6 months, 12 months and 24 months. 
Reduction of Gas6 during ageing was shown to be in a tissue-specific manner. The 
decrease in the level of Gas6 was most significant in the frontal cortex; here, the 
level of Gas6 in the 24 month old rat was reduced by more than 84% compared to the 
6 month-old animal. In the other two regions tested, striatum and hippocampus, the 
reduction in the Gas6 level was about 55% (145). 
In terms of its biological role, Gas6 is implicated in a wide range of functions within 
the nervous system. For example, it is involved in chemotaxis, mitogenesis, cell 
growth as well as myelination. All of theses functions are achieved via Gas6 binding 
and activation of TAM receptors. Gas6 inhibits serum deprivation-induced apoptosis 
of GnRH neurons through activation of ERK and PI3K/Akt signalling pathways. In 
addition, Gas6-Axl was shown to play a part in migration of GnRH neurons from the 
olfactory bulb towards the hypothalamus (106). Aside from the CNS, Gas6 has also 
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been shown to induce Schwann cell growth, which could be effected via Tyro3 
and/or Axl (146, 147). 
The aim of the work in this chapter is to investigate the expression pattern of TAM 
receptors and Gas6 in the mouse CNS and to find out if they undergo significant 
changes during development. In order to do so, we analysed the expression of these 
proteins at both mRNA and protein levels, using extracts from the mouse cortex, 
cerebellum and optic nerve, obtained from different ages at P7, P14 and adult. An 
additional aim is to determine TAM expression as well as in pure human glial cell 
cultures, namely astrocytes and OPCs. Briefly, our results show that all three TAM 
receptors and Gas6 mRNA are expressed in both cortex and cerebellum at all ages; at 
the protein level, Axl and Tyro3 were present in all the brain regions tested, and at all 
ages, as well as in adult optic nerve. Furthermore, mRNA expression of all three 
TAMs was significantly increased with age in the cortex. At protein level, expression 
of Tyro3 was significantly higher in the cortex vs cerebellum in P14 and adult, 
whereas for Axl, it appeared to be higher in the cerebellum in P7 and P14. We also 
determined expression of the TAM receptors and Gas6 in human oligodendrocytes 
and astrocytes. My data revealed the very clear expression of Tyro3 in 
oligodendrocytes whereas Axl was absent in these cells. In contrast, Gas6 was highly 
expressed in astrocytes, but no Gas6 was observed in oligodendrocytes. Therefore, 
these data suggest that Tyro3 is most likely the main TAM receptor in 
oligodendrocytes. 
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3.2 Results 
3.2.1 Identification of the most stable reference gene for 
mRNA expression analysis of mouse CNS tissues 
In research, quantitative gene expression analysis in a variety of samples and tissues 
requires for the expression of the gene of interest (GOI) to be normalised against a 
carefully selected internal control, or “reference” or “housekeeping”, gene. As a 
major aim of this thesis was to determine the expression of genes in mouse CNS 
tissues, the approach was taken to first determine which gene, out of a selection of 
12, could be the most stable, and therefore the most appropriate, reference gene in 
mouse CNS for our planned subsequent qRT-PCR experiments. This approach was 
taken also to have extra certainty of the robustness of the data to be obtained, as the 
best reference gene would be determined for the very tissues to be analysed later for 
TAMs and Gas6. We analysed 12 commonly used housekeeping genes (included in a 
commercial kit) and determined their relative expression stability. In this pairwise 
method, the analysis was based on the principle that the expression ratio of two 
internal control genes is the same in all samples, regardless of the experimental 
condition or tissue or cell type. Therefore, in real life the variation of the expression 
of these two internal controls reflects the fact that one (or both) of the housekeeping 
genes is (are) not constantly expressed, and increasing the variation in the expression 
ratio corresponds to a reduction in expression stability. In this method, each 
housekeeping gene is paired with all other housekeeping genes, and the gene stability 
measure M is obtained as the average pairwise variation of one internal control gene 
with all other internal controls. (148). 
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The expression stability of each candidate housekeeping gene, including CSNK2A2, 
FBXW2, APX038, AP3D1, HCATSF1, GAPDH, 18S, ZFP91, PAK1IP1, MON2, 
CDC40 and ACTB, was obtained using the pairwise method. The values from the 
qPCR experiment for testing various housekeeping genes were analysed in qbase
PLUS
 
software to create a stability measure (M) (148). The genes were analysed in a 
number of different ways. The stability was compared (i) between various brain 
regions within the same age (Figure 17), or (ii) it was compared between different 
ages within the same brain region (Figure 18). We identified four different 
housekeeping genes for each group that appeared to be the most stable compared to 
others; these are shown in figures 17 and 18 below as well as table 4 and table 5. 
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Figure 17. Assessing the stability of various housekeeping genes between mouse cortex and 
cerebellum at different ages. Total mRNA was extracted from cortex and cerebellum from P7, P14 
and adult mice. The mRNA from all samples was used in qPCR to obtain the most stable 
housekeeping gene. For each age, four of the most stable internal controls were identified. The lower 
the M value, the more stable the gene. A) At P7, PAK1IP1, MON2, CDC40, ACTB appeared to be the 
most stable ones, and in B) P14, HCATSF1, CDC40, CSNK2A2, ZFP91 had the lowest M value, 
whereas in C) Adult, FEX038, ZFP91, MON2 and CDC40 were identified as the most stable 
housekeeping genes. 
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Figure 18. Assessing the stability of various housekeeping genes between different ages (P7, P14 and 
adult) in various brain regions. Total mRNA was extracted from cortex and cerebellum from P7, P14 
and adult mice. The mRNA from all samples was used in qPCR to obtain the most stable 
housekeeping gene. For each age, four of the most stable internal controls were identified. The lower 
the M value, the more stable the gene. In A) Cortex, AP3D1, HCATSF1, FBXW2, MON2 were the 
most stable genes, whereas in B) Cerebellum, HCATSF1, CDC40, CSNK2A2 and ZFP91 had the 
lowest M value. 
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Table 4. Most stable housekeeping genes in mouse CNS tissue. Stability was compared across cortex 
and cerebellum within ages. 
Groups Most stable genes in cortex and 
cerebellum 
P7 PAK1IP1, MON2, CDC40, ACTB 
P14 HCATSF1, CDC40, CSNK2A2, ZFP91 
Adult FEX038, ZFP91, MON2, CDC40 
 
 
 
Table 5. Most stable housekeeping genes in CNS tissues of mice at different ages. Stability was 
across ages within cortex and cerebellum. 
Groups Most stable genes across different Ages 
(P7, P14, Adult) 
Cortex MON2, FBXW2, HCATSF1, AP3D1 
Cerebellum HCATSF1, CDC40, CSNK2A2, ZFP91 
 
Among the genes identified in Table 1 and Table 2 as the most stable genes in 
different groups, CDC40 was selected as the ideal internal control gene, since it 
appeared in four of the groups out of five. 
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3.2.2 mRNA expression of Gas6 and TAM receptors in 
mouse CNS 
In order to obtain a comprehensive picture of the whole TAM RTK subfamily and 
Gas6 in the mouse CNS, qPCR was performed on mRNA from different regions of 
the CNS. In order to determine whether the expression of TAM receptors and Gas6 is 
altered throughout development, we performed qPCR to quantify their mRNA level 
in P7, P14 and adult mouse brain regions. Axl mRNA expression was lower in 
cerebellum in all ages when compared to cortex, however in the cortex Axl 
expression appeared to increase from P7 to adult. The other receptors of the family, 
Tyro3 and Mer, also appeared to increase in expression in the cortex during 
development. Within the cerebellum, Tyro3 was significantly higher in the adult 
cerebellum as compared to P7 and P14 cerebellum. We also analysed the expression 
of Gas6; no significant change was observed during development.  
In summary, TAM and Gas6 mRNA expression were detected in cortex and 
cerebellum of P7, P14 and adult mice and in adult optic nerve (Figure 19), and 
mRNA expression of all 3 TAMs increased significantly with age in the cortex but 
not in the cerebellum. It should be noted that we did not compare the relative 
expression of the different genes against each other (e.g. Axl vs Tyro3), since these 
values are arbitrary and are only used to denote relative expression within a sample 
set for only one and the same gene. This is due to the fact that the primer/probe sets 
for different genes will not have the same amplification dynamics in PCR and so 
cannot be comparable. Therefore, the qPCR expression data in Figure 19 is only 
valid for comparing between samples for one gene, and not for comparing between 
samples for different genes. 
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Figure 19. Expression of TAM receptors and Gas6 in different mouse brain regions and at different 
postnatal ages. qPCR expression analysis of mRNA for Gas6 and TAM receptors. Values represent 
mean ± SEM of relative gene expression; n=4 for all samples except for optic nerve (n=3) and P14 
cerebellum (n=2). All samples were normalised against Cdc40 as internal control; *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 for comparisons as indicated. Columns containing letter a are significant 
compared to cortex of the same age, and columns containing letter b are significant compared to 
cerebellum of the same age. 
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3.2.3 Protein expression of TAM receptors in mouse CNS 
We carried out western blot analysis of endogenous Axl and Tyro3 proteins in cortex 
and cerebellum extracts from P7, P14 and adult, as well as optic nerve from adult 
mice. In all the samples tested, Axl displayed a double band, one at 120 kDa and the 
other at 140 kDa, which reflects different levels of protein maturation and 
glycosylation in the cells of the tissue. However, only one band at 140 kDa was 
observed for Tyro3 in all the samples. We also tried to analyse whether these 
proteins undergo any significant change during development, and therefore all the 
Tyro3 bands and the lower bands for Axl were normalised to bands for GAPDH 
protein as loading control. These quantified data together indicate no significant 
difference in levels of Axl or Tyro3 proteins; however in P14 and adult cortex Tyro3 
appeared to be significantly higher when compared to cerebellum of the same age, 
whereas the opposite was true for Axl (Figure 20). 
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Figure 20. Western blot analysis of Axl and Tyro3 proteins in mouse CNS tissues. Both Axl and Mer 
are detected in extracts from all different mouse brain regions and ages. The lanes correspond to the 
following: 1) P7 cortex, 2) P7 cerebellum, 3) P14 cortex, 4) P14 cerebellum, 5) adult cortex, 6) adult 
cerebellum, 7) adult optic nerve. The graphs show the densitometric analysis of the bands. Values 
represent mean ± SEM of relative protein expression; n=4 for all samples. All samples were 
normalised against GAPDH as loading control; *P<0.05, ***P<0.001 for comparisons as indicated, 
student t-test. 
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3.2.4 Immunoflourecent staining of Tyro3 in the mouse 
CNS 
Not much data has been published about the expression pattern of TAM receptors 
and Gas6 within various regions of the CNS and different neuronal cells at protein 
level using IHC, due to unavailability of specific antibodies against these proteins. 
However we attempted to characterise the expression of these proteins in various 
regions of the CNS and different cell types using our antibodies, although we could 
not confirm the specificity of our antibodies, therefore our IHC results are 
inconclusive.  
As an example, we tried to characterise the expression of Tyro3 in various regions of 
the CNS and also in neurons. We double stained Tyro3 antibody (C-20, Santa Cruze 
(add dilution, cat number and company name to methods section)), with a specific 
cell membrane marker, Kv 2.1 (add details to methods section), and a neuronal 
marker, Tuj1 (add details in the methods section). Our results indicated the 
expression of Tyro3 in neurons within the dentate gyrus of hippocampus as well as 
the cortex, although these results are inconclusive (Fig 21).  
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Figure 21. Double immunofluorescent staining of Tyro3 (red) and CNS markers (green). Staining 
with (A) Kv2.1 in adult cortex; (B) Tuj1 in adult cortex; (C) Tuj1 in dentate gyrus of hippocampus 
(scale bar = 20 µm). 
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3.2.4 Expression of Tyro3, Axl and Gas6 in human glial cell 
cultures 
By using in situ hybridisation, the expression of TAM receptors and Gas6 in various 
regions of the CNS has been reported previously (144). Nevertheless, their presence 
on different types of glial cells remains unclear. To confirm their expression pattern 
exclusively in glial cells, we performed qPCR and immunohistochemistry studies. 
RNA extracts were obtained from cultured human cerebellar astrocytes and human 
OPCs/oligodendrocytes, and the expression of Tyro3 Axl and Gas6 was analysed at 
mRNA level. My data revealed the unique expression of Tyro3 on 
OPCs/oligodendrocytes, whereas Axl was absent on these cells. In astrocytes, both 
Axl and Tyro3 were present. There was no Gas6 expressed on oligodendrocytes, 
whereas Gas6 was substantially expressed in astrocytes.  
We attempted to perform western blot to confirm this unique expression pattern at 
protein level, but we were not able to extract sufficient amount of proteins from these 
cultures for western blotting. We therefore performed immunohistochemistry on 
these cell lines using antibodies against Tyro3 and Axl. Although signal was 
obtained, the specificity of the antibodies had not previously been reported. 
Therefore, we performed an experiment for antibody specificity and validity. One 
antibody against Tyro3 and one antibody against Axl were tested. The suppliers 
stated that both antibodies react with the mature forms of Tyro3 and Axl within 
mouse and human tissues. HEK-293 cells were used as negative control since they 
do not express Tyro3 and Axl (personal communication with Dr S.Hafizi), and SNB-
19 cells were used as positive control since they do express Tyro3 and Axl, as well as 
human cerebellar astroctyes. Both antibodies showed a positive signal in SNB-19 
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cells as well as in HEK293 cells, which confirm that both antibodies were not 
reliable for immunohistochemistry (Figure 22). 
 
Figure 22. mRNA expression of Axl, Tyro3 and Gas6 in human OPCs and astrocytes (A) and 
assessing the specificity of Axl and Tyro3 antibodies (B&C). A) In human OPCs almost no Axl was 
expressed, whereas the expression of Tyro3 was high. In astrocytes both Axl and Tyro3 were 
expressed. No Gas6 was present in OPCs, however it was highly expressed in Astrocytes. B) The Axl 
antibody showed a positive signal in HEK-293 cells as well as C) Tyro3 antibody. HEK-293 cells 
were used as negative control since they do not express any Axl or Tyro3. SNB-19 is the positive 
control, they express both Axl and Tyro3. In negative (-ve) control, the cells were not incubated with 
primary antibody and only secondary antibody incubation was performed. (Scale bar = 100μm).  
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3.3 Discussion 
The three homologous TAM receptors and their common ligand Gas6 are expressed 
widely throughout the body (149, 150). However, their expression profiles in the 
CNS, and their functional roles therein, remain to be comprehensively characterised. 
In the present study, we show that the mRNA for Gas6 and all three TAM receptors 
is present in the mouse brain, as well as Tyro3 and Axl at protein level, and that their 
expression increases during post-natal development as myelination progresses, 
reaching peak levels in the adult brain. In addition, we also showed the unique, and 
mutually exclusive, expression patterns of Tyro3 and Axl receptors, as well as Gas6, 
in pure cultures of human astrocytes and OPCs/oligodendrocytes. 
According to our gene expression analysis, all three TAM receptors and Gas6 were 
observed to be expressed throughout various brain regions analysed. In previous 
studies of the expression of these proteins in the CNS, Tyro3 was reported to be the 
primary TAM receptor mediating the actions of Gas6 in the CNS, since it was 
expressed in more regions and at higher levels compared to Axl and Mer (142). In 
addition, our observations that Tyro3 and Axl gene expression increases during 
development in the CNS are in line with previous time course expression data 
showing Tyro3 protein to be very low at embryonic stages whilst its expression 
begins to increase shortly after birth, dramatically increasing between postnatal days 
P3 and P15, reaching its peak level at P24, and remaining at that level thereafter in 
the adult (142). Although most myelination occurs early in life, myelination carries 
on at least into late adolescence and, in some regions of the CNS, may increase 
throughout much of adult life (46). Therefore, considering the unique expression of 
Tyro3 in oligodendrocytes and absence of Axl in these cells, we can surmise that the 
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concomitant temporal profiles of myelination and Tyro3 expression in the 
developing mouse CNS suggest that Tyro3 plays a role in oligodendrocyte 
development/maturation and myelination. 
Tyro3 has also been observed as the main TAM receptor in neurons of the CNS, with 
its highest expression in cortex and CA1 region of the hippocampus (142). However, 
up until now, there has been a lack of comprehensive studies revealing the 
expression pattern of TAM receptors and Gas6 in glial cells of the CNS, which 
therefore represented a gap in this area of research. Therefore, we attempted to 
analyse their expression in pure cultures of human glial cells, namely human OPCs 
and astrocytes, by qPCR analysis of Tyro3, Axl and Gas6 genes. We found Tyro3 to 
be highly expressed in cultured human OPCs, in which Axl expression was absent. 
This key finding therefore suggests that Gas6 acts directly on 
OPCs/oligodendrocytes via the Tyro3 receptor to affect their fate and/or function. In 
contrast, Tyro3 expression was low in astrocytes relative to OPCs, whilst Gas6 
expression was high in astrocytes; this therefore suggests an indirect and supportive 
role for astrocytes in regulating the fate and function of OPCs/oligodendrocytes, by 
providing the ligand through paracrine signalling. It can be argued that a direct 
comparison of the level Tyro3 or Axl between astrocytes and oligodendrocytes 
cannot be accurately made, as these are distinct glial cell types in culture and 
moreover are derived from different brain regions as well as different human brains. 
However, if the levels of Axl and Tyro3 are compared in the same cell line it can be 
concluded that Tyro3 is the main functional receptor in oligodendrocytes, since Axl 
expression is nearly zero in these cells. Furthermore, the expression of Gas6 in 
different neuronal cells including purkinje neurons, motor neurons of spinal cord as 
well as large DRG neurons has been reported previously (144, 147) which also 
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suggest the same indirect supportive role for neurones in regulating oligodendrocytes 
development and function. 
Our western blot analyses also showed that both Axl and Tyro3 proteins were present 
in all the brain regions tested. The expression of Tyro3 appeared to be higher in 
cortex compared to cerebellum in P14 and adult. In the Axl blot, a double band was 
observed at both 120 kDa and 140 kDa, which represent different levels of 
glycosylation of Axl, which is well known. In a study aimed at investigating the 
processing of full length Axl receptor, the two bands at approximately 120 kDa and 
140 kDa were reported (151). In this study, cell lysates of a secondary nude mouse 
tumour cell line were immunoprecipitated with a polyclonal antibody against the first 
Ig loop of Axl, which were then analysed by western blot. Several bands for Axl, at 
104, 120 and 140 kDa were observed; the smaller bands, 104 and 120 kDa, were 
shown to be unglycosylated and partially glycosylated forms of Axl and precursors 
of the full length receptor (151). In our results, the partially glycosylated form of Axl 
did not show a significant change during development, whereas the full length, fully 
mature, form of Axl appeared to be reduced from P7 to adult, particularly in the 
cortex. Also, unlike Tyro3, Axl appeared to be higher in cerebellum compared to 
cortex in P14 and adult. 
In addition to gene expression analysis, we also attempted to characterise TAM 
receptors and Gas6 protein in various brain regions and glial cells by 
immunofluorescence staining. However, the results were inconclusive due to our 
antibodies’ specificities not being confirmed for this method; indeed both Axl and 
Tyro3 antibodies showed a positive signal for the mouse proteins in human HEK293 
cells, which do not express these receptors. Although there are published data 
showing positive immunostaining of Tyro3 antibody in the Schwann cells and 
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neurons of the PNS (Figure 23) (91), no data were presented to confirm the 
specificity of the antibody used in that study. 
 
Figure 23. Positive immunostaining of Tyro3 antibody in Schwann cells and neurons of the PNS. 
This image is taken from a published paper. β Tubulin was used as a neuronal marker, and GFAP and 
S100β were used as Schwann cell markers in the PNS (91). 
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Chapter 4 
 
 
 
 
 
The effect of Gas6/TAM signalling 
on oligodendrogenesis and 
myelination 
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4.1 Introduction 
The effect of Gas6/TAM signalling specifically in glial cells has not been widely 
investigated. In 1996, Gas6 was shown to be a positive regulator of human Schwann 
cell proliferation as well as growth and survival (147). A couple of years after, Gas6 
was identified as a growth factor for human oligodendrocytes (108). The main focus 
of this chapter is to investigate the functional effect of Gas6 in the CNS and to 
measure the regulatory effect of Gas6 on glial cell development, in particular 
oligodendrocytes, using in vitro demyelination model. 
The OPCs that are produced throughout development in limited areas of the brain 
have a high migratory capacity and can populate different regions of the CNS to 
produce oligodendrocytes and myelinate the axons within the brain and spinal cord 
during the postnatal period. Some of these OPCs that are produced during 
development remain in the immature state and are slow proliferating or quiescent 
cells; these cells constitute 2-9% of total cells of the CNS (34). In case of 
demyelination, most of the oligodendrocytes are eliminated and the rest do not seem 
to be proliferating, and thus most likely are not contributing to remyelination and 
tissue repair. In contrast, other studies have shown that, following demyelination, the 
OPCs react and start to proliferate and increase in number, which then migrate to the 
lesion sites. During remyelination, the density of oligodendrocytes rises at the 
expense of numbers of OPCs, which indicates that the OPCs are ultimately 
differentiating into mature myelinating oligodendrocytes. For example, OPCs can 
generate myelinating oligodendrocytes in a toxin-induced demyelination model (34). 
As mentioned previously, remyelination usually occurs spontaneously at early stages 
of MS, although it is incomplete and as the disease develops into progressive stages, 
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remyelination completely fails. Most of the oligodendrocytes that are involved in 
remyelination are derived from resident OPCs that are widely distributed throughout 
the brain parenchyma (152). When demyelination occurs, the OPCs are stimulated 
and as a result, they start to proliferate faster and move to the lesion sites, where they 
contribute to tissue repair and myelin formation. In addition to the OPCs from brain 
parenchyma, neural stem cells (NSCs) from the subventricular zone (SVZ) can also 
contribute to remyelination. Following demyelination, NSCs are activated and start 
to proliferate and increase in number, which then travel to the nearby corpus 
callosum, and by undergoing oligodendrogenesis, they form myelinating cells and 
start to express myelin proteins. However, the contribution of NSCs to remyelination 
compared to OPCs is thought to be minor (152). Therefore, as the role of OPCs in 
particular, out of the various progenitor cell lines, seems to be key to the process of 
remyelination, it is important to study OPC development and identify the factors 
involved in this process in order to be able to induce their maturation for a successful 
remyelination. Therefore, one aim of this chapter is to investigate the possible 
regulatory effect of Gas6 on OPCs development in an in vitro culture model. In order 
to do so, we used optic nerves from Sox-10-EGFP transgenic mice in culture in order 
to evaluate the effect of Gas6 on OPCs development. Briefly, these data revealed that 
addition of Gas6 to the optic nerves resulted in a significant increase in the number 
of OPCs/oligodendrocytes. 
Currently most of the treatments for MS are anti-inflammatory agents that are aimed 
at decreasing the number of relapses in the patient. However, there are currently no 
neuroprotective treatments that can reduce progressive disability in patients. Thus, 
one strategy to induce neuroprotection is to improve the efficiency of remyelination 
and regeneration of axons, which can be achieved by testing various growth factors 
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in animal models of MS (153). Since MS is a very complex disorder, no animal 
model can capture the entire spectrum of heterogeneity of human MS and its variety 
in clinical and radiological presentation. Indeed, during the past few years, 
researchers have challenged the animal models for demyelination and have raised the 
question of whether these models are reliable since they do not represent all the 
aspect of the disease in human. For instance, in animal models the initiation of 
demyelination is highly artificial, and the time period for the onset of symptoms is 
different in animals compared to humans. In animals, the symptoms can be detected 
within weeks or days following the induction of the disease, whereas in humans the 
physiological processes of the disease are undetected for years prior the onset of the 
symptoms (154). Nevertheless, an animal model could still be useful for studying the 
development of the disease and identifying new therapeutic targets. 
Among all the animal models, three of the most popular ones are as follows: 1) 
experimental autoimmune/allergic encephalomyelitis (EAE), 2) viral induced 
models, 3) toxin-induced models of demyelination, using either cuprizone or 
lysophosphatidylcholine (lysolecithin) (154). EAE is one of the most commonly used 
models of MS, and represents the pathology and symptoms of the disorder in many 
ways, whilst also differing significantly in many other aspects of the disease. Most of 
our understanding about the autoimmune and the inflammatory process of the disease 
come from study of this model. EAE is a condition that is induced by immunisation 
of a mouse with injection of an antigen including proteolipoprotein (PLP), MBP, 
MOG, MAG as well as S100β (155, 156). It is mediated by T-helper (Th) cells, and 
involves the infiltration of the T cells and monocytes into the CNS (157). In the 
mouse, EAE was induced for the first time over 60 years ago (157, 158). Since then, 
a large number of encephalitogenic peptides have been discovered and mice are still 
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the most popular animal for the model due to the wide availability of various 
transgenic and knockout mice. EAE can be induced in different mouse strains; for 
example, in the SJL mouse it can be induced by immunisation with a number of 
myelin proteins including PLP, MBP and MOG. It also can be induced in other 
mouse strains, including C57/BL6, PL/J and B10.PL (157).  
In order to assess the effect of Gas6 on oligodendrogenesis, we used the optic nerve 
from adult Sox10–EGFP reporter mice, in which the reporter is expressed by 
myelinating oligodendrocytes, which make up the bulk of glia in the optic nerve, 
together with adult OPCs, which make up 3-5% of cells in the adult optic nerve 
(159). In this chapter, we also evaluated the regulatory effect of Gas6 in a 
lysolecithin-induced demyelination model in vitro. Briefly, we showed that in the 
presence of Gas6, demyelination is attenuated and axon degeneration was reduced, 
whilst no significant effect of Gas6 was observed on remyelination post damage. 
 
4.2 Results 
4.2.1 Gas6 promotes oligodendrogenesis in the mouse optic 
nerve 
Optic nerves were isolated with retina intact and maintained in organotypic culture 
for 3 days, in control medium or medium containing Gas6. Samples also included 
recombinant Gas6 that had been produced in the presence of warfarin, which blocks 
the vitamin K-dependent γ-carboxylation of the protein post-translation (160) and 
therefore produces Gas6 that is uncarboxylated and inactive. Also recombinant 
extracellular domain of Axl (Axl/Fc) was another treatment co-incubated with Gas6, 
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which can act as a ligand antagonist or trap by quenching the ligand before it binds to 
the receptor. After 3 days, optic nerves were fixed and whole-mounted for confocal 
analysis and cell counts. The results show that Gas6 significantly increased the 
number of Sox10-GFP positive cells and this effect was absent with either Axl/Fc or 
warfarin (Fig. 3; p<0.001). These results were obtained from a number of 
experiments performed on different days, using separate cultures from different 
animals (Figure 24). 
 
 
Figure 24. Effect of Gas6 on number of OPCs/oligodendrocytes in cultured mouse optic nerves. (A) 
Confocal images of optic nerves treated with mock medium (-Gas6) and Gas6, showing Sox10+ cells 
with green fluorescence. (B) Cell counts from images taken from optic nerves treated with Gas6 in the 
absence or presence of two Gas6 antagonists: soluble Axl receptor (Axl/Fc) & Warfarin-Gas6. Values 
represent mean±SEM (control & Gas6, n=8; Axl/Fc+Gas6, n=2; Warfarin-Gas6, n=4; n numbers 
represent number of separate experiments); ***P<0.001 vs control (SEM values are as follows: 
Mock=5.0648, Gas6=3.5669, Axl/Fc+Gas6=4.0488, Warfarin-Gas6=3.4071, ANOVA with 
Bonferroni correction. 
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4.2.2 Gas6 attenuates demyelination by lysolecithin in brain 
slice cultures 
Having observed that Gas6 promotes oligodendrogenesis and myelination in the 
adult optic nerve, we next examined whether Gas6 could attenuate demyelination 
during a toxic injury, using lysolecithin (LPC) to cause destruction to the myelin in 
an organotypic cerebellar slice culture model, which also features spontaneous repair 
(161, 162). Cerebellar slices were obtained from mice aged between P8-12 and 
cultured for 3 days to allow myelin formation to occur prior to adding LPC for 24h, 
in normal medium or medium containing Gas6; the LPC was removed and was 
followed by a further 3 days culture (figure 25). Myelin loss was observed in slices 
treated with LPC, whereas demyelination was significantly decreased by 
approximately two-fold in slice cultures co-incubated with Gas6 (Fig. 4; p<0.05) 
(Figure 26). 
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Figure 25. Schematic diagram of organotypic cerebellar slice culture preparation (A), and the 
timescale for LPC-induced demyelination and remyelination (B) Timeline 1 indicates the timescale 
for the demyelination experiment - LPC and Gas6 were added on day 3, and after 24 h incubation, 
LPC was removed and the sections were incubated in Gas6 for a further 3 days. Timeline 2 represents 
the timescale for the remyelination experiment - on day 3 LPC was added to the culture to induce 
demyelination, and after 24 h incubation, LPC was removed and the sections were incubated in fresh 
culture medium until day 7, when sections were incubated in culture medium containing Gas6 in order 
to induce remyelination. 
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Figure 26. Gas6 significantly attenuates demyelination in a toxin-induced demyelination model. (A) 
Cerebellar slice cultures were treated with vehicle (methanol), LPC+Mock medium (-Gas6) and 
LPC+Gas6 and stained with MBP antibody. For each treatment within an experiment, one cerebellar 
slice was used, and one field of view per slice was analysed. Images were taken from the top end of 
the lobules were the axons spread out. Scale bar = 50 µm. (B) Quantification of myelination through 
the number of MBP+ axons with lengths greater than 50 µm. Values represent mean ± SEM (n=6 
experiments); *P<0.05 for comparison indicated, ANOVA with Bonferroni correction. 
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We also tried to investigate whether Gas6 could enhance remyelination in the slice 
culture model. Therefore, Gas6 was added to the culture three days after LPC 
removal in order to determine whether it speeds up the process of remyelination 
(Timeline 2, Figure 25). No statistical difference was observed in the extent of 
remyelination when comparing mock treated with Gas6 treated sections (Figure 27). 
However this experiment was performed only once, and since no promising data was 
obtained, it was not repeated. 
 
 
 
 
Figure 27. The effect of Gas6 on remyelination. Gas6 was added to cerebellar slices 3 days following 
LPC withdrawal, and slices were incubated with mock and Gas6 for further 3 days. Gas6 did not have 
a significant effect on remyelination (n=3 Fields of view per treatment). 
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4.2.3 Gas enhances MBP production in optic nerve culture 
model 
Increased production of MBP can be used as an indication of maturation and 
differentiation of oligodendrocytes, which is a crucial step in inducing successful 
remyelination in the MS patient. Therefore, we determined alterations in the level of 
MBP protein in optic nerves in presence of Gas6 (Figure 28). The protein extracts 
from cultured optic nerves were analysed by western blot and band intensities were 
quantified by densitometric analysis, normalising against GAPDH protein as loading 
control. Our results demonstrate that compared to mock treated optic nerves, Gas6 
stimulation (400ng/ml) resulted in a significant increase in the level of MBP protein. 
As MBP is a marker for mature myelinating oligodendrocytes, (163), although 
increase in its expression do not necessarily represent the formation of myelin 
compact, since as well as mature myelinating oligodendrocytes, MBP is also present 
in premyelinating oligodendrocytes, but this result shows that Gas6 can be a positive 
regulator of oligodendrocytes maturation and differentiation. 
 
Figure 28. Effect of Gas6 on myelin production through MBP expression in cultured optic nerves. 
Representative western blots are shown of proteins of MBP and GAPDH as loading control in optic 
nerve lysates. The graph shows the densitometric quantification of protein levels relative to GAPDH 
protein in those samples. Values represent mean ± SEM (n=6 blots); *P<0.05 vs control, student t-
test. Gas6 significantly increased the level of MBP in optic nerve cultures. 
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4.3 Discussion 
Gas6 has previously been shown to promote survival of cells responsible for 
myelination in both CNS and PNS, including oligodendrocytes and Schwann cells. 
Addition of Gas6 resulted in protection of human foetal oligodendrocytes from 
death, and increasing proliferation of human Schwann cells in culture. It can also 
protects cortical and hippocampal neurons from undergoing apoptosis (164-166), as 
well as contributing to GnRH hypothalamic neuron survival via activation of 
ERK/PI3K pathways (167, 168). Therefore, Gas6/TAM signalling can be involved in 
a crucial important survival pathway for several neurons and glial cells that are 
responsible for myelination in the CNS and PNS (169). However, the effect of 
Gas6/TAM signalling on oligodendrocyte proliferation and maturation has not been 
widely investigated. Therefore, in this chapter we aimed to investigate the regulatory 
role of Gas6 on oligodendrocyte proliferation and its effect in reducing 
demyelination in an in vitro toxin-induced MS model. 
In addition to brain, our qPCR analysis of adult mouse optic nerve demonstrated that 
Gas6/TAM signalling components are also present in this tissue, with relative levels 
of expression indicated in the following order Tyro3>Axl>Mer. Also, Gas6 
stimulation of optic nerves from the Sox10-EGFP mouse further confirmed the 
presence and activity of TAM receptors in CNS white matter, through which they 
promote the generation of oligodendrocyte lineage cells. The Sox10-EGFP reporter 
identifies both oligodendrocytes and OPCs, since Sox10 marks all stages of 
oligodendrocyte development (121). However in the adult, OPCs are continuously 
generating new oligodendrocytes and are the likely targets of Gas6 in our study (36). 
Although my data indicated that stimulation of optic nerves with Gas6 results in an 
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increase in the number of Sox10 positive cells, but it is still not clear whether this 
increase in number is as a result of more cell proliferation or less cell death, or even 
upregulation of GFP as a result of Gas6 treatment. Therefore, this experiment require 
further investigation using proliferation markers, such as BrdU, or cell death 
markers, such as caspase-3, in order to reveal the actual pathway that is being 
affected by Gas6.  
In addition to oligodendrogenesis, Gas6 stimulated increases the levels of MBP 
protein in the adult optic nerve, which indicates that Gas6 also promotes myelination 
in mature oligodendrocytes (170). As MBP is a well-established marker for mature 
myelinating oligodendrocytes, upregulation of MBP therefore indicated 
oligodendrocytes maturation and differentiation (171). This step is crucial in 
developing new regenerative therapies to treat MS, since one important reason for 
failure of remyelination is that the OPCs that have migrated to the lesion sites usually 
fail to differentiate into fully mature oligodendrocytes (172); thus a key aim is to find 
new approaches for stimulating OPCs differentiation. Taken together, these 
observations together demonstrate that Gas6 boosts both the number of OPCs as well 
as mature myelinating oligodendrocytes. In this regard, it is worthwhile considering 
protein S, a protein homologous to Gas6 that is also a TAM receptor ligand. 
However, its expression appears to be restricted in the CNS, with low levels of 
protein S mRNA observed in locus coeruleus and high levels of mRNA in the 
choroid plexus (144). Furthermore, the expression of protein S appears to be 
primarily neuronal, having been detected in the cortex, hippocampal pyramidal 
neurons and granule neurons of the dentate gyrus of the rabbit brain (173, 174). It is 
therefore also possible that neurone-derived protein S could stimulate 
oligodendrogenesis via Tyro3 (see later chapter) in the same way as Gas6; however, 
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the affinity of Gas6 for Tyro3 is higher than protein S, which strengthens the 
hypothesis that Gas6 is the main driver of TAM-mediated oligodendrogenesis in 
CNS white matter. 
Gas6 stimulation also led to attenuation of demyelination in a cerebellar slice culture 
model of demyelination by lysolecithin (161), which is one of the most commonly 
used toxins to induce focal demyelination in different parts of the brain (175). Our 
results show that treatment with Gas6 significantly reduced the extent of 
demyelination that continues for days after exposure to lysolecithin (161). This is 
consistent with studies in the cuprizone model of demyelination, which showed 
systemic administration of Gas6 to enhance remyelination (176), whilst Gas6 
ablation decreased the number of myelinating oligodendrocytes and delayed recovery 
(177). However, our method of quantifying the extent of demyelination has some 
advantages and disadvantages. Counting the number of MBP
+
 segments longer than 
50 μm tells us that we are looking at the fully myelinated sections (possibly axons), 
and not partially myelinated ones, thus we can say that we are excluding the 
damaged myelin segments. However, this approach has some disadvantages, for 
example we can not claim that we are looking at myelinated axons since no axonal 
marker (such as neurofilament) was used, also the values my not be very accurate 
since it is very difficult to distinguish most of the axons visually, although this 
applies to all sections regardless of the treatment. 
Together, these studies demonstrate that Gas6/TAM signalling plays a major role in 
oligodendrocyte generation and myelination in the adult CNS. However, our 
experiment was focused on the protective effect of Gas6 during demyelinating 
injury, whereas it is also important to investigate the acceleratory effect of Gas6 on 
remyelination after damage. Thus far, we did not observe an enhanced remyelination 
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when Gas6 was added 3 days after LPC damage. However, further detailed time-
course studies are warranted to explore the time window during which Gas6 can be 
effective as an enhancer of remyelination post damage. Furthermore, although Gas6 
increases MBP and blocks demyelination in culture, it is also worthwhile to measure 
the axon diameter or g-ratio by electron microscopy to determine specifically the 
location of myelination as being around axons, and hence contributing to increased 
axon thickness. Also, although this study was focused on the non-microglial response 
to Gas6, it is nevertheless possible, considering the phagocytosis-mediating role of 
the TAM receptor Mer (83), which Gas6 could also activate in microglia in our 
culture model; this requires further investigation. 
In addition to the toxin induced demyelination model, Gas6 was also tested in EAE 
model of demyelination, and was shown to be protective during the course of EAE 
and enhanced remyelination. In the Gas6 knockout mice, the absence of Gas6 was 
detrimental during EAE, inflammation was increased in the spinal cord and 
remyelination was delayed, and proinflammatory cytokines/chemokines were 
significantly increased (105). 
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Chapter 5 
 
 
 
 
 
 
The signalling mechanisms by 
which Gas6 stimulates myelination 
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5.1 Introduction 
Signalling via the Gas6-TAM receptor axis is thought to be an important positive 
regulator of CNS remyelination following demyelinating injury (112). However, the 
components of the signalling pathway through which Gas6 exerts its effect have not 
been identified. A number of studies were aimed at determining the downstream 
signalling targets of TAM receptors. In a yeast-two hybrid study, the interacting 
partners of Axl receptor were identified, and the interaction of Axl with other 
signalling components including Grb2 and PI3K were confirmed. In addition, SOCS-
1, Nck2, RanBPM and C1-TEN were identified as interacting partners of Axl 
receptor (76, 178). Upon receptor activation downstream signalling pathways are 
triggered via phosphorylation of tyrosine kinase of the intracellular domain of the 
receptor (76, 179). Activation of PI3K is an important modulator of cell survival, 
proliferation and migration, which can be achieved via phosphorylation of Axl (76, 
178). Binding of Gas6 to Axl results in phosphorylation and activation of Akt, which 
is a serine-threonine kinase and can regulate cell survival. Akt activation occurs 
through the action of PI3K, which itself becomes activated through direct binding to 
phosphorylated Axl, and then phosphorylates phosphoinositides in the membrane to 
attract Akt (180). Later on, Gas6 was shown to induce oligodendrocyte survival via 
activation of PI3K/Akt pathway (108). In the same study, RNA samples from O4
+
 
foetal oligodendrocytes isolated from spinal cord were used in a microarray analysis. 
Axl and Mer were found to be upregulated more than fourfold in these cells; 
however, it was not determined which of these two TAM RTKs was responsible for 
mediating the survival effect of Gas6 on foetal oligodendrocytes (108). In addition to 
Axl, through another yeast-two hybrid system PI3K was shown to be a binding 
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partner for Tyro3, and stimulation of rat Tyro3 with human protein S resulted in 
activation of PI3K and Akt (76, 181). In addition, it has been shown that 
phosphorylation of Tyro3 as a result of Gas6 binding, stimulates mouse osteoclastic 
bone reabsorption via Ras-extracellular regulated kinase (ERK) activation (76, 134). 
ERK was also shown to be downstream of Axl signalling (76, 182). ERK is involved 
in oligodendrocytes survival, development and myelination (183-186). 
Activation of TAM receptors by ligands have also been shown to increase the uptake 
of apoptotic cells. A recent study on the effect of TAM/Gas6 signalling in 
macrophages was investigated and was shown that stimulation of bone marrow-
derived macrophages (BMDMs) within an immune suppressive compartment 
resulted in the upregulation of Mer with reduced expression of Axl. Conversely, 
treatment of these macrophages with a pro-inflammatory cytokine resulted in an 
increase in Axl expression and a decrease in Mer expression, suggesting that the 
expression of Axl is correlated with various types of inflammation. Untreated 
macrophages required Mer for their phagocytic activity, but not Axl, whereas 
macrophages that were treated with a pro-inflammatory cytokine required Axl to 
phagocytose apoptotic cells, but not Mer (187, 188). 
The main focus of this chapter was to investigate the signalling mechanisms through 
which Gas6 exerts its positive regulatory role on OPCs/oligodendrocytes 
proliferation and or maturation. Therefore, we performed optic nerve culture and 
investigated the downstream targets of TAM receptors following stimulation by 
Gas6. We showed that after 72 h stimulation with Gas6 the level of phosphorylated 
STAT3 was significantly increased. In addition, we analysed the effect of Gas6 on 84 
different MS related genes in optic nerves by qRT-PCR array. We identified 16 
genes that were changed following 72 h incubation with Gas6 (Table 3). Eight genes 
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were downregulated by more than two old, including Epha1, Gfap and Mmp9, whilst 
eight genes were upregulated by more than twofold, including Il10. 
The signal transducers and activators of transcription (STATs) are a family of seven 
highly homologous proteins, composed of STAT1, STAT2, SATA3, STAT4, 
STAT5a, STAT5b as well as STAT6. The structure of STAT3 is similar to other 
proteins of the family; it contains an N-terminal domain, a coiled-coil domain, a Src 
homology 2 (SH2) domain, a DNA binding domain and a C-terminal transactivation 
domain (189). Following activation, STAT proteins can bind to specific DNA motifs 
via the DNA binding region and initiate transcription of STAT target genes (190, 
191). Activation of STAT3 is mainly mediated by interleukin 6 (IL-6), Janus kinases 
(JAKs), Epidermal growth factor receptor (EGFR) and Src, all of which can 
phosphorylate STAT3 (191). In case of injury to the CNS, STAT3 becomes activated 
or phosphorylated which results in activation of signalling pathways that lead to 
secretion of molecules from damaged cells. These molecules include EGF and some 
factors that bind to gp130 receptor, such as IL-6, leukaemia inhibitory factor (LIF) 
and ciliary neurotrophic factor (192). In most of the cells STAT3 is expressed in the 
cytoplasm in the inactivated form, and once molecules such as IL-6 and LIF bind to 
their specific receptors on the cell membrane, this further results in activation of 
JAK1 and JAK2 (receptor-associated tyrosine kinases) inside the cell. JAKs 
phosphorylation results in activation of STAT3 in the cytoplasm, which involves its 
dimerisation and then translocation into the nucleus, where it regulates the 
expression of specific genes including SOCS3, VEGF, c-Myc and IL-6 itself (193, 
194). In addition, phosphorylation of STAT3 regulates a number of cellular 
processes including cell growth and survival as well as proliferation (193). 
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Eph receptors are another family of RTKs, for which ephrins serve as the ligands 
(195). With 16 different members, the Eph family is considered the largest RTK 
family (196). Ephrin-A, which is the ligand for EphA receptors, is anchored on the 
plasma membrane through a glycosylphosphatidylinositol (GPI) linkage, but ephrin-
B, the ligand for EphB receptors, is a protein that contains membrane domains. As 
ephrins are also membrane bound proteins attached to the cell membrane, the 
interaction between the receptor and the ligand occurs when there is contact between 
Eph receptors and ephrin presenting cells (197). It has been shown that in active MS 
lesions, ephrins -A1 to -A4 and EphA1, A3, A4, A6 and A7 receptors are expressed 
in perivascular mononuclear inflammatory cells, macrophages as well as reactive 
astrocytes (195). The Eph receptors are involved in a number of developmental 
processes such as cell migration and axonal guidance (198). In addition, several other 
biological functions have also been described for Eph receptors, including vascular 
development, tissue-border formation and synaptic plasticity (117). 
In MS, involvement of B lymphocytes has been well documented, which migrate 
across the BBB in MS patients and initiate the injury within the CNS. The exact 
mechanism through which these cells cross the BBB is not known yet; although 
matrix metalloproteinase-9 (Mmp-9) has been identified as one of the key molecules 
in disruption of the BBB and degradation of MBP as a consequent result (199). 
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5.2 Methods and materials 
5.2.1 IL-10 enzyme linked immunosorbent assay (ELISA) 
In order to determine the effect of Gas6 on IL-10 secretion at protein level, a 
commercial IL-10 ELISA kit was used to measure the level of IL-10 released. Optic 
nerve culture was set up as described before and samples were treated with mock and 
Gas6 (at concentrations described before). However the culture conditions were 
slightly modified in order to increase the concentration of IL-10 in the media: the 
number of samples per treatment was increased to 10 optic nerves and also the 
volume of the culture media was reduced to half (1 ml); also, the media was not 
replaced with fresh media, with the samples kept in the same media throughout the 
whole incubation period. After 3 days of incubation, the condition media was 
collected and the dry weight of each set of treated optic nerves was measured (excess 
liquid removed on a tissue) The collected media were then assayed for IL-10 protein 
by ELISA using a kit (431417; BioLegend; London) according to the manufacturer’s 
instruction. The IL-10 concentrations were determined after normalisation against 
the dry weight of total optic nerves in each treatment. 
 
5.3 Results 
5.3.1 Gas6 activates STAT3 signalling in the optic nerve 
The JAK/STAT signalling pathway is a primary target of Gas6 signalling (200), and 
has been shown to promote oligodendrocyte regeneration and remyelination (201), as 
well as being a promising therapeutic target in multiple animal models of MS (202). 
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Therefore, we used western blot to determine STAT3 activation through detecting 
levels of phosphorylated STAT3 (p-STAT3) (Figure 29). The protein extracts from 
cultured adult optic nerves were analysed and western blot band intensities quantified 
by densitometric analysis, normalising against GAPDH protein. The results 
demonstrate that compared to controls, Gas6 stimulation (400 ng/ml) resulted in a 
significant increases in p-STAT3 protein (Figure 29; p<0.01), which was increased 
approximately threefold. The results demonstrate that Gas6 activates STAT3 
signalling, which can be involved in stimulation of OPCs proliferation in the adult 
optic nerve. 
 
 
 
 
Figure 29. Effect of Gas6 on activation of intracellular STAT3 in cultured optic nerves. 
Representative western blot is shown of proteins pSTAT3. The graph accompanying the blot show the 
densitometric quantification of protein levels relative to GAPDH protein in those samples. Values 
represent mean ± SEM (n=6 blots); **P<0.01 vs control, student t-test. Gas6 significantly increased 
the phosphorylation of STAT3 in optic nerve cultures. 
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5.3.2 Gas6 stimulates STAT3 phosphorylation in mature 
oligodendrocytes and astrocytes 
Having observed by western blot that Gas6 stimulates STAT3 phosphorylation in 
cultured optic nerves, we then investigated the specific cell types in which this 
STAT3 activation occurred, through confocal microscopic analysis of organotypic 
brain slice cultures. Slices of cerebellum were obtained from mice between P8 to 
P12. After 3 days incubation in normal media, they were incubated in the media 
containing Gas6 (400ng/ml) for 3 h. Then, fixed cerebellar sections were double-
stained with p-STAT3 antibody together with antibodies for mature oligodendrocyte, 
astrocyte and neuronal markers. The double immunostaining of Gas6-treated tissues 
showed p-STAT3 to be present predominantly in mature oligodendrocytes and also 
to a lesser extent in some astrocytes, but not in neurons (Figure 30). 
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Figure 30. Gas6 activates STAT3 in mature oligodendrocytes and astrocytes. Cerebellar slices were 
treated with mock or Gas6 medium for 3 h, and fixed sections were double stained for A) p-STAT3 
and APC (mature oligodendrocyte marker), B) p-STAT3 and GFAP (astrocyte marker), C) p-STAT3 
and NeuN (neuronal marker) (Scale bar = 20 µm). The stainings reveal that p-STAT3 is present in 
oligodendrocytes and astrocytes but not in neurons. The arrows point to cells that are both GFAP+ and 
p-STAT3+. 
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5.3.3 Gas6 effect on oligodendrocytes proliferation and 
myelination occurs via Tyro3 activation 
Having observed that oligodendrocytes express Tyro3, we attempted to determine 
whether Tyro3 was the TAM receptor that mediated the observed effects of Gas6. 
For this, we performed western blots to investigate levels of phosphorylated 
(activated) Tyro3 (p-Tyro3) in cultured mouse optic nerves treated with Gas6 for 3 h. 
Gas6 stimulated a significant increase in p-Tyro3 protein levels in optic nerves, 
showing that Gas6 directly activates Tyro3 in white matter (Figure 31 A). The 
apparent discrepancy between the molecular weight of total Tyro3 (~140 kDa) and p-
Tyro3 (~100 kDa) is due to the respective antibodies binding to different forms of 
Tyro3. The anti-Tyro3 antibody is highly selective for the fully mature Tyro3, 
whereas the anti-p-Tyro3 recognises the smaller band species of Tyro3. We also 
performed experiments in the presence of a specific small molecule inhibitor of Axl, 
BGB324 (124, 203), in order to investigate whether Gas6 could induce myelin 
production also via Axl activation. Blocking Axl did not affect the Gas6 effect on 
myelination, further indicating that the myelination effect occurs specifically via 
Tyro3 receptor (Figure 31 B). 
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Figure 31. Gas6 activates Tyro3 receptor after 3 h stimulation in culture. (A) Representative western 
blot of p-Tyro3 protein in optic nerve lysate. The graph shows the densitometric quantification of 
protein level relative to actin in the same sample. Values represent mean ± SEM (n=5 blots); 
**P<0.01 vs control, student t-test. Gas6 significantly increased the activation of Tyro3. (B) The 
effect of a specific Axl small molecule inhibitor on the Gas6 effect in culture. BGB324 did not block 
the effect of Gas6 on myelin production, confirming Tyro3 to be the main receptor involved. 
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5.3.4 Gas6 alters MS-related gene expression in cultured 
optic nerves in a pro-myelinating direction 
The effect of Gas6 on expression of 84 different MS-related genes (Table 6) was 
examined in the adult optic nerve, using the Mouse Multiple Sclerosis qPCR array 
(Qiagen). Sixteen genes were identified as being significantly altered by Gas6 
treatment compared to controls (Table 7), eight being upregulated ≥2 fold and eight 
downregulated ≥2 fold. Among those, some of the altered genes were selected for 
further individual analysis by qPCR, including the genes for matrix 
metalloproteinase-9 (MMP9), which is able to mediate BBB injury (204), the 
astrocyte marker glial fibrillary acidic protein (GFAP) (205), and Epha1, which is an 
RTK (206), as well as interleukin 10 (IL-10), which is an anti-inflammatory cytokine 
that can also provides neuroprotection (207, 208). The individual follow-up qPCR 
analyses confirmed that Mmp9, Gfap and Epha1 genes were all downregulated, and 
Il10 was upregulated in the optic nerve following Gas6 treatment (Figure. 32). 
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Table 6. The genes analysed in a qPCR array with the effect of Gas6. 
 
  
Disease Aspect Gene List 
Myelination Cd9, Hexb, Ifng, Mal, Mbp, Ntf3, Plp1, Pmp22, Sod1, Tgfb1 
T-cell activation & signalling Apc, Cd28, Cd4, Egr1, Foxp3, Icam1, Ifng, Il10, Il18, Il1b, Il2ra (CD25), 
Il6, Il6st (gp130), Mapk1 (Erk2), Sod1, Tgfb1, Vcam1 
Adaptive Immunity C1s1, Cd40 (Tnfrsf5), Foxp3, Icam1, Ifng, Il10, Il18, Il1b, Il6st (gp130), 
Tgfb1, Vegfa 
Cytokines & Chemokines Ccl12 (MCP-5, Scya12), Ccl3 (Mip-1a), Ccl5 (RANTES), Ccl7 (mcp3), 
Csf1 (Mcsf), Cxcl10 (INP10), Cxcl11 (Itac, Ip9), Cxcl9 (Mig), Fasl 
(Tnfsf6), Ifng, Il10, Il18, Il1b, Il6, Lta (Tnfb), Tgfb2, Tnf, Vegfa. 
Inflammation Regulation of Inflammation: Ccl5 (RANTES), Ednra, Gpx1, Il6, Il6st 
(gp130), Jak2, Tnfrsf1a (Tnfr1) 
Inflammatory Response: C1s1, Ccl12 (MCP-5, Scya12), Ccl3 (Mip-1a), 
Ccl7 (mcp3), Ccr1, Ccr5, Cd40 (Tnfrsf5), Cd44, Cxcl10 (INP10), Cxcl11 
(Itac, Ip9), Cxcl9 (Mig), Fn1, Hif1a, Il10, Il13, Il1b, Il2ra (CD25), Itgb2, 
Nfkb1, Stat3, Tgfb1, Tnf, Tnfrsf1b 
Apoptosis Neuronal Apoptosis: Akt1s1 (PRAS40), Bax, Bcl2, Bcl2l1 (Bcl-XL), Erbb3, 
Gpx1, Jak2, Jun, Ntf3, Sod1, Tgfb2, Tnf. 
Other Apoptosis Genes: Il10, Mapk1 (Erk2), Tnfrsf1b, Il6st (gp130), 
Hdac1, Raf1, Apc, App, Ccl12 (MCP-5, Scya12), Cd28, Fasl (Tnfsf6), Ifng, 
Il1b, Il2ra (CD25), Il6, Itgb2, Mmp9, Nfkb1, Tgfb1, Tnfrsf1a (Tnfr1), Adm, 
Cd44, Lta (Tnfb), Mal, Vegfa 
Cell Adhesion Molecules Apc, App, Bcl2, Ccl12 (MCP-5, Scya12), Ccl5 (RANTES), Ccr1, Cd4, 
Cd44, Cd9, Csf1 (Mcsf), Cxcr3, Erbb3, Ezr, Fn1, Icam1, Il18, Il1b, Itgb2, 
Jak2, Mag, Map2k1 (Mek1), Tgfb1, Tgfb2, Tnf, Vcam1 
Cellular Stress Adm, Bcl2, Gpx1, Hif1a, Ifng, Il1b, Jak2, Jun, Ptpn11, Sod1, Tgfb2, Tnf 
Receptors Ccr1, Ccr5, Cd28, Cd4, Cd40 (Tnfrsf5), Cd44, Cxcr3, Ednra, Epha1, H2-
Eb1, Icam1, Il2ra (CD25), Il6st (gp130), Itgb2, Nr2f1, Tnfrsf1a (Tnfr1), 
Tnfrsf1b 
Transcription Factors Egr1, Foxp3, Hdac1, Hif1a, Jun, Myc, Nfkb1, Nr2f1, Stat3 
Other Multiple Sclerosis Genes Aspa, Edc4, Gfap, Gnai2, Grb2, Jak1, Phgdh, Rangap1, Top1, Tubb4a, 
Ywhah 
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Table 7. Summary of genes in cultured mouse optic nerves altered by Gas6 stimulation by ≥2 fold. 
The upper part of the table are upregulated genes (indicated in blue), and the lower part are the 
downregulated genes (indicated in orange). 
Gene 
Symbol 
AVG ΔCt Fold Up- or Down-Regulation 
Gas6 Mock ΔΔCt 2
-ΔΔCt
 
Ccl3 3.06 4.18 -1.12 2.173469725 
Ccl7 0.45 1.62 -1.17 2.250116969 
Cxcl11 8.86 10.31 -1.45 2.732080514 
Fasl 11.71 13.39 -1.68 3.20427951 
H2-Eb1 12.12 14.07 -1.95 3.863745316 
Il10 12.16 13.85 -1.69 3.226567037 
Il13 11.82 13.29 -1.47 2.770218936 
Il1b 8.65 9.69 -1.04 2.056227653 
Ednra 8.08 6.65 1.43 0.371131 
Epha1 9.36 8.06 1.3 0.406126198 
Gfap 1.06 -0.38 1.44 0.368567304 
Mag 2.09 0.79 1.3 0.406126198 
Mmp9 6.43 5.41 1.02 0.493116352 
Nr2f1 7.27 5.47 1.8 0.287174589 
Tubb4 3.04 2.01 1.03 0.489710149 
Vcam1 2.5 1.3 1.2 0.435275282 
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Figure 32. Effect of Gas6 on expression of selected MS-related genes in cultured mouse optic nerves. 
qRT-PCR was performed on extracts from mock and Gas6-treated optic nerve cultures, using specific 
primer/probe sets, and normalising expression against the Gapdh gene. Treatment of optic nerves with 
Gas6 resulted in downregulation of Epha1, Gfap and Mmp9 genes and upregulation of Il10. Values 
represent mean ± SEM (n=4 qPCR experiments for all genes except for Epha1 (n=2)). 
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5.3.5 Gas6 stimulates MBP/myelin production via 
endogenous IL-10 
We then investigated whether Gas6 results in upregulation of IL-10 at protein level. 
Optic nerve cultures were treated with Gas6 and mock media, and the level of IL-10 
secreted in the conditioned media was measured by specific ELISA. Due to time 
limitations, only one experiment was performed; however, this did show that more 
IL-10 was measured in the media of optic nerves that were treated with Gas6 (no 
statistical analysis possible) (Figure 32 A). 
Having made the tentative observation that Gas6 may stimulate upregulation of 
endogenous IL-10 in optic nerve, we hypothesised that IL-10 may mediate the 
positive effect of Gas6 on MBP upregulation; it had previously been shown that 
administration of IL-10 resulted in an increase in the thickness of myelin sheaths as 
well as boosting the level of myelination in rats (209). Therefore, an adult optic 
nerve culture experiment was set up with the inclusion of an anti-IL-10 neutralising 
antibody (5 g/ml) together with the Gas6 in order to block the Gas6 stimulatory 
effect on MBP protein levels. The protein extracts from treated optic nerves were 
analysed by MBP western blot (Figure 33 B). Normalising against GAPDH protein 
for semi-quantitative analysis, the results show that presence of the anti-IL-10 
antibody significantly attenuated the stimulatory effect of Gas6 on MBP protein level 
(Figure 33 B; *P<0.05, **P<0.01 vs Gas6). Ideally, it would have been better to 
include another control group showing the direct effect of IL-10 treatment on MBP 
protein level in optic nerves, but although the IL-10 did not work in my system, this 
data indicates that the myelinating effect of Gas6 may be occurring via endogenous 
IL-10 secretion. 
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Figure 33. Secretion of IL-10 from optic nerves with the effect of Gas6 and its role in myelination. A) 
Gas6 stimulate secretion of IL-10 from optic nerve tissue in culture. Samples were treated with Gas6 
and mock as control, the level of IL-10 was measured by sandwich ELISA. These data indicates that 
Gas6 results in production of IL-10 at protein level. B) Effect of exogenous Gas6 (400 ng/mL) on 
MBP protein levels in cultured mouse optic nerve. Anti-mouse IL-10 antibody (5 ug/mL) was pre-
incubated with cultures for 1 h prior to Gas6 addition. Data derived from densitometric quantification 
of MBP western blot bands normalised against GAPDH protein levels. Values represent mean±SEM 
(n=4 blots); *P<0.05, **P<0.01 vs Gas6. 
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5.4 Discussion 
5.4.1 Gas6 and STAT3 
In this study we investigated the signalling mechanisms through which Gas6 
mediates its effect on OPCs/oligodendrocytes development and myelination. We 
found that, in addition to an increased amount of MBP, incubation with Gas6 in 
culture resulted in an activation of the signalling transducer STAT3 in optic nerves. 
STAT3 is a cytoplasmic transcription factor, which once is activated, dimerises and 
translocates into the nucleus and regulates gene transcription. It controls a large 
number of genes that are involved in apoptosis, cell migration, cell cycle regulation 
and angiogenesis as well as modulation of immune suppressive factors (210). STAT3 
can be activated by two very different cytokines, IL-6, a pro-inflammatory cytokine 
that leads to some inflammatory diseases, and IL-10, which is an anti-inflammatory 
cytokine, which suppresses the activation of macrophages. Although both IL-6 and 
IL-10 act via STAT3, the reason they show such different characteristics could be 
due to the different functions of SOCS3 on IL-6 and IL-10 receptors. SOCS3 
(suppressor of cytokine signalling 3) specifically inhibits STAT3 by binding to its 
activating receptors (211). As the binding of SOCS3 to the IL-10 receptor is thought 
to be inefficient or weak, STAT3 activation via IL-10 can be robust and prolonged, 
whereas, IL-6 activation of STAT3 is transient, since the binding of SOCS3 to the 
IL-6 receptor is stronger. Therefore, this differential role of SOCS3 on the cytokine 
receptor is thought to be an important mechanism for distinguishing the anti-
inflammatory properties of IL-10 and inflammatory activity of IL-6 via STAT3 
activation (211, 212). 
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In addition to the proliferative role of STAT3 on mesangial cells (200), it has been 
shown in a recent study that STAT3 is an essential factor for effective myelination 
and OPCs development. In this study, STAT3 phosphorylation overlapped with 
myelination during development, and also blockade of STAT3 activation resulted in 
decreased OPCs differentiation (213). STAT3 also enhanced remyelination in an in 
vivo demyelination model employing lysolecithin injury, and loss of STAT3 
signalling dampened the remyelination process (213). These results, together with 
our observation that Gas6 stimulation leads to activation of STAT3 in 
oligodendrocytes, in conjunction with Gas6 having a positive regulatory role on 
OPCs/oligodendrocytes cell number and its effect in remyelination models, suggest 
that likely these positive regulatory functions of Gas6 are occurring via STAT3 
activation. 
 
5.4.2 Gas6 and IL-10 
From a qPCR mini-array, we observed Gas6 to induce significant changes in 
expression of genes relevant to glial biology and MS. Amongst these, the anti-
inflammatory cytokine Il10 was increased threefold. It has been shown that mice 
lacking IL-10 develop more severe experimental autoimmune encephalomyelitis 
(EAE) compared to wildtype controls, whilst overexpression or administration of IL-
10 protected the animal from EAE and reduced disease severity. Moreover, treatment 
of MS patients with interferon beta (IFNβ) is thought to be mediated at least in part 
by induction of IL-10 in immune cells (214). Furthermore, IL-10 can also result in 
prolonged activation of STAT3, which leads to an anti-inflammatory outcome (212). 
Therefore, our dual observation of Gas6 stimulating activation of STAT3 as well as 
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upregulation of IL-10 indicates the possibility that Gas6 upregulates IL-10 
expression and consequently STAT3 activation. Therefore, this data also highlight 
Gas6 as a potential anti-inflammatory molecule with immune suppressive properties 
that can be used in dampening the immune response in immune mediated disorders 
including MS. 
The anti-inflammatory function of IL-10 on microglia has been shown to occur 
indirectly via secretion of TGF-β by astrocytes (215). It has also been shown that 
astrocytes express the IL-10 receptor on their membranes, and once activated by IL-
10, which is most likely released by active microglia in the brain (216), astrocytes 
start to secrete TGF-β. Consequently, TGF-β acts on the microglia through which it 
exerts its anti-inflammatory function (215). As well as microglia, TGF-β has also 
been shown to affect oligodendrocytes and promote their generation and myelination 
(217). In addition, the role of IL-10 in increasing axonal sprouting and decreasing 
scar formation was tested in an end-to-side (ETS) repair model, which is a type of 
surgical treatment in case of peripheral nerve injuries (209). In the ETS lesion model, 
as a result of IL-10 application, myelination was significantly increased with a 
concomitant significant decrease in scar formation (209). Therefore, these studies 
together suggest a positive regulatory role for IL-10 in myelination, which likely 
occurs via STAT3 activation. 
From these and other observations, we suggest that the signalling mechanism behind 
the myelin-upregulatory effect of Gas6, and possibly its effect on OPCs 
development, involves action of endogenously upregulated IL-10, most likely 
through activation of Mer receptor on microglia. As a result, IL-10 activates the IL-
10 receptor on astrocytes, which then release TGF-β to target the oligodendrocytes 
and result in activation of STAT3 in these cells (as TGF-β signalling activates 
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STAT3 (218)). This has the eventual effect of increasing the level of myelin and 
remyelination. 
 
5.4.3 Gas6 and GFAP 
In addition, we also observed Gas6 to cause downregulation of the genes for Gfap, 
Mmp9 and EphA1 in optic nerves. GFAP is an astrocyte-specific protein, which 
when expressed in neural progenitor cells of the CNS, can drive them towards 
differentiation into astrocytes (219). Therefore, our observations suggest that Gas6 
might serve to suppress astrocyte development by downregulating GFAP, whilst 
concomitantly pushing OPCs down the pathway towards proliferation and 
differentiation. 
 
5.4.4 Gas6 and MMP9 
Disruption of the blood-brain barrier (BBB) has been considered as one of the initial 
steps in the development of disease in MS patients (220). The role of MMP9, at least 
produced by active B lymphocytes, in the disruption of the BBB and degradation of 
MBP protein is well recognised (221). MMP9 is a proteolytic enzyme that degrades 
type IV collagen, laminin and fibronectin, all of which are major components of the 
basement membrane of the BBB (222). During a relapse course of MS, active B cells 
increase the expression and secretion of MMP9 protein, which would ultimately 
result in degradation of myelin and ensuing neurological disability (221). 
Furthermore, it has been shown that, MMP9 can be secreted by OPCs that have 
proliferated at sites of demyelination in the CNS, which can also result in opening of 
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the BBB and the subsequent secondary cascades of cerebrovascular injury and 
demyelination (223). Thus, our observation of Gas6 causing an approximately 
twofold down-regulation of the Mmp-9 gene suggests that Gas6 can also, through 
MMP9, maintain BBB integrity and hence inhibit immune cell infiltration of the 
CNS in the course of MS. 
 
5.4.5 Gas6 and Epha1 
Eph receptors are the largest family of RTKs with 16 distinct members and, together 
with their ligands, the ephrins, are believed to be involved in developmental 
processes including regulation of the cytoskeleton and cell motility, cell migration 
and axonal guidance (224, 225). A study has shown Epha1 expression to be higher in 
undifferentiated human embryonic stem cells (hESCs) and human-induced 
pluripotent stem cells (hiPSCs) as compared to differentiated cells, and that the 
EphA1 expression decreased during differentiation, whereas the opposite was true 
for Axl and Tyro3 (226). Interestingly, inhibition of Axl activation by the Gas6 
ligand antagonist warfarin blocked differentiation and kept the cells in an 
undifferentiated state. Therefore, these results indicate that Axl is required for 
activation of pro-differentiation signalling pathways whilst EphA1 has the opposite 
role, and thus are in agreement with our observations of downregulation of the 
Epha1 gene by Gas6, suggesting a distinct pathway towards differentiation of stem 
cells such as OPCs into mature cells. 
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5.4.6 The role of Tyro3 in the regulatory effects of Gas6 
As our expression analysis indicated Tyro3 as the most prominent TAM receptor in 
the CNS, at least as concerns oligodendrocytes, we therefore hypothesised that the 
Gas6 effects on OPC proliferation, oligodendrocyte maturation and myelination are 
likely occurring via a direct activation of Tyro3 in these cell populations. We 
therefore utilised our optic nerve culture model to also investigate the relatively acute 
activation of Tyro3 in response to Gas6 stimulation. Thus, Gas6 stimulated a higher 
activation state of Tyro3 after 3 h in the optic nerve, as observed by increased p-
Tyro3 protein levels. This observation is supported by a recent study in the 
peripheral nervous system (PNS), that showed Tyro3 to be an important modulator of 
myelination by Schwann cells (91). 
In addition to the effect of Gas6 on remyelination, the effect of Axl in the brain 
during cuprizone toxicity has also been evaluated. In Axl knockout mice treated with 
cuprizone, no significant difference was observed in the axon diameter, myelin 
thickness and the g-ratio of myelin-containing axons compared to wildtype. Also no 
statistical difference was observed in the extent of remyelination between the two 
groups (110). This, therefore, suggest that either Axl is not the main receptor 
involved in remyelination, or the loss of signalling through all three TAM receptors 
is more harmful than loss of signalling through a single receptor. This observation is 
in consistent with our finding that shows blocking of Axl with a specific Axl 
inhibitor did not inhibit the myelin upregulation via Gas6 effect, suggesting Tyro3 to 
be the main receptor involved. Taking together these observations with my data 
about the unique expression of Tyro3 in oligodendrocytes and activation of Tyro3 as 
well as STAT3 in our optic nerve culture model by Gas6, suggest that Tyro3 is the 
main TAM receptor involved in increased myelination and or remyelination.  
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6.1 Introduction 
Vitamin K is a group of lipid-soluble vitamins comprising vitamin K1 
(orphylloquinone), vitamin K2 (ormenaquinone) and vitamin K3 (menadione). In 
1929, it was identified for the first time for its anti-haemorrhagic functions (227). 
Vitamin K has the main function of being a cofactor for the enzyme γ-glutamyl 
carboxylase, which is essential for the activation of a group of proteins known as 
vitamin K-dependent proteins (VKDPs) (106). The VKDPs include the blood 
coagulation cascade regulatory proteins factors II, VII, IX and X, proteins C, S and 
Z, as well as osteocalcin (OC) and matrix Gla protein (MGP), which are proteins 
involved in mineralisation of bone and soft-tissue. In addition to these, Gas6 was also 
identified shortly after its discovery as a VKDP, with significant homology to protein 
S (227). 
The function of vitamin K was unclear until scientists discovered the modified 
glutamate (Glu) residue in prothrombin, one of the factors involved in blood 
coagulation (228, 229). Later on, vitamin K was identified as an important factor that 
is required for post-translational modification of glutamate residues, a process known 
as γ-carboxylation (228, 230). These modified residues are now known as γ-
glutamate (Gla) residues, and they are essential to creating an active prothrombin 
protein by enabling its calcium binding activity (228). In addition to prothrombin, 14 
other VKDPs have been discovered so far, all of which contain Gla residues, among 
which Gas6 is most closely associated with the nervous system (144, 228). 
The process of γ-carboxylation is catalysed by the enzyme γ-glutamyl carboxylase 
(77). This enzyme uses oxygen and a reduced form vitamin K to add a molecule of 
carbon dioxide to the Glu residues to convert them to Gla residues (Figure 34). The 
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vitamin K used in this chemical reaction is converted into vitamin K 2,3-epoxide that 
later on by the function of vitamin K epoxide reductase (VKOR) is recycled back 
into reduced vitamin K, which can be used in the process of γ-carboxylation again 
(Figure 34). The function of VKOR enzyme can be blocked by the presence of 
warfarin (231). Most of the identified VKDPs γ-carboxylation are blood coagulation 
factors, each of which contains 9 to 12 Gla residues (232). 
 
 
Figure 34. The process of γ-carboxylation and conversion of Glu to Gla residues. Vitamin K is used 
as a cofactor for the enzyme γ-glutamyl carboxylase.  Vitamin K epoxide reductase recycles the 
vitamin K epoxide and converts it to reduced vitamin K, which can be used again. Warfarin is the 
antagonist for epoxide reductase (231). 
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As mentioned in previous chapters, Gas6 exerts its effect via binding to TAM 
receptors and thereby activating them. This binding is made complete only when 
Gas6 is modified through γ-carboxylation to possess a full set of Gla residues. As 
these Gla residues are negatively charged, they enable Gas6 to form complexes with 
about 7-8 calcium ions that gives it a positive charge; as a result, Gas6 protein can 
coordinate itself with membrane phospholipids, which positions Gas6 close to the 
TAM receptor for the optimal conformation for receptor binding and activation (77).  
The effect of warfarin and role of γ-carboxylation on the normal function of Gas6 
was evaluated for the first time in 2004. It was shown that γ-carboxylation is 
essential for Gas6 to bind to the membrane and induce its survival effects (232). 
Gas6 produced in the presence of vitamin K was fully γ-carboxylated and therefore 
could bind to membrane phospholipids, whereas uncarboxylated Gas6, which is 
produced in the presence of warfarin, could not bind to the membrane. In terms of 
the functional importance of γ-carboxylation, it was shown that cells transfected with 
Gas6 were protected from apoptosis, whilst incubation of these cells with warfarin as 
a vitamin K antagonist resulted in the abrogation of the anti-apoptotic effect of Gas6 
(232). Taken together, these data indicate the importance of vitamin K and the 
process of γ-carboxylation for the full functional effect of Gas6 via TAM receptors. 
It has previously been shown that addition of vitamin K to HEK293 cells which were 
stably transfected with Gas6 gene resulted in production of a Gas6 molecule that was 
fully functional, whereas addition of warfarin instead resulted in a decarboxylated 
Gas6 protein (232). In addition, it has also been reported that treatment of cells with 
vitamin K resulted in upregulation of VKDPs at mRNA level in vitro (233). 
Therefore, we hypothesised that administration of vitamin K to mice should result in 
upregulation of endogenous Gas6 in the body, including in the brain. Thus, the main 
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focus of this chapter was to investigate the potential of vitamin K to stimulate 
endogenous Gas6 production in the brain. This may subsequently indicate a new 
therapeutic potential role for vitamin K for people with MS. To address this, we used 
an in vivo animal model, where different doses of vitamin K were injected 
intraperitoneally in mice at various time points, after which mRNA was extracted 
from brains and livers for later analysis by qRT-PCR for mouse gas6 and pros1 
genes, coding for Gas6 and protein S respectively. Briefly, our results indicate that 
administration of vitamin K at various doses to mice had the opposite effect to that 
hypothesised, where both Gas6 and protein S genes were downregulated in both 
brain and liver as compared to control animals. This may indicate a negative 
feedback control mechanism in the body, which involves reaction to an acute 
increase in vitamin K by suppressing the upregulation of VKDPs such as Gas6 and 
protein S. 
 
6.2 Methods and materials 
6.2.1 Vitamin K injection into mice 
C57/BL6 mice aged between eight to ten weeks old were injected daily 
intraperitoneally (ip) with vitamin K and saline for ten consecutive days. Vitamin K 
(Vitamin K1; Roche) was injected at various concentrations of 0.1 to 0.2 and 0.5 
mg/kg of animal weight. After ten days of treatment, the animals were sacrificed 
humanely by cervical dislocation, and samples from brain and liver were collected 
and snap frozen using liquid nitrogen. Total RNA was extracted later and processed 
for qRT-PCR (as described in Chapter 2) to analyse changes in the level of Gas6 and 
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protein S gene expression after vitamin K or saline administration. The qRT-PCR 
data was analysed based on the relative standard curve method to determine the 
relative expression of each gene for each treatment in each tissue. For all samples, 
specific gene of interest expression was determined after normalisation against the 
gapdh gene as reference gene. Furthermore, in addition to gene expression analysis, 
the effect of vitamin K on food intake and total body weight during the ten-day 
period was also measured. 
In a separate experiment, mice aged between eight to ten weeks old were 
administered vitamin K (ip injection) at different concentrations of 0.1, 0.5 and 1 
mg/kg of animal weight for 24 hours only, followed by the analysis of the same 
parameters above. 
 
6.2.2 Experimental setup and grouping of the animals 
A total of 48 C57/BL6 mice were used for this experiment, and the experimental 
groups were designed as follows: control group (daily ip injection of saline during 
the period of 10 days), group 1 (daily ip injection of 0.1 mg/kg of vitamin K from 
day 1 to 6, and then 0.2 mg/kg from day 7 to 10), group 2 (daily ip injection of 0.5 
mg/kg for the whole period of 10 days). 
During the second phase of the experiment, the animals were divided into various 
groups based on different concentrations of vitamin K injected. The experimental 
groups were as following: control group (ip injection with saline for 24 hours), group 
1 (ip injection with 0.1 mg/kg of vitamin K for 24 hours), group 2 (ip injection with 
0.5 mg/kg of vitamin K for 24 hours) and group 3 (ip injection with 1 mg/kg of 
vitamin K for 24 hours) (Figure 35). 
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During both phases of my experiment, the animals were housed in pairs in separate 
cages. Through the first phase (in the 10 day experiment), the amount of food in the 
food hoppers of each cage was recorded on day 1 (before starting the injections), and 
then again at the end of the experiment (before collecting the samples). Through the 
second phase (in the 24 h experiment) the amount food was recorded on day 1 (prior 
to the injections) and on day 2 (before collecting the samples), therefore, I was able 
to calculate the food consumption for each group over the course of 10 days and 24 
h.  
 
Figure 35. Schematic diagram of vitamin K experiments and workflow of mouse treatments and 
groups. A) During the first phase of the experiment, mice were injected with various concentrations of 
vitamin K and PBS through a course of 10 days, receiving daily injection of the treatments. After 10 
days, samples from brain and liver were collected and analysed in qPCR. B) In the second phase, mice 
were injected with various concentrations of vitamin K and PBS, receiving one single injection during 
a 24 h period. 24 h after injection, samples from brain and liver were collected and were analysed in 
qPCR. 
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6.3 Results 
6.3.1 The effect of vitamin K administration on Gas6 and 
protein S gene expression 
qRT-PCR was performed to determine the level of Gas6 and protein S mRNA in the 
brain and liver after administration of different doses, and for different time periods, 
of vitamin K. We measured mRNA expression at two different time points: (i) 24 
hours after vitamin K injection; (ii) after 10 days of daily vitamin K injection. 
Surprisingly, the result was contradictory to our hypothesis, showing that Gas6 
expression was reduced in both brain and liver after 10 days of vitamin K injection; 
however, protein S expression in the brain did not change. At the time point of 24 
hours after a single injection, administration of both 0.2 and 0.5 mg/kg showed 
similar results, although protein S expression appeared to be slightly higher in the 
liver with 0.5 mg/kg of vitamin K (Figure 36). 
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Figure 36. Effect of vitamin K (VitK) on Gas6 and protein S mRNA, after 10 days of treatment with 
various concentrations of vitamin K. A) Mice were treated with 0.2 mg/kg of vitamin K, level of Gas6 
and protein S mRNA was measured by qPCR. Values represent mean ± SEM (n=5 mice for control 
brain, n=6 mice for VitK brain, n=3 mice for control and VitK liver). B) Mice were treated with 0.5 
mg/kg of vitamin K. Values represent mean ± SEM (n=4 mice for control brain, n=5 mice for VitK 
brain as well as control and VitK liver); *P<0.05, **P<0.01 vs control group; Student t-test. 
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In the second experiment, three various concentrations of vitamin K were tested (0.1, 
0.5 and 1 mg/kg), and 24 hours after injection the mRNA level was measured based 
on the delta Ct method (234). The results were in confirmation with my previous 
data, showing no significant increase in Gas6 expression in brain and liver vitamin 
K. However, in the case of protein S, brain expression stayed the same, whereas liver 
expression was significantly lowered at all concentrations of vitamin K (Figure 37). 
 
 
Figure 37. Effect of vitamin K on Gas6 and protein S mRNA, after 24 hours of treatment with various 
concentrations of vitamin K. Mice were treated with 0.1 mg/kg, 0.5 mg/kg and 1 mg/kg of vitamin K, 
level of Gas6 and protein S mRNA was measured by qPCR. Values represent mean ± SEM (for Gas6, 
n=5 mice for the following groups: saline brain and liver, 0.1 mg/kg liver, 0.5 mg/kg brain and liver. 
n=4 mice for 0.1 mg/kg brain, n=6 mice for 1 mg/kg brain and liver); *P<0.05, ***P<0.001 vs saline 
group; Student t-test. 
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During the 10-day and 24 hour periods of vitamin K treatment, we also monitored 
the effect of vitamin K on food intake and body weight. We observed that neither 
acute nor chronic administration of vitamin K had any significant effect on both of 
these parameters in the animals (Figure 38). 
 
 
 
Figure 38. The effect of vitamin K on the mice food intake and body weight in the course of 10 days 
and 24 hours treatment. A) The effect of vitamin K on food intake after 10 days of treatment. Values 
represent mean ± SEM (n=6 mice for saline group, n=7 mice for 0.2 mg/kg). One way ANOVA with 
Tukey correction. B) The effect of vitamin K on total body weight after 10 days of treatment. Values 
represent mean ± SEM (n=6 mice for saline group, n=7 mice for 0.2 mg/kg). One way ANOVA with 
Tukey correction. C) The effect of vitamin K on the amount of food intake after 24 hours of treatment. 
Values represent mean ± SEM (n=6 mice for all the groups). One way ANOVA with Tukey 
correction. 
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6.4 Discussion 
Among all of the VKDPs identified so far, Gas6 expression is the most identifiable 
within the nervous system, as well as protein S to a lesser extent (235). Post-
translational γ-carboxylation is believed to be crucial to the function of Gas6 (236). 
This was apparent in the first study, where Gas6 produced in the presence of warfarin 
was completely unable to stimulate phosphorylation of Axl (236). This therefore 
suggests that, while the C-terminal LG domains of Gas6 are the actual binding 
interfaces with the TAM receptors, the Gla domain can affect the activating ability of 
the ligand (235). Therefore, as vitamin K is required for the formation of Gla 
residues in Gas6, in the present study we aimed to obtain an insight into vitamin K as 
a potential new therapeutic approach for inducing tissue repair indirectly via 
stimulation of endogenous Gas6 production. We therefore treated mice with different 
doses of vitamin K and analysed the level of Gas6 and protein S mRNA in brain and 
liver at different time points. 
At first, we analysed the level of Gas6 and protein S mRNA after 10 days of 
treatment with vitamin K, but it appeared that at this time point Gas6 was lowered 
compared to control group whilst protein S was not altered; this result appeared to 
disprove the hypothesis. However, the period of vitamin K treatment could be a key 
player in explaining this odd result, as Gas6 and protein S produced as a result of 
vitamin K treatment may not be very stable for long periods. Therefore, Gas6 and 
protein S expression might actually increase as a result of vitamin K stimulation, but 
due to lack of stability, they may not remain at high levels over 10 days; this may 
explain why we did not observe upregulation of either gene at this stage. 
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Subsequent to the results of the 10-day experiment, another experiment performed to 
test whether Gas6 and protein S could be upregulated at earlier time points. Mice 
were injected with various concentrations of vitamin K and Gas6 and protein S 
mRNA were evaluated after 24 hours only. The results appeared to be similar to 
those of the previous experiment, showing no significant increases. It has previously 
been shown that addition of vitamin K to SVZ cell cultures in vitro resulted in 
secretion of fully functional VKDPs (237); however this effect of vitamin K had not 
been tested in vivo. However, it is difficult to extrapolate in vitro findings to the in 
vivo situation, as in the whole body, all the organs and control systems of the body 
are playing a part. For example, the homeostatic control of the body could be 
involved (16) and it could be possible to say that as a result of vitamin K treatment, 
Gas6 and protein S are upregulated in the body, but due to initiation of a negative 
feedback response their expression is brought back to normal. However, this 
explanation requires further experimentation to gain a definitive conclusion. 
In the process of γ-carboxylation, which uses vitamin K and oxygen as cofactor, one 
carboxyl group is added to the Glu residue in order to form the Gla residue (238). 
This process helps the binding of calcium ions to the Gla residues and thereby 
binding of the protein to negatively charged membrane phospholipids such as 
phosphatidylserine, which is more present on activated or apoptotic cell membranes. 
However, it should be noted that the whole process of γ-carboxylation with the help 
of vitamin K occurs with the protein at the post-translational level. Therefore, 
although it can be argued that examining gene expression may not be a reliable 
representative of the effect of vitamin K on VKDPs production and secretion 
nevertheless, it has been reported that treatment of cells with vitamin K resulted in 
upregulation of VKDPs at mRNA level in vitro (233), although our study is the first 
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such investigation in vivo. In addition to the process of γ-carboxylation, vitamin K 
might also function as anti-oxidant that may affect other post-transcriptional 
processes including protein folding, protein processing e.g carboxylation, trafficking, 
secretion, cell survival or apoptosis as well as some other functions. 
In conclusion, the results of this chapter’s study indicate that it cannot be ruled out 
that vitamin K does not boost endogenous expression of Gas6 and protein S in the 
brain and liver. Moreover, although vitamin K appeared not to have an affect at the 
mRNA level, gene expression levels do not strictly mirror protein expression levels. 
Hence, future experiments should be directed at analysing proteins expression after 
vitamin K treatments by e.g. western blotting. Here, antibodies against total Gas6 
and protein S would be used, together with a separate antibody against Gla residues 
in order to find out if addition of vitamin K in vivo results in enhanced γ-
carboxylation as well as secretion of VKDPs such as Gas6 and protein S. 
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7.1 General discussion 
During the nearly four years of work on this PhD project, my initial aim was to 
identify the expression patterns of TAM receptors and their ligand, Gas6, within the 
mouse CNS throughout post-natal development, particularly at time points that 
overlap the peak of myelination. A further aim was to investigate the functional 
properties of Gas6 on gliogenesis, in particular oligodendrocytes, as well as its 
potential repair effect upon myelin loss during experimental demyelination. 
Furthermore, the project aimed to probe the signalling mechanisms behind these 
functional effects of Gas6, by identifying the specific TAM receptor present on each 
glial cell type, the intracellular mediators downstream of the Gas6-TAM interaction, 
and in addition the inter-cellular signalling that involves a potential mediatory role 
for IL-10 in the Gas6 effect. I believe that I have effectively addressed the aims 
stated above and obtained data which has significantly contributed to the body of 
knowledge in this field of research. In each results chapter, I discuss the significance 
of my data in the context of the objectives set in that individual chapter. However, in 
this final chapter, I synthesise the outcomes of all results chapters of my thesis, as 
well as discuss future work that is relevant to the key areas of MS research, and how 
my work fits with those areas. 
To accomplish these aims, I made use of a variety of laboratory techniques, ranging 
from expression analysis to in vitro culture models. I shall first discuss these 
techniques and any methodological issues that I came across, followed by a 
discussion of proposed future work and other aspects that were mentioned above. 
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7.2 Technical issues 
7.2.1 Expression analysis 
The first objective of my PhD project was to evaluate the expression pattern of 
different TAM receptors and the ligand Gas6 within the CNS. I used two widely used 
techniques to accomplish this objective: qRT-PCR to evaluate gene expression and 
western blotting for detection and measurement of protein expression. These 
techniques are extremely useful for determining the presence or absence of a 
particular mRNA or protein in a tissue, and are therefore widespread in their use. 
Moreover, they both provide the ability to quantitate expression levels. In the mouse 
experiments, we were not able to determine expression at the specific level of the 
single CNS cell type, as our samples were total extracts from various whole sections 
of the brain e.g. cortex or cerebellum. Such characterisation of the receptors at 
cellular level would be beneficial in terms of identifying signalling mechanisms. 
Therefore, as another approach, I used commercially available human OPCs and 
human cerebellar astrocytes in culture. Using these, we were able to reveal the 
unique expression pattern of Tyro3, Axl and Gas6 in those cells at mRNA level. 
However Mer expression was not determined due to technical issue with the qPCR; 
this prevented repetition of the experiment due to unavailability of human OPCs and 
the prohibitively high cost of the cultures. Another technical limitation was the 
inability to perform western blots specifically from these human glial cell cultures, as 
sufficient protein amounts could not be derived from the limited supplies of those 
slow or non-growing cells. 
A further shortcoming was the inability to perform successful western blots of Mer 
and Gas6 protein expression in mouse CNS due to lack of reliable antibodies. 
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Therefore, all data on protein expression during mouse brain development was on 
Tyro3 and Axl. In addition, lack of reliable antibodies also prevented reliable 
characterisation of expression of all TAM receptors and Gas6 by 
immunohistochemistry at the cellular level, with the exception of (phosphorylated) 
Tyro3. Therefore, more time and resources to test a larger number of antibodies and 
for various applications would enable a complete determination of the expression 
profiles of Gas6 and TAMs throughout the CNS at various ages and in various 
regions. 
 
7.2.2 Optic nerve culture 
For part of this study, I utilised optic nerves in culture, a model of white matter 
tissue, to explore the functional effects of Gas6 on gliogenesis and myelination, as 
well as the signalling mechanisms involved in the processes.  However there were a 
few technical limitations that prevented us from further investigation. Optic nerve 
culture is a suitable technique to perform some basic analysis on glial cells, although 
a major practical and economic limitation is that it requires a large number of 
animals (as each animal provides two optic nerves). For example, western blot or 
qPCR analyses required a large number of mice to be able to extract enough proteins 
or mRNA for quantification. In addition, the optic nerves are very tiny and very 
difficult to section, which makes it difficult to perform IHC analysis. On the other 
side, they are a good source of myelin and contain all types of CNS glial cells (239), 
however, no neuronal cell body can be found in this tissue, which makes it a suitable 
model to study glial cells biology and development. Although it cannot be used to 
evaluate the effect of different component on neuroprotection. 
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7.2.3 Evaluation of de/remyelination in LPC-induced 
demyelination model 
Inducing demyelination in cerebellar slice culture is a simple and reliable model to 
investigate the effect of various components on demyelination as well as 
remyelination. However, despite these advantages, the model has some limitations. 
One is that only a tiny slice of the cerebellum, comprising only a small portion of the 
CNS, is analysed; therefore, the CNS region is not studied as a whole. Furthermore, 
another significant drawback could be the absence of the immune system in this in 
vitro model, given that the role of immune response in progression of MS is 
unequivocal (240). The other disadvantage, like all other in vitro models, is the 
exclusion of the whole body as one single unit, and therefore, when a component is 
tested in an in vitro model the result is preliminary, because the same component 
may not have the same effect in a condition when the whole body is playing a part. 
On the other side, this model has some advantages. The sections can be kept alive in 
culture for nearly a month that makes it possible to test various time points within 
one experiment, and one or two animals usually provides enough sections for one 
experiment. Also, organotypic cerebellar slice culture model provides a basic and 
inexpensive system to investigated the effect various components on demyelination 
and remyelination, which makes it suitable to study new therapeutic targets before 
going into in vivo studies. It is also a good representative of the whole brain since it 
contains both grey and white matter as well as all the cell types that can be found in 
the CNS, including neurons and all glial cells. Thus, in addition to demyelination and 
remyelination, the secondary effect of the tested component on various cell types can 
also be evaluated. In general organotypic cerebellar slice culture model reduce the 
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usage of animals and has a good potential for studying therapeutics as well as 
biology of remyelination (162). 
In order to develop a new therapy for MS, it is crucial to stimulate the mechanism of 
self-repair in patients. In this thesis, I have provided data to point to Gas6 as a 
protein with the ability to dampen the damage in a demyelination model. We also 
attempted to investigate the stimulatory effect of Gas6 on remyelination. Although a 
positive effect of Gas6 was not observed; nevertheless, one cannot exclude the 
potential role for Gas6 in the repair mechanism, as this experiment required technical 
and design refinement, including analysing various time points after demyelination. 
 
7.3 MS therapeutic pathways 
Although there is currently no cure for MS, a number of treatments are available that 
are proven to be helpful in managing the condition. The main objectives of these 
therapies are to help the CNS to regain its normal function after an attack, inhibiting 
further attacks and preventing disability during the course of MS (58). As mentioned 
in previous chapters, there are a number of strategies that can be followed in MS 
therapy, the most important of which are as follows: 
1) To target the immune response by developing immunosuppressive or 
immunomodulatory treatments that can reduce the activation of microglia and 
decrease the level of immune cells and their products in the CNS. 
2) To induce regeneration by developing drugs that can stimulate endogenous 
remyelination and oligodendrocytes differentiation. 
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7.3.1 Immunomodulation 
At early stages of disease progression, people suffer from relapses and acute axonal 
loss. By progression of the disease into the progressive phase, inflammation 
decreases in the peripheral circulation, but instead, it becomes compartmentalised in 
the CNS (241-243). The shift from inflammation to neurodegeneration as the main 
underlying pathology underlies the need for early interference of inflammation in 
order to delay the progression of disability in MS patients (241, 244). During the past 
couple of years many treatments have become available that interfere with the 
progression of the disease. The main intervention points of the current MS therapies 
are as follows: antigen presentation, peripheral immune response, the BBB and the 
target tissue within the CNS (241, 245). 
In normal unaffected individuals, once T cells and B cells become activated in the 
peripheral circulation, then they result in clonal expansion and proliferation of 
effector cells, although this process is controlled by T regulatory (T-reg) cells. But, 
in people suffering MS, T-reg cells fail to control active T and B cells, and as a result 
of this failure, the activated immune cells are permitted to cross the BBB and induce 
the immune response in the CNS (241, 246). 
There are five distinct types of immunotherapy for treatment of MS patients, which 
are as follows (241): 
Type 1: immunomodulation 
Type 2: general immunosuppression 
Type 3: immune-selective intervention – blockade type 
Type 4: immune-selective intervention – sequestering type 
Type 5: immune-selective intervention – depleting type 
The Type 1 contains those immunomodulators that reduce the secretion of cytokines 
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and chemokines, and they inhibit the penetration of activated T cells across the BBB. 
This group includes treatments like IFN-, glatiramer acetate, dimethyl fumarate and 
teriflunomide. Type 2 agents provide general immunosuppression, such as 
mitoantrone and cyclophosphamide (241). Type 3 agents block the infiltration of 
active T cells through the BBB; this group includes natalizumab (241, 247), which is 
a monoclonal antibody that binds to the surface of human leukocytes (248, 249). 
Type 4 agents are mainly involved in reducing the infiltration of lymphocytes into 
the CNS; fingolimod falls within this type (241, 250). The last one, Type 5, is a new 
strategy in the treatment of MS. This group is represented by alemtuzumab that is 
another monoclonal antibody against CD52, which is a marker on the surface of 
some cells including B and T lymphocytes, thymocytes as well as monocytes (251, 
252). Alemtuzumab leads to depletion of T and B cells that contain the CD52 
marker; as T-reg cells possess a very low expression of CD52, they will not be 
affected (241, 253). 
1. Comparison of Gas6 with Type 1 and 2 immunotherapies: Gas6 has been 
shown previously to possess immunomodulatory characteristics, as it was 
shown that triple knockout mice, which lack all three TAM receptors, 
develop a severe lymphoproliferative disorder accompanied by broad-
spectrum autoimmunity. It was shown that in cultured triple knockout 
macrophages the level of antigen presenting cells (APCs) was elevated and 
also they produced excessive amounts of the pro-inflammatory cytokine IL-
12. Thus, it was concluded that signalling through TAM receptors function as 
a regulatory mechanism that reduces the severity and time course of 
inflammatory immune responses (132). These data indicate that Gas6 may be 
able to control the immune system and has similar characteristics compared 
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to Type 1 and Type 2 immunomodulatory and immunosuppressive therapies. 
2. Comparison of Gas6 with Type 3 immunotherapy: According to our 
observations from gene changes analysis with the effect of Gas6, Gas6 
resulted in downregulation of Mmp9 gene for nearly twofold. MMPs 
comprise a large family of proteases that are usually activated by 
inflammatory stimulations. Once activated, they regulate a number of 
pathophysiological pathways such as the regulation of growth factors, death 
receptors as well as a number of other signalling molecules (254-256). 
Among those, MMP9 has been found to be associated with 
neuroinflammation (256). Once the neuroinflammatory pathways have been 
initiated, MMP9 along with MMP2 and MMP3 increase the permeability of 
the BBB, and as a result immune cells invade the CNS (254, 257, 258). 
Blocking of MMPs has been shown to restore the integrity of the BBB (254, 
259). Moreover, MMP9 has been shown to be upregulated in the CSF of MS 
patients, and treatment with prednisolone, which maintained BBB integrity, 
was shown downregulate the level of MMP9 in the CSF (260). Therefore, our 
observations on Gas6, which was shown to downregulate Mmp9 gene 
expression, suggest that Gas6 may function as a type 3 immunotherapy with 
the ability to maintain the integrity of the BBB, subsequently reducing the 
infiltration of immune cells, including active T cells and B cells, into the CNS 
(Figure 32). 
3. Comparison of Gas6 with type 4 and 5 immunotherapies: As shown in 
previous chapters, treatment of optic nerves with Gas6 resulted in 
upregulation of IL-10 gene expression by approximately more than twofold. 
IL-10 is an anti-inflammatory cytokine that is known to have 
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immunomodulatory functions and is capable of reducing inflammation in a 
number of pathophysiological conditions (261). The anti-inflammatory 
functions of IL-10 are believed to be mediated by STAT3 activation, and are 
related with deactivation of immune cells including monocytes/macrophages 
and dendritic cells (261-265). In the EAE model, disease severity was 
increased in the absence of IL-10, whereas, on the other hand, overexpression 
of IL-10 protected the animal from EAE and treatment with IL-10 reduced 
disease severity (214, 266, 267). Therefore, our observations on the effect of 
Gas6 on IL-10 upregulation as well as STAT3 activation in the optic nerve 
suggest that Gas6 has the ability to deactivate immune cells, including 
monocytes/macrophages as well as dendritic cells, via the IL-10/STAT3 
pathway, therefore also showing similar characteristics to Type 5 
immunotherapies (Figure 32). However, this requires further investigation 
that will be discussed later on in this chapter. 
Taken all observations together, it can be proposed that Gas6 has properties enabling 
it to fall into almost all categories of immunotherapies for MS. These therefore 
makes it a good potential therapeutic target for treating MS, although further 
investigation is required to unravel further the signalling mechanisms involved in the 
functions of Gas6 and indeed the TAM receptors. 
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7.3.2 Regeneration 
The other approach for MS therapy is to stimulate regeneration in the CNS, which is 
mostly known as the process of remyelination (discussed in Chapter 1). 
Remyelination is one of the best documented examples of tissue repair in the human 
brain. The regeneration of neurons and their axons is very limited in the adult CNS; 
however the myelin sheath can be repaired very effectively (268). The process of 
remyelination is a very crucial step in the MS therapy, since it results in restoration 
of conduction of action potentials through the axons (269) in addition to providing 
axonal protection (270). In this regenerative process, there are a series of important 
steps, each of which should be considered in the development of new therapies for 
MS: 
1) Activation and proliferation of OPCs 
2) Migration of newly formed OPCs to the lesion sites 
3) Differentiation of OPCs into mature myelinating oligodendrocytes 
4) Interaction of premature oligodendrocytes with damaged axons (65). 
 
It is well established that within an area where remyelination is on going, a larger 
number of oligodendrocytes are present as compared to an equivalent area under 
normal conditions, where no remyelination is occurring. Remyelination also occurs 
in areas that have been depleted of oligodendrocytes experimentally. These 
observations together indicate that the process of remyelination involves the 
formation of new mature myelinating oligodendrocytes (271-273). This relies on the 
generation of new OPCs and particularly their differentiation into mature cells for a 
successful remyelination. 
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The role of Gas6 in remyelination was shown in a cuprizone-induced demyelination 
model (107). However, the effect of Gas6 on OPC development was not reported in 
that study. In the present study, one of our most significant findings was the positive 
regulatory effect of Gas6 on OPCs/oligodendrocytes number in optic nerves, where 
we showed Gas6 to increase the number of Sox-10 positive cells by approximately 
20% (Figure 39). Although it is uncertain as to whether this effect is due to increased 
OPCs proliferation, decreased cell death (cell survival or inhibition of apoptosis) or 
even an upregulation in the level of GFP, this effect of Gas6 can be beneficial to the 
process of remyelination, as the activation and proliferation of OPCs is the first event 
to occur after demyelination. In addition to the effect on OPCs proliferation, we also 
observed that treatment of optic nerves in culture with Gas6 significantly boosted the 
level of MBP. As MBP is the product of mature oligodendrocytes and is used as a 
marker for these cells (discussed in Chapter 1), this result further indicates that Gas6 
promotes OPCs differentiation and maturation in addition to boosting their cell 
number. This latter observation indicates Gas6 as a potential inducer of OPCs 
differentiation in culture, which is crucial in the process of remyelination, as one 
important reason for remyelination failure is the failure of OPCs to differentiate into 
mature cells at lesion sites (Figure 39). Furthermore, Gas6 also caused 
downregulation of EphA1 in cultured optic nerves, which further supports a positive 
role for Gas6 in OPCs differentiation (discussed in Chapter 5) (Figure 39). Although 
we did not investigate the role of neuronal activities in these potential pathways, but 
considering the fact that Gas6 is expressed in neurons within the CNS (discussed in 
chapter 3), it could be noted that neurons can regulate oligodendrocytes development 
and myelination via paracrine function by releasing Gas6. 
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Taking the current and previous observations together, Gas6-TAM signalling may be 
a novel, multifaceted therapeutic target for MS treatment. Enabling the actions of 
Gas6 to have an immunomodulatory function through control of immune response 
via the IL-10/STAT3 pathway, or dampening the infiltration of immune cells across 
the BBB. In addition, and distinctly, Gas6-TAM signalling can also be regenerative 
as it can reduce the damage in demyelinating areas of the brain as well as increasing 
remyelination and enhancing OPCs proliferation and differentiation. 
 
Figure 39. Schematic overview of our experimental findings on Gas6 and glial cells so far. Gas 
stimulates gene expression towards a pro-myelinating phenotype. This includes OPC proliferation and 
oligodendrocyte maturation and myelin formation via Tyro3 RTK. Also, Gas6 suppresses expression 
of Mmp9 and Epha1 genes, which contribute to OPC differentiation and BBB integrity, respectively. 
In addition, my preliminary data also show that Gas6 upregulates IL-10 in the optic nerve, which can 
come from microglia, which in turn regulate astrocyte function towards a repair phenotype. Line 
arrows are proven pathways, whereas dotted line arrows are putative pathways. 
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7.4 Priorities in current and future MS research and 
relevance to this project 
7.4.1 Future focus 
By considering the current trend of MS research and various gaps that still exist in 
the field, it would be possible to mention the future focus and priorities in MS 
research, which mostly will be about developing new treatments that can induce 
repair as well as being effective in reducing inflammation in the progressive form of 
MS. The following different areas of MS research in the future is based on a report 
published by MS Society of UK (MS Society Research Strategy 2013-17). 
 
7.4.1.1 Genetic factors 
It is very well established that genetic factors are involved in MS and there are a 
number of observations that suggest they also affect the phenotypic expression of the 
disease (274, 275). Nowadays, the involvement of alleles at human leukocyte antigen 
(HLA) region in MS, are well documented (217, 276). Recently, through large-scale 
genome wide association studies (GWAS) as well as chip-based follow-up studies 
that was done by the International MS Genetics Consortium, over one hundred non-
HLA single nucleotide polymorphisms (SNPs) related to MS were identified (277-
279). However, it is accepted that there is a need for putting more effort into the 
genetics of MS and also translating the current knowledge to improve diagnosis as 
well as developing new treatments. 
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7.4.1.2 Environmental factors 
Despite advances in the genetics of MS and identifying risk genes involved in the 
process of the disease, there are still many questions that remain unanswered as the 
discovered genes can only describe a small proportion of the total heritability of MS 
and even a far smaller segment of what actually occurs in MS as a whole (280). This 
gap, in combination with changes that occur in patients as a result of migration (281), 
the earlier characteristic geographic distribution (282) as well as the higher risk in 
women of western world compared to men (283), indicate that environmental factors 
also play an important role, as well as genetic factors, in the aetiology of MS (280). 
Therefore, as well as genetic, further research is needed in order to develop 
prognostic markers. But, the emphasis should be on finding new strategies based on 
our current knowledge, in order to prevent or decrease the risk of MS. 
 
7.4.1.3 Immunology 
MS is widely known as an immune mediated condition that is regulated by a 
complex relation of genetic factors and some environmental insults (58). Since there 
has been an increase in the number of immune modulatory and suppressive agents, 
the basic research on the immune system or the projects that are focused on 
developing new treatments that reduce the number of relapses in MS patients, are not 
the priority in research. On the other hand, the emphasis of the immune aspect of MS 
research should be related to neurodegenration and progressive form of MS. Thus, 
the focus should be on types of research that are aimed to develop new therapies that 
prevent or at least reduce the neurodegeneration, as well as being effective in the 
progressive form of MS. 
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7.4.1.4 Neurobiology 
As discussed previously, MS is a condition that mainly affects the myelin sheath and 
oligodendrocytes as well as neurons and their axons (59). There are many treatments 
available that mainly target the immune abnormalities to control the progression of 
the disease (284). Since there is currently no medication for the progressive stage of 
the disease where neurons and their axons are continuously degenerated, there is a 
need for developing a therapy that is effective in progressive forms of the disease 
(285). Therefore, although research is still ongoing in order to improve the immune 
modulatory treatments, the direction of research on MS is now being directed 
towards a new treatment strategy that involves inducing myelin repair and 
neuroprotection (286-288). Hence, more basic research is needed in neurobiology to 
increase our knowledge of neurodegeneration in MS patients, which will help us to 
find new strategies to prevent this process. In addition, developing new treatments 
that can inhibit or reduce the rate of neurodegeneration as well testing them in 
clinical trials should also be emphasised. 
 
7.4.1.5 Glial cell biology 
It should be noted that in course of MS, as well as the destructive phase, there is a 
regenerative response that eventually leads to remyelination and regaining of the 
ability to conduct signals through axons. Glial cells, in particular oligodendrocytes, 
mainly conduct this process of regeneration (289). It is well established that one of 
the characteristics of MS lesions are reactive astrocytes (290), also in the MS lesions, 
macrophages/microglia are responsible for removing debris (291), and OPCs are 
recruited to the sites of damage, where they differentiate into mature cells to produce 
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new myelin and induce remyelination (292). However, as discussed before (Chapter 
1), this regenerative process usually fails due to various reasons, and hence the 
research is still ongoing on this aspect of the disease. Thus, in addition to the need to 
study neurobiology, further investigation is required to increase our knowledge about 
glial cells and their functions that can be beneficial to MS patients, in particular 
myelin biology and the process of remyelination. As well as further basic research, 
the emphasis also should be on developing new regenerative agents that can help the 
CNS to regain its normal function as well as testing these treatments in clinical trials. 
 
7.4.2 Future work 
In this PhD project, we have shown various effects of Gas6 on glial cell 
development, demyelination and its stimulatory and inhibitory effect on different 
genes involved in MS, all of which indicate Gas6 as a potential therapeutic target for 
MS. My data paved the way for future researchers to follow this path to use Gas6 in 
order to develop new treatment that can stimulate regeneration as well as regulating 
the immune response. 
 
7.4.2.1 The role of IL-10 in the myelinating function of Gas6 
As discussed previously (Chapter 5), we showed that Gas6 markedly upregulated IL-
10 in the optic nerve in vitro. Although we showed a clear increase in the level of IL-
10, we still do not know which cell type contributes to IL-10 production, and what 
the cellular target of the IL-10 is. However there is evidence that shows within the 
CNS microglia cells are the major source of IL-10, and that cytokine affects 
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astrocytes via the activation of IL-10 receptor. Therefore, it requires further 
investigation to find out the source of IL-10 (most likely microglia) and the TAM 
receptor involved (possibly Mer) and the target of produced IL-10 (maybe 
astrocytes), in order to reveal a novel signalling pathway for Gas6/TAM complex 
that possibly could be involved in anti-inflammatory properties and also myelination 
and OPCs maturation. 
 
7.4.2.2 The role of individual TAM receptors in mediating the Gas6 
effects in vitro, using TAM receptor knockout mice. 
We showed that Gas6 directly stimulates oligodendrocytes most likely via activation 
of the Tyro3 receptor. We also found astrocytes to be a source of Gas6, which is 
consistent with the role of astrocytes in supporting oligodendrocyte differentiation 
and myelination (293). However, although we found Mer gene expression to be 
highest in the cortex, we do not know the cell-specific expression profile of Mer. 
However, we anticipate that Mer is the main TAM receptor in the microglia as well 
as any infiltrating macrophages, based on previous studies (138). In order to 
determine more clearly the role of each specific TAM receptor in the various effects 
of Gas6, TAM receptor single knockout mice could be utilised, e.g. to discriminate 
between direct oligodendrogenesis and indirect IL-10 upregulation. Single receptor 
knockout mice can also be useful in the EAE model, although Mer knockout animals 
should only be used for in vitro culture experiments, as we believe that the 
heightened immune response occurring in the EAE in vivo model of 
neuroinflammation would be greatly amplified by lack of this receptor (as has 
already been shown in knockout studies (294)) and hence Gas6 would be ineffective 
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or its effect indiscernible in this model. However, utilisation of these tissues in both 
optic nerve and brain slice cultures would provide valuable insights into the TAM 
receptor-specific effects of Gas6 that we have so far observed. 
 
7.4.2.3 Vitamin K as a booster of endogenous levels of Gas6 in the 
brain and thereby potential therapeutic promoter of myelination 
Although our results as well as previous observations, indicate that Gas6 has a 
therapeutic benefit, Gas6 is however a ~75-kDa protein and therefore unlikely to be a 
viable clinical agent in itself for promoting myelination, since there are a few issues 
that limit the ability of Gas6 as a therapeutic agent. The first one is Gas6 being a 
sizeable protein, which if injected into the body as a clinical agent would most likely 
become degraded before even reaching the lesion sites in the CNS. The second 
aspect is the size of Gas6, which is approximately 75 kDa; hence, even if it does not 
become degraded in the blood it would be unlikely to cross the BBB and enter the 
CNS. Therefore, practical alternative therapeutic options include an agent that can 
cross the BBB and act as a Gas6-like ligand, or else stimulate the CNS cells so that 
they produce their own endogenous Gas6. For the latter, we hypothesised that 
therapeutic administration of vitamin K, the necessary co-factor for the -
carboxylation of vitamin K-dependent proteins (VKDPs) in the body, may be a 
potential booster of endogenous Gas6 in the brain, and hence be a potential 
alternative to exogenous Gas6 (discussed in Chapter 6). Although we did not look at 
protein changes with the effect of vitamin K, My preliminary data nevertheless show 
that vitamin K has a significant effect on the expression of Gas6 and protein S at 
gene level. However, this approach has some disadvantages, for example, all the 
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clotting factors are VKDPs, so administration of vitamin K in an in vivo system can 
leads to overexpression of these proteins that can result in sever blood clotting and 
death of the animal. This type of investigation therefore requires further research, 
including performing analysis at protein and cell/tissue levels. 
 
7.4.3 Gas6 in the future of MS research 
According to our observations, Gas6 is involved in a number of processes, including 
OPCs development and differentiation, demyelination, and regulating BBB and 
inflammation. Considering the future focus of MS research, the effect of Gas6 can be 
investigated in a number of different areas, including immunology, neuroprotection 
as well as glial cell biology and drug development. 
Overall, what mentioned in this PhD thesis help us to understand the basic biology of 
MS and reveal new signalling pathways that lead to cell development and 
differentiation as well as protecting the CNS from further damage. Thus, indicating a 
new potential therapy for MS that is able to dampen the inflammation and induce 
self-repair in the CNS.  
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